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ABSTRACT 
 
Pea protein-polysaccharide microcapsules (2.0 % (w/v) of pea protein isolate (PPI), mixed 
with either sodium alginate, iota-carrageenan or gellan gum (0.5 % (w/v)), containing 
Bifidobacterium adolescentis were tested in a series of in vitro survival experiments to evaluate the 
ability of microcapsules to protect the bacterium under simulated stomach conditions, as well as their 
ability to release the encapsulated bacteria under simulated conditions of the lower gut. All tested 
capsule formulations provided significant protection for bifidobacteria relative to non-encapsulated 
bacteria. PPI-alginate and PPI-iota-carrageenan microcapsules released 70-79 % of encapsulated 
bacteria, with higher cell numbers being released from freeze-dried capsules. The number of released 
cells from PPI-gellan gum microcapsules was ~ 26-30 % lower. A rat feeding study was conducted 
with the test bacterium encapsulated in PPI-alginate. Bifidobacterium adolescentis-specific PCR and 
qPCR analyses confirmed the presence of DNA from this species in animal fecal samples, but only 
during the period of capsule intake.  
Using a mixture of two lactobacilli (a combination of Lactobacillus rhamnosus strain R0011 
and Lactobacillus helveticus strain R0052; Lacidofil
®
, Lallemand Health Solutions, Montreal, QC, 
Canada) known to relieve Citrobacter rodentium colitis in mice, we assessed the impact of 
immobilization of these cells (PPI-alginate) using this animal disease model. The main objective was 
to determine whether PPI-alginate encapsulation matrix interfered with the ability of probiotic 
bacteria to reduce the symptoms of colitis. Animals were fed rodent AIN93G diets (control) or 
AIN93G diets supplemented with either freeze dried or microencapsulated bacterial cells. A second 
control consisting of PPI-alginate microcapsules only was also fed to mice. Half of the animals in 
each treatment group were infected with C. rodentium. Daily monitoring of disease symptoms, 
analyses of histopathological changes in intestinal tissues, cytokine expression levels, and bacterial 
densities in fecal samples were assessed. Additionally, 16S rRNA gene sequencing of the mucosal 
microbial communities in the distal colon was conducted. Infection of mice with C. rodentium led to 
a marked progression of infectious colitis, as evidenced from symptomatic and histopathological 
data, changes in cytokine expression levels, and alteration of composition of mucosa-associated 
bacterial communities. Probiotic administration affected disease markers in the cecum but not in the 
colon, but had no significant impact on cytokine profiles in infected animals. Based on cytokine 
expression analyses and histopathological data, it was evident that encapsulation contributed to the 
development of inflammation and worsened symptoms in this experimental animal model. In 
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general, the results of this study suggest that even though the tested encapsulation materials are 
generally recognized as safe, they may in fact contribute to the development of an inflammatory 
response in certain animal disease models when administered in the capsule form.  
In the last study, PPI–alginate microcapsules with or without a chitosan coating and 
containing Lactobacillus rhamnosus R0011 and Lactobacillus helveticus R0052 were produced by 
extrusion and tested for survivability during storage and under in vitro gastrointestinal conditions. 
Storage at 4°C had no negative impact on capsule protective ability in both types of capsules. PPI-
alginate microcapsules with chitosan containing showed much higher bacterial survival counts than 
microcapsules without extra coating during challenge tests even after the storage period.   
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1 INTRODUCTION 
 
1.1 Overview 
 This research focuses on evaluating materials for microencapsulating probiotic bacteria to 
provide protection from the detrimental conditions of the upper gastrointestinal tract (GIT) and their 
controlled release under simulated intestinal conditions. According to the current definition of the 
Food and Agriculture Organization/World Health Organization, probiotics are defined as "Live 
microorganisms which when administered in adequate amounts confer a health benefit on the host" 
(FAO/WHO, 2001). Probiotic bacteria used in the research were strains of lactobacilli and 
bifidobacteria. Lactobacilli are used most often in probiotic research. Among the purported 
beneficial effects, these bacteria can improve digestion, absorption and availability of nutrients 
(Wallace et al., 2011). Furthermore, lactobacilli are capable of hydrolyzing compounds that limit the 
bioavailability of minerals, like tannin and phytate, due to tannin acylhydrolase and phytase 
activities (Turpin et al., 2010). The purported benefits of bifidobacteria include, but are not limited 
to, reducing the number of harmful organisms in the intestine, producing antimicrobial substances 
and stimulating the body's immune response (Holzapfel and Schillinger, 2002; Wen et al., 2012). 
The highly-acidic stomach environment reduces the number of viable probiotic cells; hence, the 
search for novel protective strategies remains ongoing. Biopolymers of plant and bacterial origin are 
reported to be successful candidates for this purpose as they are generally recognized as safe, and 
have gel-forming capabilities. Biopolymer-based microcapsules thus offer a potential strategy for 
delivery of viable probiotic bacteria during passage through the harsh GIT environment, with 
subsequent benefits to human health.   
Specifically, three hydrocolloid polymers, combined with pea protein isolate (PPI), were 
tested for their ability to protect bacterial cells: sodium alginate, iota-carrageenan and gellan gum. 
All of these biopolymers are widely used in food production, commercially available at a reasonable 
cost and form gels in the presence of calcium ions (Champagne and Fustier, 2007; 
Chávarri et al., 2010; Luna et al., 2010).  
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           According to previous studies (Kotikalapudi et al., 2010; Klemmer et al., 2011), PPI was 
shown to enhance the survival of bacterial cells immobilized inside PPI-alginate microcapsules. 
Since carrageenans and gellan gum have also been used for the delivery of various substances into 
the GIT, the protective properties of PPI to enhance survivial within these matrices
was also examined. Anaerobic Bifidobacterium adolescentis was used for encapsulation to test 
microcapsule composition both in vitro and in vivo.  
Subsequently, the effects of the chosen microcapsule composition on the activity of 
probiotics in an animal model of a human disease (e.g., enhancing or interfering with probiotic 
effects) were examined. The goal was to evaluate the ability of PPI-alginate microcapsules to safely 
and effectively deliver probiotics in a mouse colitis model system and to study the effects of capsule 
composition on both disease symptoms and the microbiome, using various health-related (cytokine 
product, inflammation, etc.) and microbial parameters (bacterial numbers). A final study focused on 
improving capsule formulation by incorporating chitosan into the matrix. The survival of probiotics 
in PPI-alginate microcapsules with or without chitosan coating was investigated during storage and 
in simulated gastrointestinal environment.  
 
1.2 Objectives 
The overall objectives of this research were: i) to develop a method for producing protective 
microcapsules containing probiotic bacteria, utilizing a complex of PPI and one of three biopolymers 
- sodium alginate, iota-carrageenan or gellan gum, ii) to investigate the effect of the microcapsule 
composition on the survival of bacteria during exposure to the simulated conditions of the upper GIT 
and on the release of bacterial cells from microcapsules under simulated intestinal conditions; iii) to 
determine, using an animal model, the numbers of probiotic bacterium delivered to the lower GIT, as 
well as any impact that the capsular materials may have on the host; and iv) to determine the impact 
of encapsulation materials on the ability of probiotic bacteria to restore microbial balance in the 
animal GIT, resulting from pathogenic infection.  
1.3 Hypotheses 
The following hypotheses were tested as part of this research:  
 The addition of PPI to hydrocolloids (alginate, iota-carrageenan, gellan gum) will enhance 
the survival of B. adolescentis immobilized within microcapsules (compared to planktonic 
bacteria) under simulated upper GIT conditions and allow the release of the entrapped 
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bacteria under simulated intestinal conditions;  
 The selected microcapsule composition will allow delivery of Bifidobacterium adolescentis 
into the lower GIT of laboratory animals at detectable concentrations; 
 The encapsulation of probiotics, selected in vitro for their antagonistic properties against a 
pathogen, will not interfere with their ability to treat or alleviate the symptoms of induced 
infectious disease in an animal model; 
 The additional improvement (outer chitosan layer) will enhance protective properties of 
microcapsules. 
 
 1
Chapters 2.1-2.3: Varankovich, N. V., Nickerson, M. T., and Korber, D. R. (2015). Probiotic-based 
strategies for therapeutic and prophylactic use against multiple gastrointestinal diseases. Front 
Microbiol 685, 1-14. 
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2 LITERATURE REVIEW
1
 
 
2.1 Microbial ecology of the human gastrointestinal tract 
The human intestinal microbiota is a complex ecosystem with considerable impact on human 
health and well-being, contributing to maturation of the immune system and providing a direct 
barrier against pathogen colonization (Doré and Corthier, 2010). It consists of bacteria, archaea, 
some protozoa, anaerobic fungi and different bacteriophages and viruses, and it has been estimated 
that more than 1000 species of microbes inhabit the human intestine (Tuohy et al., 2012). The 
presence of a great number of microbes (up to 5×10
11
 bacterial cells per gram of intestinal contents) 
suggests strong regulatory effects on the human host, and recent findings suggest that gut microbiota 
can have a considerable impact on both our weight and mood (Duca et al., 2014; Naseribafrouei et 
al., 2014). The composition and function of human microbial populations associated with various 
body sites have been studied with the help of metagenomic tools as part of two recent initiatives – 
the NIH Human Microbiome Project (HMP) and the European Metagenomics of the Human 
Intestine (metaHIT) project (NIH HMP Working Group et al., 2009; Dusko Ehrlich et al., 2011).  
Bacteria that initially colonize the lower GIT of an infant are facultative anaerobes, such as 
Escherichia coli and Streptococcus spp. These species metabolize oxygen in the gut, thereby 
creating anaerobic conditions. Subsequent colonization largely depends on food profile and 
environmental factors (i.e., sanitary conditions). After the full formation of the gastrointestinal 
microflora, its composition has been shown to include such genera as Bacteroides,
Bifidobacterium, Eubacterium, Clostridium, Lactobacillus, Fusobacterium and various Gram-
positive cocci (Fooks et al., 1999; Wallace et al., 2011).  
Within the GIT, the microbiota perform various functions, such as digestion of nutrients and 
maturation of intestinal epithelial cells. Studies on mice have shown a number of significant effects 
of microbiota on the host. In ex-germ-free, reconventionalized mice, their intestinal epithelium was 
thicker, short-chain fatty acids were produced at significantly higher concentrations, and there was a 
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normal level of immunological activity present, compared to germ-free animals (Aureli et al., 2011). 
Microbes also have the ability to affect physiologic parameters, providing systemic effects on blood 
lipids and generally influencing the immune system, as well as inhibiting harmful bacteria 
(Mikelsaar, 2011). Pathogen inhibition by human intestinal microbiota may provide significant 
human health benefits through protection against infection as a natural barrier against pathogen 
exposure in the gastrointestinal tract (Wallace et al., 2011). Factors such as food contamination by 
pathogens, as well as the high load of antibiotics in animal feed, resulting in the presence of these 
substances in animal-based food products, can influence the microbial ecology of human 
gastrointestinal tract (Sapkota et al., 2007). Using molecular genetic tools, it has been shown that 
antibiotics could induce significant alterations in the dominant colonic flora that are not detectable 
using bacteriological (culture-based) techniques, with effects lasting for up to two months (Mangin 
et al., 1999). Several more specific disorders involve disruption of the human microflora ecology: 
acute gastroenteritis, Clostridium difficile infection (CDI), necrotising enterocolitis in neonates, 
irritable bowel syndrome and Helicobacter pylori infection (Kotzampassi and Giamarellos-
Bourboulis, 2012). Probiotics are currently being examined for their potential treatments of the 
aforementioned disorders.  
 
2.2 Probiotic bacteria 
As defined by the Food and Agriculture Organization/World Health Organization, probiotics 
are are "live microorganisms which when administered in adequate amounts confer a health benefit 
on the host" (FAO/WHO, 2001). The most common probiotics include representatives of 
lactobacilli, enterococci, bifidobacteria and yeasts (Table 2.1). In addition, bacterial mixtures may 
potentially be used to achieve the complex beneficial effect of probiotics (Caballero-Franco et al., 
2007). 
Presumed health benefits of probiotics include reducing harmful organisms in the intestine, 
producing antimicrobial factors and stimulating the body's immune response (Collado et al., 2007; 
Foligné et al., 2010; Konieczna et al., 2013). Some of the potential beneficial effects of probiotics, 
seen in animal studies (e.g., lowering of cholesterol level) are yet to be substantiated by well-
controlled clinical trials. However, there are a growing number of studies providing data on effects 
of probiotic bacteria on the human immune system and on microflora of the gastrointestinal tract 
(Holzapfel and Schillinger, 2002; Foligné et al., 2007; Verdú et al., 2009; Wen et al., 2012). 
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Table 2.1. Microorganisms with reported probiotic potential. 
Probiotic 
group 
Species 
 
Details of a representative study Reference 
Bifidobacteria B. animalis Fermented oak milk with B. animalis 
subsp. lactis BB-12
®
; double-blind 
randomized placebo-controlled 
clinical trial; n = 209; 35 % 
improvement in bowel movement. 
Pitkala et al., 2007 
(See Jurgersen et 
al. (2014) for the 
review) 
B. breve B. breve M16-V powder with or 
without starch; F344/Du rat pups; n 
= 46; downregulation of the 
expression of inflammatory 
molecules. 
Shimakawa et al., 
2003 
B. adolescentis B. adolescentis ATCC 101; female 
germ-free rats; n = 30; significant 
modulation of both systemic and the 
intestinal immune response to 
Bacteroides thetaiotaomicron DSMZ 
2079.  
Scharek et al., 
2000 
B. longum B. longum, isolated from human 
GIT; double-blind randomized 
placebo-controlled clinical trial; n= 
29; significant inhibitory effect on 
viral gastroenteritis symptoms. 
Lee et al., 2014b 
B. infantis B. infantis 35624 was administered 
by gavage; C57BL/6 mice; n=64; 
decrease in the severity of dextran 
sulfate sodium-induced colitis, 
immunomodulation. 
Konieczna et al., 
2013 
Lactobacilli L. acidophilus L. acidophilus - SDC, administered 
in capsules; double-blind 
randomized placebo-controlled 
clinical trial; n = 40; 23.6 % 
reduction (compared to placebo) in 
the severity (pain, discomfort) of 
Irritable Bowel Syndrome. 
Sinn et al., 2008 
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Table 2.1. Microorganisms with reported probiotic potential. Continued.  
Probiotic 
group 
Species 
 
Details of a representative study Reference 
 L. fermentum 
L. amylovorus 
Microencapsulated bacteria; double-
blind randomized placebo controlled 
clinical trial; n = 28, obese adults; L. 
fermentum – 3.0 % loss in total fat 
mass, L. amylovorum – 4.0 % loss in 
total fat mass, a significant reduction 
in the abundance of Clostridial 
cluster IV. 
Omar et al., 2013 
L. rhamnosus L. rhamnosus GG powder; double-
blind randomized clinical trial; n = 
559; decrease in frequency and 
duration of acute watery diarrhea. 
Basu et al., 2009 
L. paracasei L. paracasei ST11, lyophilized form; 
double-blind randomized placebo-
controlled clinical trial; n = 230, 
male infants and young children; 
significant benefit in the 
management of children with 
nonrotavirus-induced diarrhea. 
Sarker et al., 2005 
L. johnsonii L. johnsonii La1 in dietary product; 
double-blind randomized placebo-
controlled clinical trial; n = 326, 
children, found positive for 
Helicobacter pylori; significant 
decrease in σ13CO2 above baseline 
values (outcome of a test for H. 
pylori). 
Cruchet et al., 2003 
L. reuteri L. reuteri SD 2112; randomized 
controlled clinical tral; n = 40, 
infants and children; significant 
decrease in diarrhea symptoms. 
Shornikova et al., 
1997 
 Pediococcus 
pentosaceus 
P. pentosaceus NB-17; mouse spleen 
cells were co-cultivated with heat-
killed bacteria; in vitro investigation 
of the production of cytokines; 
effective stimulation of immune 
activities and allergic inhibitory 
effects. 
Jonganurakkun et 
al., 2008 
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Table 2.1. Microorganisms with reported probiotic potential. Continued.  
Probiotic 
group 
Species 
 
Details of a representative study Reference 
 Oenococcus 
oeni 
O. oeni 9115; female BALB/c mice 
with 2, 4, 6-trinitrobenzene sulfonic 
acid-induced experimental colitis; n 
= 20; significant decrease in severity 
of colitis. 
Several O. oeni strains were able to 
modulate the immune response of 
immunocompetent cells in vitro. 
Foligné et al., 2010 
 
Enterococci E. durans E. durans LAB18s; in vitro study; 
antimicrobial activity, antioxidant 
ability, evidenced in both culture 
supernatants and intracellular 
extracts; resistance to acidic 
conditions (pH 3) and bile salts. 
Pieniz et al., 2014 
E. faecium E. faecium MMRA; in vitro study; 
genes, coding enterocins A, B, P and 
X; high survival rates under stress 
caused by acidic pHs (2-5) or bile 
salts (0.3 %), and a high adhesive 
potential. 
Rehaiem et al., 
2014 
E. faecalis E. faecalis UGRA10; in vitro study; 
production of AS-48 enterocin; 
ability to form biofilms and to adhere 
to Caco 2 and HeLa 229 cells. 
Cebrián et al., 2012 
E. lactis E. lactis IITRHR1 was administered 
by gavage; male Wistar rats with 
acetaminophen-induced 
hepatotoxicity; n = 42; pretreatment 
with the bacterium lowered the level 
of biomarkers of hepatotoxicity in 
serum; significant increase in the 
level of antioxidant; modulation of 
key apoptotic/anti-apoptotic proteins 
(cytochrome-c, Bcl2, Bax, 
expression of caspases). 
Sharma et al., 2012 
Yeasts Saccharomyces 
boulardii 
Granulated S. boulardii; double-
blind randomized placebo-controlled 
clinical trial; n = 200, children with 
acute diarrhea; significant decrease 
in severity of symptoms and duration 
of hospital stay. 
Kurugol and 
Koturoglu, 2005  
(See Kelesidis and 
Pothoulakis (2010) 
for the review) 
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Increasingly, reports of the human/animal microbiome playing a central role in other key aspects of 
health functionality are emerging, including beneficial impacts on the treatment of metabolic 
disorders, such as obesity and type II diabetes, improvement of bowel function in patients with 
colorectal cancer, potential cognitive and mood-enhancing benefits, antidepressant and anxiolytic 
(antianxiety) activity (Desbonnet et al., 2008; Bravo et al., 2011; DiBaise et al., 2012; Lee et al., 
2014a; Owen et al., 2014). The latter anxiolytic effect has even led to the emergence of the new 
term, “psychobiotic”, coined by Dinan et al. (2013) as “a live organism that, when ingested in 
adequate amounts, produces a health benefit in patients suffering from psychiatric illness”. 
Products containing probiotic bacteria generally include supplements and foods. Live 
probiotics are commonly-available in fermented dairy products and probiotic-fortified foods. These 
bacteria are added into numerous foods and beverages, ranging from yoghurts to breakfast cereals. 
There are also tablets, capsules, powders and sachets containing probiotics in freeze-dried form. 
Functional foods, defined as food preparations with various health-related properties, often include 
bacterial strains with declared probiotic properties (Turroni et al., 2011). The scientific interest 
towards probiotics is growing exponentially: the search for published papers featuring keyword 
“probiotic” in NIH PubMed database revealed 7265 articles for the period from 2000 to 2010, with 
953 of them being clinical trials. Within the following 5 years (up to May 20
th
 2015), the frequency 
of publications doubled with 7979 papers being published during that period, including 778 clinical 
trials. 
2.2.1 Lactic acid bacteria  
Lactic acid bacteria (LAB) are Gram-positive, non-spore forming cocci, coccobacilli or rods, 
which generally have non-respiratory (fermentative) metabolism and lack true catalase. Unlike 
bifidobacteria, which are active in the lower colon, lactobacilli are generally found in the upper GIT 
(Turroni et al., 2011). LAB are also normal members of the human microflora, and found in the oral 
cavity, the small intestine, and the vaginal epithelium, where they are thought to play beneficial roles 
(Gomes and Malcata, 1999). Among the purported beneficial effects, lactobacilli have been claimed 
to improve digestion, absorption and availability of nutrients (Wallace et al., 2011). Furthermore, 
LAB are capable of hydrolyzing compounds that limit the bioavailability of minerals, like tannin and 
phytate, due to tannin acylhydrolase and phytase activities (Turpin et al., 2010). In addition, it was 
shown that some lactobacilli strains could improve mineral absorption in Caco-2 cells and improve 
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the nutritional status of the host by producing B-group vitamins. More recently, the role of 
lactobacilli in energy homeostasis, particularly in obese patients, has been the object of an increased 
interest (Guo et al., 2010; Mikelsaar, 2011). A further potential impact of LAB is their ability to 
inhibit or kill Helicobacter pylori, which is now regarded as the major cause of gastritis and peptic 
ulcers and is a risk factor for gastric malignancy (Hamilton-Miller, 2003). In addition, both 
Lactobacillus spp. and Bifidobacterium spp. reportedly reduce the side effects of Helicobacter pylori 
eradication therapy (Canducci et al., 2002).  
Pediococci are also related to the LAB group and are utilized in industrial fermentations of 
foods and silage (Raccach, 2014). Pediocin-producing Pediococcus spp. strains are of potential 
interest to food safety (Raccach, 2014), with three of them potentially possessing probiotic properties 
– P. pentosaceus, P. parvulus and P. acidilactici. Osmanagaoglu et al. (2010) comprehensively 
studied the potential of a human P. pentosaceus isolate for probiotic use, and reported that the strain 
produced an anti-Listerial bacteriocin, had excellent autoaggregation characteristics and was also 
able to co-aggregate with Salmonella enterica serotype Typhimurium and enterotoxigenic 
Escherichia coli (Osmanagaoglu et al., 2010). Antagonistic activity against Listeria monocytogenes 
was also discovered in P. acidilactici (Guerra and Pastrana, 2002). Clinical trials employing another 
strain of Pediococcus spp. revealed that the administration of P. parvulus decreased serum 
cholesterol levels and increased counts of faecal Bifidobacterium spp. (Mårtensson et al., 2005).  
Another group of LAB promoted as probiotics are enterococci, which reportedly help in the 
maintenance of normal intestinal microflora and stimulate the immune system (Bhardwaj et al., 
2008). Studies of potential probiotic properties of E. faecium showed its efficacy in reducing the 
recovery period of acute diarrhoea (Benyacoub et al., 2003). Another study by Pieniz et al. (2014) 
showed that E. durans possessed antimicrobial activity and antioxidant ability and was resistant to 
simulated gastric juice and bile salts. Though enterococci have probiotic potential, they are 
considered opportunistic pathogens for humans as they might cause nosocomial infection and are 
also known to possess resistance to vancomycin (Tambyah, 2004). Additionally, Enterococci can 
cause haemorragic shock in pigs with possible subsequent transition of infection to humans (Lu et 
al., 2002). Due to these controversial properties, the use of enterococci as probiotics remains under 
debate. 
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2.2.2 Bifidobacteria 
Bifidobacteria are major constituents of the GIT microbiota of humans. They are Gram-
positive, non-motile, often-branched, anaerobic saccharolytic bacteria (Gomes and Malcata, 1999). 
In the gut environment, bifidobacteria have a commensal relationship with their hosts, and contribute 
to host nutrition by utilizing complex carbohydrates, which are important sources of carbon and 
energy, but are not degraded in the stomach or intestine (Biavati, 1994). These substances include 
plant-derived dietary fibre and diet-related carbohydrates, such as starch, galactan, sucrose, 
amylopectin and pullulan (Ventura et al., 2007, 2012). Their capacity to metabolize non-digestible 
dietary carbohydrates (prebiotics) can be used for selective stimulation of certain strains colonizing 
the intestinal tract. bifidobacteria used as probiotics include strains belonging to species of 
Bifidobacterium lactis, B. bifidum, B. animalis, B. thermophilum, B. breve, B. longum, B. infantis 
and B. adolescentis (Table 2.1). These bacteria have been shown to inhibit the adherence of 
enterotoxigenic E. coli, enteropathogenic E. coli and C. difficile to intestinal epithelial cells, an 
important trait for use of these bacteria as probiotics (Tsai et al., 2008). Additional purported 
beneficial effects of bifidobacterial strains include the prevention or alleviation of infectious 
diarrhoea and the improvement of inflammatory bowel disease symptoms (Sanz, 2007). 
bifidobacteria have also been shown to modulate the host's immune response against other 
indigenous microflora (e.g., B. adolescentis down-regulates humoral immunity to Bacteroides 
thetaiotaomicron; Scharek et al., 2000). Some bifidobacterial strains suppress H. pylori-induced 
genes in human epithelial cells (Shirasawa et al., 2010) while other Bifidobacterium spp. cells and 
culture supernatants exerted inhibitory effects against Streptococcus mutans and Streptococcus 
sobrinus, important etiological agents in human dental caries (Lee et al., 2011).  
 
2.2.3 Yeasts 
Saccharomyces boulardii is one of the best-studied probiotic species with a long history of 
use in treatment of multiple gastrointestinal disorders. The administration of this probiotic in 
lyophilized form was found effective in cases of diarrhoea by decreasing the duration of the disease, 
regardless of its cause (McFarland, 2007; Dinleyici et al., 2012; Shan et al., 2013). It has also been 
reported that S. boulardii prevented and treated relapses of inflammatory bowel disease, including 
moderate cases of ulcerative colitis (Guslandi et al., 2000, 2003; Choi et al., 2011). Interesting 
results have also been reported by Lim et al. (2015), suggesting that yeasts can enhance the growth 
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of other probiotics under acidic conditions: Saccharomyces cerevisiae EC-1118 was found to 
significantly enhance the viability of the probiotic strain Lactobacillus rhamnosus HN001 at pH 2.5 
to 4.0. The use of S. boulardii in reduction of C. difficile infection relapse is still under debate due to 
controversial results of clinical trials (Flatley et al., 2015). Among other yeasts species, Torulaspora 
delbrueckii, Debaromyces hansenii, Yarrowia lipolytica, Kluyveromyces lactis, Kluyveromyces 
marxianus and Kluyveromyces lodderae have shown strong antagonistic effect against pathogenic 
bacteria and high acid tolerance (Kumura et al., 2004; Psani and Kotzekidou, 2006; Chen et 
al., 2010). Despite an excellent record of safe use, yeasts may still be the cause of localized 
infections in immunocompromised patients (Thygesen, Glerup and Tarp, 2012). 
 
2.2.4 Akkermansia muciniphila 
Another recently-described microorganism with possible probiotic potential is Akkermansia 
muciniphila - a mucin-degrading bacterium that resides within intestinal mucus layers (Derrien et al., 
2004). According to several studies, obese patients have significantly lower amounts of this 
bacterium in their GIT (Collado et al., 2008; Karlsson et al., 2012). The genome sequence of A. 
muciniphila suggests the ability of this bacterium to metabolize a variety of complex carbohydrates, 
as well as synthesize multiple amino acids, vitamins and cofactors (van Passel et al., 2011). Its 
influence on metabolic processes in the GIT has not been fully investigated; however, it has already 
been shown that this bacterium may be a potential treatment for obesity and its associated metabolic 
disorders (Everard et al., 2013). Shin and colleagues have shown that oral administration of A. 
muciniphila to mice induced Foxp3 regulatory T cells in the visceral adipose tissue, which attenuated 
adipose tissue inflammation (Shin et al., 2014). Based on these results it has been suggested that 
pharmacological manipulation of the gut microbiota in favour of A. muciniphila might be beneficial 
in the treatment of diabetes. 
 
2.2.5 Faecalibacterium prausnitzii and other clostridia 
Another bacterium that has been demonstrated to have a considerable impact on human 
gastrointestinal microbiota is Faecalibacterium prausnitzii of the Clostridium spp. cluster IV. This 
microorganism accounts for 5-15 % of the total fecal microbiota, making it one of the most abundant 
butyrate-producing bacteria in the GIT (Hold et al., 2003; Flint et al., 2012). Since butyrate is a 
primary energy source for intestinal epithelial cells, it is essential for maintenance of epithelial 
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barrier integrity. Based on animal studies multiple beneficial effects of butyrate also include 
reduction of cancer progression, protection against pathogens and stimulation of the immune system 
(Macfarlane and Macfarlane, 2011; Ríos-Covián et al., 2016). The reduction of F. prausnitzii counts 
in fecal and biopsy samples has been observed in multiple studies of inflammatory bowel disease 
(especially, ileal Crohn‟s disease and ulcerative colitis) (Wang et al., 2007; Swidsinski et al., 2008; 
Andoh et al., 2012). The first gnotobiotic rodent model with F. prausnitzii showed that it could 
influence gut physiology by modifying goblet cells and mucin glycosylation, thereby affecting the 
quality and quantity of produced mucus (Wrzosek et al., 2013).  
Other bacteria within the class Clostridia might also find use as potential probiotics, since 
they are highly abundant in human GIT microbiota and may play an important role in metabolism 
and immune system function. Atarashi and colleagues have shown that a mixture of 17 strains of 
Clostridium spp., belonging to clusters IV, XIV and XVIII, were able to suppress experimental 
colitis in mice through induction of interleukin-10-producing regulatory T cells (Atarashi et al., 
2013). A similar mechanism of colitis suppression via IL-10 production by induced macrophages 
was observed using strain Clostridium butyricum MIYAIRI 588 (Hayashi et al., 2013).  According 
to another recent study, when mixed with B. infantis, C. butyricum was effective in treatment of 
experimental antibiotic-associated diarrhea in mice, and the beneficial effect of the mixture was 
superior to single clostridial strains (Ling et al., 2015). However, though clostridia have potential for 
use as probiotics, there is still not enough evidence to support their medical efficacy and safety for 
humans. 
 
2.3 In vitro and in vivo systems used to study probiotic effects 
Novel probiotic-based strategies for therapeutic and prophylactic use against multiple GIT 
diseases are gaining popularity worldwide. Their effectiveness has been predicted by numerous 
animal model studies. However, the initial step in confirming probiotic effects is the extensive 
characterization of a bacterial strain to be used as a probiotic, which is usually performed under in 
vitro conditions by studying bacterial acid resistance, bile resistance, carbon source utilization, and 
aggregative properties, or ex vivo for their ability to adhere to mammalian cells (Kotikalapudi et al., 
2010; Wood et al., 2012). Similarly, probiotic delivery methods, such as lyophilization or 
encapsulation, are also tested for their in vitro protective potential under simulated gastric conditions 
(Klemmer et al., 2011; Wood et al., 2012; Khan et al., 2013; Wang et al., 2014). The most popular 
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materials used for encapsulation of bacteria are alginate, carrageenans and gums, since they are easy 
to process, resistant to low pH and freezing, and are generally recognized as safe (Gbassi and 
Vandamme, 2012). We have recently reported the efficient delivery of B. adolescentis, encapsulated 
for this purpose in an alginate-pea protein protective matrix, into the lower gut of rats (Varankovich 
et al., 2015a).  
Apart from basic systems consisting of synthetic gastric juice solutions (low pH, 37˚C), more 
complex systems have been developed, such as SHIME (Simulator of the Human Intestinal 
Microbial Ecosystem), designed to simulate different parts of human gastrointestinal tract (Cook et 
al., 2012). Probiotic strains and methods for their delivery, preselected in vitro, are subsequently 
tested in animal models. 
Traditionally-used animal models include mice and rats. Larger animals like rabbits, dogs 
and pigs are generally considered to have more common features with the physiology and microflora 
of the human gastrointestinal tract (Kararli, 1995). However, rodents are cheap, standardized, and 
have short life-cycles; thus, they have seen extensive use in large-scale research. Investigation of 
probiotic effects on animal microflora may be approached by: i) examining the quantitative and 
qualitative characteristics of bacterial microflora in animals using cultivation and/or molecular 
biology techniques, such as real-time polymerase chain reaction (qPCR), next-generation sequencing 
(NGS), and fluorescence in situ hybridization (FISH), or ii) evaluating treatment efficiency 
indirectly by using it to cure an artificially-induced disease. 
Distribution of specific species of microorganisms is still being studied in healthy humans 
and compared with those of patients with various gastrointestinal diseases. Perturbations of 
microbiota, even in case of alterations in numbers of a single species (i.e. A. muciniphila), might be a 
cause (and an indicator) of the development of disease (Karlsson et al., 2012). In this case, probiotic 
treatment might be useful in restoring microbiota balance in the gut. An interesting example of 
quantitative/qualitative analysis of animal gut microbiota after probiotic administration can be found 
in the study by Wang et al. (2015): 454 pyrosequencing of fecal bacterial 16S rRNA genes in obese 
vs. lean mice showed that the probiotic strains shifted the overall structure of the gut microbiota of 
obese animals toward that of lean mice fed a normal diet, with significant changes observed in 83 
operational taxonomic units. Due to complicated analyses required to understand specific 
mechanisms of disease development, as well as the mode of action of a certain probiotic 
microorganism, the use of disease models is generally more widespread.  
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2.3.1 Rodent models of GIT diseases 
Generally, in order to establish a disease model, mice are infected with the pathogen or 
irritant either one time or continuously (Pawlowski et al., 2010; Bhinder et al., 2013). Subsequently, 
animals are treated with probiotics with concomitant monitoring of the disease symptoms and 
evaluation of changes in the gut microflora. Following this approach, Verdú et al. (2008) infected 
mice with Helicobacter pylori for 4-6 months to investigate the effect of probiotic therapy on upper 
gastrointestinal dysfunction induced by chronic H. pylori infection. The authors reported that 
delayed gastric emptying in mice normalized significantly faster with probiotic treatment, compared 
to control groups, where the dysfunction was observed during a 2 month period after pathogen 
administration was ceased. Mice and rats have also been used to evaluate the efficiency of probiotics 
for the treatment of Salmonella and E. coli O157:H7 infections (Asahara et al., 2001, 2004), 
inflammatory bowel disease (Shiba et al., 2003) and immune suppression (Lollo et al., 2012). 
Asahara et al. (2001) showed that intestinal growth and subsequent extra-intestinal translocation of 
orally-infected Salmonella typhimurium in mice were inhibited during administration of probiotic B. 
breve. Later, the same group reported B. breve was also effective in protecting mice against Shiga 
toxic-producing E. coli 0157:H7 (Asahara et al., 2004). Extrapolation of results achieved in animal 
studies and in vitro experiments to humans remains a difficult challenge. Many factors, such as 
differences in physiology and microflora composition of gastrointestinal systems, must be 
considered before interpreting the outcome. 
The majority of in vivo experiments investigating the effects of probiotics on pathogenic 
bacterial populations use gnotobiotic mice (usually with human microflora systems in their GIT) 
(Bernet-Camard et al., 1997; Aiba et al., 1998, Gill et al., 2001; Pawlowski et al., 2010). For 
instance, in a study by Shiba et al. (2003), probiotic B. infantis 1222 was found to significantly 
suppress the systemic antibody response raised by Bacteroides vulgatus, a representative pathogenic 
Bacteroides spp. species, in a gnotobiotic mice model of inflammatory bowel disease. The use of 
conventional mice as a model for investigating human diseases is more problematic due to 
significant differences in animal and human gut microflora. Nevertheless, it is possible to use 
murine-specific organisms as models for the study of human pathogens. For instance, Ge et al. 
(2001) used Helicobacter hepaticus infection as an animal model for examining the pathogenesis of 
gastrointestinal diseases in humans caused by H. pylori. More recently, Bhinder et al. (2013) 
described the Citrobacter rodentium mouse model for the study of pathogen and host contributions 
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during infectious colitis. Citrobacter rodentium is a murine-specific bacterial pathogen, closely-
related to enteropathogenic and enterohaemorrhagic strains of E. coli (Borenstein et al., 2008). 
Several C. rodentium infection studies involving mice models have shown probiotics to reduce the 
severity of symptoms and prevent death caused by the pathogenic agent (Chen et al., 2005; Gareau 
et al., 2010; Rodrigues et al., 2012; Mackos et al., 2013). Chen et al. (2005) successfully treated C. 
rodentium-induced murine colitis with probiotic L. acidophilus. Gareau et al. (2010) similarly 
reported that L. rhamnosus, combined with L. helveticus, were effective in prevention and treatment 
of the same disease state in mice. Later, another group showed that L. reuteri was able to attenuate 
the severity of murine colitis caused by C. rodentium (Mackos et al., 2013). Further investigation of 
host-pathogen and probiotic-pathogen interactions will likely provide better insight into treatment of 
C. rodentium infection in mice, and possibly E. coli infections in humans. However, confirmation of 
probiotic benefits and possible side effects will ultimately require human trials.  
 
2.3.2 Human clinical trials 
Human studies generally take the form of randomized clinical trials involving participants 
with some type of intestinal disorder. After assessment of eligibility and recruitment, participants are 
given either probiotic treatment or a placebo as a control. Results of these experiments have 
provided enough evidence for considering probiotics effective treatment for multiple GIT-associated 
diseases, such as acute gastroenteritis (Huang et al., 2002), irritable bowel syndrome (Nikfar et al., 
2002) and necrotizing enterocolitis (Alfaleh et al., 2011). Some trials showing the efficacy of 
bacteria of interest in the treatment of specific gastrointestinal disorders are listed in Table 2.2. In 
one recent trial aimed to assess the efficiency of S. cerevisiae in treatment of irritable bowel 
syndrome, 179 adults diagnosed with this condition were randomized to receive once-daily 500 mg 
of S. cerevisiae or placebo for 8 weeks. Cardinal symptoms (abdominal pain/discomfort, 
bloating/distension, bowel movement difficulty) were recorded daily after a 2-week run-in period. 
The results showed that abdominal pain/discomfort scores were significantly reduced during 
probiotic intake (Pineton et al., 2015). A major trial involving 362 participants was conducted by 
Whorwell and colleagues in order to study the effect of B. infantis on symptoms of irritable bowel 
syndrome: probiotic administration lead to improvements in the majority of symptoms by more than 
20 % compared to placebo (Whorwell et al., 2006). Another human clinical trial proved the efficacy 
of Lactobacillus GG in treatment of H. pylori infection: daily administration of the probiotic led to 
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significant reduction in disease symptoms (diarrhea, nausea and taste disturbances) (Armuzzi et al., 
2001).   
Though the majority of animal studies and human trials have not been successful in 
providing sufficient proof to substantiate claimed beneficial properties of probiotics, data from 
multiple lines of research involving humans suggests that certain strains of probiotic bacteria 
suppress gastrointestinal pathogens by simple competition by prevailing in numbers, and by 
producing antibacterial factors (bacteriocins and small organic molecules, such as fatty acids). 
However, more details into the mechanisms of action of probiotics on gut microbiota are essential.  
  
 
Table 2.2. Some of the major human trials of probiotics for the treatment of gastrointestinal diseases 
 
Probiotic strain Disease Number of 
participants 
Reported outcome Reference 
Lactobacillus 
rhamnosus GG 
 
Helicobacter 
pylori infection 
60 Significant reduction (p = 0.04) of diarrhea, 
nausea and taste disturbances in the treatment 
group.  
Armuzzi et al., 2001 
 
Antibiotic-
associated 
diarrhea in 
children 
 
188 Significant reduction of the incidence of 
antibiotic-associated diarrhea in children treated 
with oral antibiotics for common childhood 
infections. 
Vanderhoof et al., 1999 
167 The treatment effect on the incidence of diarrhea 
(95 % confidence interval) was -11 % (-21 % - 0 
%). 
Arvola et al., 1999 
Bifidobacterium 
bifidum 
Irritable bowel 
syndrome 
 
122 Overall responder rates (decrease in symptoms 
severity) were 57 % in the treatment group, but 
only 21 % in the placebo group (P=0.0001) 
Guglielmetti et al., 2011 
Bifidobacterium 
infantis 
362 The improvement in overall symptom assessment 
exceeded placebo by more than 20 % (p < 0.02) 
Whorwell et al., 2006 
S. cerevisiae 179 The proportion of responders, reporting 
improvement in abdominal pain/discomfort, was 
significantly higher (p = 0.04) in the treated group 
than the placebo group (63 % vs 47 %, OR = 
1.88, 95 %, CI: 0.99-3.57). 
Pineton et al., 2015 
VSL#3*  
 
Pouchitis 
 
40 Three patients (15 %) in the treatment group had 
relapses of the disease within the 9-month follow-
up period, compared with 20 (100 %) in the 
placebo group (p < 0.001). 
Gionchetti et al., 2000 
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Table 2.2. Some of the major human trials of probiotics for the treatment of gastrointestinal diseases. Continued. 
Probiotic strain Disease Number of 
participants 
Reported outcome Reference 
 Pouchitis 
 
40 Two of the 20 patients (10 %) in the treatment 
group had an episode of acute pouchitis compared 
with 8 of the 20 patients (40 %) treated with 
placebo (log-rank test, z = 2.273; p < 0.05). 
Gionchetti et al., 2003 
 
34 Treatment of patients with mild to moderate 
stages of disease, not responding to conventional 
therapy, with probiotic resulted in a combined 
induction of remission/response rate of 77 % with 
no adverse events. 
Bibiloni et al., 2005 
Ulcerative colitis 124 The efficacy of probiotic was significant 
(recurrence rate 34.6 %, compared with 64.7 % 
on placebo; p = 0.04) in patients with recurrent 
CDD, but not in patients with initial CDD 
(recurrence rate 19.3 % compared with 24.2 % on 
placebo; p = 0.86). 
McFarland et al., 1994 
Saccharomyces 
boulardii 
Clostridium 
difficile-
associated 
diarrhea (CDD) 
 
168 A significant decrease in recurrences of CDD was 
observed only in patients treated with high-dose 
vancomycin (2 g/day) and probiotic (16.7 %), 
compared with those who received high-dose 
vancomycin and placebo (50 %; p = 0.05). 
Surawicz et al., 2000 
211 The mean (+/-SD) duration of diarrhea was 1.69 
days (0.6) in patients given probiotic, compared 
with 2.81 days (0.9) in those given placebo. 
Buydens and 
Debeuckelaere, 1996 
Enterococcus 
faecium SF68 
Acute diarrhea 123 The probiotic was shown to be effective in 
reducing the incidence of antibiotic-associated 
diarrhoea in comparison with placebo (8.7 % 
compared with 27.2 %, respectively). 
Wunderlich et al., 1989 
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Table 2.2. Some of the major human trials of probiotics for the treatment of gastrointestinal diseases. Continued. 
Probiotic strain Disease Number of 
participants 
Reported outcome Reference 
 Antibiotic-
associated 
diarrhea 
94 Prophylaxis with the probiotic significantly 
decreased the frequency of diarrhea from 71 % to 
43 % (p = 0.019). 
Black et al., 1989 
Mixture of 
lactobacilli, 
bifidobacteria and 
streprococci 
Travellers‟ 
diarrhea 
186 Enteral administration of the probiotic in neonatal 
intensive care setup significantly reduced 
morbidity due to necrotising enterocolitis in very 
low birth weight newborn. 
Samanta et al., 2009 
Mixture of B. 
infantis, B. 
bifidum, B. 
longum and L. 
acidophilus 
Necrotizing 
enterocolitis in 
newborns 
   
*A mixture of Lactobacillus casei, L. plantarum, L. acidophilus, L. delbrueckii subsp. bulgaricus, Bifidobacterium longum, B. breve, B. 
infantis and Streptococcus salivarius subsp. Thermophiles. 2
0
 
 21 
 
2.4 Immunomodulatory properties of probiotics 
The high densities of microorganisms in the GIT can potentially have serious impact on the 
host immune system. Control of bacterial exposure to the immune system is accomplished by two 
mechanisms: i) stratification – minimization of direct contact between microflora and colon walls by 
mucus layers, and ii) compartmentalization – limiting bacterial exposure to specific intestinal sites 
with the help of antibacterial proteins (i.e., RegIII) and immunoglobulin A (IgA), which restrict 
bacterial numbers that contact epithelium (Hooper, 2012). Increase of IgA excretion provides better 
protection from pathogens; hence, probiotic strains capable of inducing excretion of this molecule 
could be beneficial for human health, since unlike many other antigens they are safe. Evidence for 
this was found in a study by Link-Amster et al. (1994) who proved that consumption of fermented 
milk containing Bifidobacterium bifidum and Lactobacillus acidophilus La1 following vaccination 
against Salmonella typhi Ty21 showed a significant increase in IgA serum concentration.   
Another mechanism of immune effects of probiotics is their ability to influence monocyte-
derived dendritic cells (DC) to drive the development of regulatory T-cells (Treg). Treg cells help to 
maintain tolerance to self-antigens. They limit the activity of T-helper cells, thus restricting the 
immune response, which is especially important during transplantation of organs and autoimmune 
diseases. Several studies have shown the ability of probiotic strains of Lactobacillus reuteri, 
Lactobacillus casei and Bifidobacterium bifidum to promote (through dendritic cells) the 
differentiation of T-cells into Treg cells (Smits et al., 2005; Lopez et al., 2011; Lopez et al., 2012). 
Some probiotics can modulate the expression of different T-helper subsets. Alteration of the 
Th1/Th2 ratio towards Th1 causes a pro-inflammatory effect, whereas increased excretion of Th2 cells 
promotes an anti-inflammatory effect. In experiments on murine models it was found that L. casei, L. 
delbrueckii subsp. bulgaricus and L. acidophilus increased the systemic production of IgG1, typical 
of a Th1 response, and L. acidophilus enhanced production of IgG2a (Th2 response) (Perdigon et al., 
2002).  
Results of many studies involving different probiotic strains suggest the possibility of 
specific application of various probiotic strains depending on the kind of systemic reaction that is 
needed (Perdigon et al., 2002; Mohamadzadeh et al., 2005; Rigby et al., 2005). However, no pattern 
has been discovered even at the species-level, which means that each bacterial strain has to be 
examined separately for its effect on immune system.  
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2.5 Characterization of complex microbial communities  
2.5.1 Culture-dependent and culture-independent methods 
Complementary information received from both culture-dependent and culture-independent 
techniques is generally required to generate a comprehensive view of a microbial community.  
Traditional culture-dependent methods include using selective media for detection and 
cultivation of specific genera of microorganisms. This approach is well-suited for quantifying 
bacterial numbers, does not require special equipment, and is able to provide physiological and 
morphological data. However, not every microbe is culturable and not every metabolic and 
physiological requirement is reproduced in vitro (Spratt, 2004). Due to these limitations, selective 
media typically allows the detection of a relatively-small fraction of microorganisms; hence, cultural 
analyses may produce erroneous or biased results. In addition, cultivation and subsequent 
identification of isolates using culture-dependent techniques is also time-consuming. 
The advent of molecular-based techniques has greatly improved the precision and reliability 
of research outcomes and allows the analysis of non-cultivable members of the bacterial community 
(Tannock, 2002). Classical culture-independent methods include the polymerase chain reaction 
(PCR; specific amplification of a target DNA sequence), fluorescence in situ hybridization (FISH; 
direct detection of a target DNA or RNA site by a fluorescently-labelled probe molecule), denaturing 
gradient gel electrophoresis (DGGE), where DNA with the identical sequences migrate within a gel 
the same distance forming a “band” (Ye et al., 2001; Namsolleck et al., 2004; Sha et al., 2013). The 
DGGE analysis of the PCR-amplified 16S rRNA gene is now routinely-used to examine the 
diversity of microbial communities. The improved version of this reaction – real time PCR (qPCR, 
RT-PCR), allows amplifying and simultaneously-quantifying a targeted DNA molecule; hence, it has 
become a widely-used tool for analyzing microbiological communities (Heid et al., 1996; Gibson et 
al., 1996; Kanno et al., 2009). Though new technologies are constantly being developed and tend to 
be more effective in terms of sequence coverage, the ability of PCR to specifically-target particular 
markers, even at the strain level, allow it to remain a popular method in the molecular microbiology 
(Smith and Osborn, 2009). 
 
2.5.2 Next-generation sequencing and metagenomics 
Over the last two decades, capillary-based, semi-automated sequencing technology has 
gradually been replaced by next-generation sequencing (NGS) (Swerdlow and Gesteland, 1990; 
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Shendure and Ji, 2008; Karger and Guttman, 2009; Scholz et al., 2012). Several platforms used in 
NGS involve different biochemistry approaches; however, they have common functional scheme 
which includes the following steps: 1) fragmentation of DNA, 2) addition of adaptors/linkers; 3) 
purification, 3) amplification (on beads or glass), and 4) sequencing (by DNA-polymerase synthesis 
or ligation). Amplification steps as well as sequencing techniques differ for every platform. The 454 
Sequencing (Life Sciences, 2004) and SOLiD (Life Technologies, 2008) platforms use emulsion-
PCR, where the PCR reaction takes place in oil-in-water emulsion. Illumina technology involves 
bridge-PCR on the surface of glass flow cells (Fedurco, 2006; Mardis, 2008; Turcatti, 2008). The Ion 
Semiconductor Sequencing (or Ion Torrent), released by Ion Torrent Systems Inc. in 2010 (Rusk, 
2011) uses detection of hydrogen ions that are released during the polymerization of DNA, which is 
promoted as being a more-sensitive approach for the detection of each sequencing step than the use 
of CCD-cameras and lasers for detecting of light flashes (454 Sequencing) or fluorescence (Illumina) 
(Merriman et al., 2012).  
Perhaps the most promising area for high throughput DNA sequencing is the nanopore 
sequencing, which allows identification of single molecules using nanopores, built into a synthetic 
membrane (Clarke et al., 2009). Minute changes in ionic current across a membrane are measured 
and recorded when a single DNA molecule is driven through a nanopore (Stoddart et al., 2009). In 
contrast to other sequencing techniques, this approach allows direct targeting of single DNA 
molecules, enabling real-time sequencing, where reads are available for analysis as soon as they 
have passed through the sequencer. Though the platform has a high error rates (~ 12-35 % in reading 
accuracy) its real-time nature might be particularly important for clinical diagnostic applications and 
pathogen detection (Ashton et al., 2015; Laver et al., 2015; Chu et al., 2017). 
Both classical molecular biology methods and next-generation sequencing are widely-used 
for examining environmentally-derived samples of microbiological communities, as well as for 
animal and human microflora analysis. The genomic analysis by direct extraction and analysis of 
DNA from an assemblage of microorganisms is referred to as metagenomics and allows by-passing 
the need to isolate and culture individual members of a complex community, using direct genomic 
analysis instead (Handelsman, 2004). Generally, metagenomic analysis includes isolating of DNA, 
amplifying all genes of interest found in the sample, sequencing PCR products and, finally, 
classifying the data according to a database of assigned sequences. The gene of interest for analysis 
of bacterial communities is most commonly 16S rRNA; however chaperonin-60 (cpn60) gene was 
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also used for this purpose (Links et al., 2012). Examples of the metagenomic approach for the 
analysis of microflora can be found in the works of Ventura et al. (2009) and Riboulet-Bisson et al. 
(2012). The alternative to amplicon metagenomic sequencing is a shotgun approach, where all DNA, 
extracted from the community, is sheared into tiny fragments that are independently sequenced 
(Sharpton, 2014).  
Successful metagenomic analysis of a microbial community might be limited by a shortage 
of reference genomes. This limitation will seemingly be resolved soon with the rapid development of 
relevant and specialized databases. One of the major global research initiatives that has produced a 
massive amount of genomic data is The Human Microbiome Project (HMP). It was launched in 2008 
by an initiative of United States‟ National Institutes of Health and should be finished by the end of 
this year. HMP “focuses on describing the diversity of microbial species that are associated with 
health and disease” (Nelson et al., 2010). Different laboratories working on the project are using 
culture-independent approaches for microbial community characterization, such as metagenomics or 
whole genome sequencing. Detailed information and extensive databases can be obtained at 
www.hmpdacc.org. 
 
2.6 Prebiotics 
According to Roberfroid (2007), a prebiotic is a “selectively fermented ingredient that allows 
specific changes, both in the composition and/or activity in the gastrointestinal microflora, that 
confers benefits upon host well-being and health”. Currently, the majority of prebiotics used in food 
manufacturing are short-chain carbohydrates consisting of 3-10 monomers that are non-digestible by 
human or animal enzymes (Saad et al., 2013).  There are a large variety of these substances, 
including: inulin, fructo-oligosaccharides (FOS), galactooligosaccharides (GOS), isomalto-
oligosaccharides (IMO), xylo-oligosaccharides (XOS) and soy oligosaccharides (SOS). Most of 
these compounds are synthesized from more fundamental molecules (i.e., sucrose) or isolated from 
the depolymerisation of plant polysaccharides (Ouwehand, 2007; Kelly, 2009).  In food production, 
prebiotics see application as either as food supplements (powders, syrups) or are incorporated into 
food products (yogurts, breads) (Charalampopoulos and Rastall, 2012).  
Claims associated with prebiotic use include optimized colonic function and metabolism, 
reduced colonic pH, decreased nitrogenous end-products and reductive enzyme production, 
increased expression of binding proteins or certain biomarkers in the field of lipid and mineral 
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metabolism, and immune system modulation (Roberfroid, 2007; Saad et al., 2013). When combined 
with probiotic microorganisms (Lactobacillus spp., Bifidobacterium spp.), prebiotics are 
hypothesized to increase populations of helpful commensal bacteria (Davis et al., 2010), inhibit 
various human and animal pathogenic bacteria strains (Fooks et al., 1999; Saad et al., 2013), 
contribute to the treating of Clostridium difficile-associated diarrhoea and colitis disorders (Licht et 
al., 2012), and modify immune response by stimulating or inhibiting the secretion of various 
cytokines and interferons, modulating of NK (natural killer) cell activity and effecting lymphocyte 
proliferation (Delgado et al., 2011).  
Inulin-type prebiotics are fructans that have β(2→1) fructosyl-fructose glycosidic bonds and 
are resistant to enzymatic hydrolysis in the human GIT (Kelly, 2009). This class of prebiotics 
includes inulins and fructooligosaccharides (FOS). Inulins are polysaccharides, composed of 20 to 
several thousand fructose units, joined by a β (2→1) glycosidic bonds, with a terminal glucose. 
Fructooligosaccharides (FOS) are a subgroup of inulins, consisting of polymers with a degree of 
polymerization (DP) ≤10. Several clinical trials demonstrated a significant bifidogenic ability of 
inulin and its short-chain derivatives (Gibson et al., 1995; Buddington et al., 1996; Kleessen et al., 
1997; Closa-Monasterolo et al., 2013). It has also been reported that the addition of FOS to 
microcapsules containing B. adolescentis improved survival of the bacterium under simulated 
stomach conditions (Wood, 2010).  
One more prospective group of prebiotics are xylo-oligosaccharides (XOS) – sugar oligomers 
made up of xylose units linked through β-(1→4)-bonds (Aachary et al., 2011). According to Zeng et 
al. (2007), XOS accelerated the growth of B. adolescentis in vitro by 20 %. Investigation of 
fermentability of XOS by probiotic bacteria showed higher growth rates for B. adolescentis than B. 
longum, B. infantis and B. breve (total XOS consumption from the medium reached 77 % after 24 h) 
(Gullon et al., 2008). Arabinoxylan oligosaccharides (AXOS), which are XOS with arabinose side 
chains, are new prebiotics with the already-proven ability to increase the concentration of 
bifidobacteria in the intestines of animals (Van Craeyveld et al., 2008; Neyrinck et al., 2012). 
Results of clinical trials have also revealed the significant increase in the population of bifidobacteria 
after AXOS intake, thus suggesting the use of these polysaccharides as prospective prebiotics 
(Cloetens et al., 2008).  
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2.7 Protective methods and coatings 
The effective delivery of probiotics in sufficiently high numbers to the intestine for a benefit 
to be realized remains a practical challenge. When entering the stomach, bacteria are exposed to 
adverse environmental conditions such as low pH and pepsin. The probiotic food product should 
contain protective substances that prevent the number of viable bacteria from becoming reduced so 
that they can reach the colon in sufficient number in order to provide a functional effect or benefit to 
the human or animal host. The most efficient method for protection of bacteria from harmful 
influence of acid and bile is their encapsulation within single or multiple biopolymer coatings, 
varying of biopolymer concentration and increasing of initial cell loads (Chandramouli et al., 2004; 
Petrović et al., 2007; Annan et al., 2008). The survival of bacteria is related to the structural integrity 
of capsules, which involves various testing of different wall components to select favourable 
variants, such as microcapsules that are insoluble at acidic pH but dissolve when exposed to the 
alkaline pH of the intestine (Narayani and Rao, 1995a, 1995b; Nickerson et al., 2006). Capsules also 
need to be non-toxic and pepsin-resistant.  
One additional important factor that has a significant impact on the survival of bacterial cells 
in acidic environments is the size of the capsules. To ensure significant protection, microcapsules 
should be 1-3 mm in size, a size that can be unfavourable for the incorporation of microcapsules into 
food products due to textural/organoleptic effects (Champagne and Fustier, 2007). Alternatively, 
microcapsules with diameters 40-80 μm were insufficient to provide the required protection 
(Truelstrup Hansen et al., 2002).  In any event, the size of the protective microcapsules need to be 
determined in each case according to the intended use.  
With respect to capsule wall composition, preference is usually given to natural 
hydrocolloids and gums that are generally recognized as safe (GRAS) for human health and show 
good protection of bacterial cells when challenged with the acidic environment of the gut: alginate, 
carrageenans and gums (Holzapfel and Schillinger, 2002; Shah et al., 2007; Bajaj et al., 2007; 
Morris et al., 2012). These biopolymers possess such useful features as viscosity (thickening or 
gelling), water binding, emulsion stabilization, adhesion, foam stabilization and film formation 
(Chaplin, 2012). Due to these properties, it is easy to achieve various textures and forms by altering 
and combining physical factors.  
Two commonly-used polymers for immobilizing viable bacterial cells are sodium alginate 
and k-carrageenan (McMaster et al., 2005; Petrović et al., 2007; Annan et al., 2008). Gellan and 
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xanthan have also been used for capsule formation. These two polymers, when applied as a mixture, 
show significant protection of cells from synthetic stomach juice in vitro (Sun and Griffiths, 2000; 
McMaster et al., 2005). Another microencapsulation variation involves rennet-gelation of milk 
proteins and compression capsulation (bacterial powders are first compressed into a pellet, which is 
then encapsulated with a coating material of a combination of sodium alginate and hydroxypropyl 
cellulose by further compression) (Chan and Zhang, 2005; Heidebach et al., 2009).  
One of the main criteria for success of any candidate protective coating approach is for it to 
promote the survival of bacteria in amounts equal to or greater than 7 Log CFU/ml
-1
 after being 
exposed to unfavorable conditions in stomach (Kotikalapudi et al., 2009).  
 
2.7.1 Alginate 
According to many  studies examining the immobilization of live bacteria (Champagne and 
Fustier, 2007; Annan et al., 2008; Chávarri et al., 2010; Voo et al., 2011), the most common 
material for encapsulation is alginate. This biopolymer is of algal origin and composed of (1 → 4)-
linked β-D-mannuronic (M) and α-L-guluronic acid (G) residues (Voo et al., 2011). Water-holding 
capacity and solubility of alginate depends on various extrinsic factors such as pH, ionic strength and 
the origin of ions. For example, when sodium alginate is added to aqueous calcium chloride, it forms 
a water-insoluble, gelatinous substance known as calcium alginate (Fig. 2.1). This property of 
alginate has been widely-used for the entrapment of probiotic bacteria. Bacterial cultures are added 
into an aqueous alginate solution, and in the presence of calcium chloride, leads to the formation of 
alginate microcapsules containing the bacteria.  
 
Figure 2.1. Two-dimensional network structure of calcium alginate (adapted from Degen et al., 
2015). 
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Since Bifidobacterium strains prefer anaerobic conditions, compared to other probiotic 
microorganisms (e.g., streptococci), it is preferable to use alginate microcapsules for their delivery 
into the GIT (Champagne and Fustier, 2007). Though alginate is widely-used for bacterial cell 
encapsulation, it is associated with certain disadvantages, including low tolerance to stomach acids 
(Krasaekoopt et al., 2003). 
 
2.7.2 Iota-carrageenan 
Carrageenans are also extracted from algae, specifically from Eucheumu spinosum (Gunning 
et al., 1998). These algal polysaccharides have a linear structure and high molecular weight. They 
are composed of sulfated and non-sulfated galactose and 3,6-anhydrogalactose units, joined by 
alternating -(1,3) and -(1,4) glycosidic bonds. Various types of carrageenans (kappa, iota, lambda) 
differ mostly in their degree of sulfate substitution (Hambleton et al., 2009). Iota carrageenan has 
more sulphate groups than kappa, which makes it more hydrophilic (Luna et al., 2010;Fig. 2.2).  
 
Figure 2.2. Molecular structure of iota carrageenan (adapted from Hamman, 2010). 
In aqueous solutions, iota-carrageenan dissolves at temperatures 60 to 80°C and produce 
thermo-reversible gels on cooling to room temperature (Gbassi and Vandamme, 2012). However, 
high temperatures combined with pH < 3.5 can cause damage to the molecular structure. In 
comparison with kappa-carrageenan, the iota- form is more stable after being subjected to freeze-
drying (Imeson, 2000). According to an X-ray investigation conducted by Janaswamy and 
Chandrasekaran (2002), calcium ions and water molecules mediate interactions between the sulfate 
groups of neighboring helices, thereby stabilizing the three-dimensional structure of iota-
carrageenan.  
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2.7.3 Gellan gum 
Gellan gum is produced by the aerobic, Gram-negative bacterium, Pseudomonas elodea, as a 
fermentation product which is extractable with isopropyl alcohol. It is an anionic deacetylated 
exocellular polysaccharide of high molecular weight (Shah et al., 2007). Gellan gum structure is 
based upon repeating tetrasaccharide units that include one α-L-rhamnose, one β-D-glucuronic acid 
and two β-D-glucose residues (Fig. 2.3).  
 
Figure. 2.3. Repeating units of chemical structure of deacetylated gellan gum (adapted from Bajaj, 
2007). 
Deacylation transforms soft, elastic thermo-reversible native gellan gum to harder and more 
brittle gels with higher thermal stability. Deacylated gellan gums are water-soluble, resistant to pH 
3.5-10 and form double-helices on cooling in the presence of monovalent or divalent cations, which 
results in gelation (Shah et al., 2007; Morris et al., 2012). Several studies have demonstrated the 
utility of using gellan gum as a wall material for probiotic-containing microcapsules. However, 
others have reported that it is better to use gellan gum in combination with other polymers, such as 
xanthan gum, jamilan and sodium alginate, as it changes viscoelastic behaviour of the mixture, 
improving functional properties of capsules (Chen et al., 2007; Jiménez-Pranteda et al., 2012a, 
2012b). 
 
2.7.4 Pea protein isolate 
The use of pea protein isolate (PPI) in the food industry is gaining popularity due to its 
hypoallergenic properties and low concentrations of by-products (8-12 % (v/w) of the protein) 
(Franco et al., 2000; Tömösközi et al., 2001). PPI is extracted from field peas (Pisum sativum) and 
contains two major globulin proteins: legumin (Lg; 350-400 kDa) and vicilin (Vn; 150 kDa) (Ducel 
et al., 2004). Several studies have proven the advantages of using PPI in combination with calcium 
alginate during the formation of probiotic-containing microcapsules (Kotikalapudi et al., 2010; 
Klemmer et al., 2011), where PPI enhanced protection of bacterial cells in the simulated gastric 
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juice. In order to form stable interactions with polyanions such as alginate, carrageenan or gellan 
gum, PPI requires an overall positive charge. Since the isoelectric point of PPI is pH ~ 4.5, 
favourable conditions for coacervation would occur at pH < 4.5. At pH > pI, PPI is negatively-
charged, which leads to segregative phase separation upon mixing with polyanions. In order to 
determine the proper conditions for formulation of stable interactions between protein and 
polysaccharide, the influence of various factors on complex formation needs to be evaluated (e.g., 
concentration, ratio, biopolymer-type, reactive groups present, molecular weight, pH, temperature, 
concentration of ions in the solution) (de Kruif et al., 2004). 
 
  
2
Varankovich, N. V., Khan, N. H., Nickerson, M. T., Kalmokoff, M., and Korber, D. R. (2015a). 
Evaluation of pea protein–polysaccharide matrices for encapsulation of acid-sensitive bacteria. Food 
Res Int 70, 118–124 
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3 IN VITRO AND IN VIVO EVALUATION OF PROTEIN–POLYSACCHARIDE 
MATRICES FOR ENCAPSULATION OF ACID-SENSITIVE BACTERIA
2
 
3.1 Abstract 
Protein-polysaccharide microcapsules containing Bifidobacterium adolescentis were 
produced and tested in a series of in vitro survival experiments to evaluate capsule protection of the 
bacterium to simulated stomach conditions, as well as their ability to release the encapsulated 
bacteria under conditions similar to those found in the lower gut. A protein fraction isolated from 
peas (pea protein isolate: PPI; 2.0 %; w/v) was mixed with each of three different polysaccharides 
(0.5 % (w/v) of either sodium alginate, iota-carrageenan and gellan gum) to produce microcapsules 
ranging in size from 2 to 3 mm diameter. All capsule formulations provided significant protection 
for cells exposed to synthetic stomach juice at 37C relative to non-encapsulated bacteria. In 
addition, PPI-alginate and PPI-iota-carrageenan microcapsules were found to dissolve in simulated 
intestinal fluid at 37C, releasing 70-79 % of their bacterial “payload” within 3 h, with higher cell 
numbers being released from the freeze-dried capsules. PPI-gellan gum microcapsules did not 
dissolve to the same extent and the number of released cells was ~ 26-30 % lower.  Following a 
temporal rat feeding study with the test bacterium encapsulated in PPI-alginate, B. adolescentis-
specific PCR and qPCR analyses confirmed the presence of DNA from this species in rat feces, but 
only during the period of capsule intake. 
  
3.2 Introduction 
The term probiotic refers to living microorganisms that confer a health benefit, when 
administered in adequate amounts (FAO/WHO, 2001). The most common microorgansims claimed 
to function as probiotics are Lactobacillus, Enterococcus, Bifidobacterium, yeasts and bacilli strains.
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In 2008, the global probiotic supplement market (i.e., pills, caplets) was worth approximately $1.5 
billion, and is expected to reach $31.1 billion by 2015, 
with a compound annual growth rate of 7.6 % over the previous 5-year period (Champagne et al., 
2011; Pedretti, 2013).  
The delivery of beneficial bacteria to the gastrointestinal system of the host is often 
implemented in two different ways: either utilizing conventional pharmaceutical delivery 
systems (polysaccharide or protein capsules, beads, etc.) or through direct incorporation in 
commercial products, such as yogurts, creams or milk (Govender et al., 2014). While the latter type 
is rarely regulated or controlled in terms of probiotic bacterial loads, conventional systems differ 
greatly in formulation processes and utilize materials of various origins: seaweed (carrageenan, 
alginate), other plants (starch, gum Arabic), bacteria (gellan and xanthan gums) and animal proteins 
(milk, gelatin) (Rokka and Rantamäki, 2010). Over the past decade, plant-based proteins have been 
experiencing greater market growth than seen for proteins of animal origin, such as in the case of 
widely-used gelatin, casein, ovalbumin and whey (Klassen, 2010). Currently, the most promising 
approach for the use of plant proteins in the area of probiotics is to blend them with polysaccharides 
to improve protein functionality and create protective capsules containing immobilized probiotic 
bacteria (Klemmer et al., 2011; Jiménez-Pranteda et al., 2013; Khan et al., 2013). The ideal capsule 
would allow the protection of entrapped cells during exposure to the harsh conditions of the upper 
gastrointestinal tract, followed by the release of bacteria in the lower gut. Encapsulation within 
single or multiple biopolymer coatings was proposed as an effective method to protect potential 
probiotics from the harmful effects of stomach acid and bile (Sun and Griffiths, 2000; Chandramouli 
et al., 2004; Petrović et al., 2007; Annan et al., 2008). With respect to capsule wall composition, 
preference has usually been given to natural hydrocolloids and gums that are generally recognized as 
safe (GRAS) and which show good protection of bacterial cells against acidic environment of the 
stomach; for example, alginate, carrageenan and gums (Holzapfel and Schillinger, 2002; Shah et al., 
2007; Bajaj et al., 2007; Morris et al., 2012).  Sodium alginate, iota-carrageenan and gellan gum are 
widely-used by the food industry and undergo gelation in the presence of divalent calcium ions, 
making them ideally suited for the extrusion-based encapsulation process. However, with the 
exception of alginate, their use as encapsulating agents has been limited. Capsules containing 
probiotics are also often dried for distribution and storage. The most promising technology in this 
regard is freeze-drying, due to milder conditions of this process that helps to prevent excessive losses 
 33 
of cell viability (Tsen et al., 2002; Kurtmann et al., 2009; Semyonov et al., 2010; Martin-Dejardin et 
al., 2013). 
The goal of this study was to further examine the suitability of pea protein isolate mixed with 
sodium alginate, iota-carrageenan or gellan gum, as protective materials for acid-sensitive 
Bifidobacterium adolescentis under simulated stomach conditions, along with the ability of the 
microcapsules to release bacterial cells under simulated conditions of the lower intestinal tract using 
both fresh and freeze-dried capsules. The efficacy of pea protein isolate-alginate (PPI-alginate) 
microcapsules as a delivery system for B. adolescentis was also tested in vivo using an animal model 
system. 
 
3.2 Materials and methods 
3.2.1 Ethics statement 
The study was carried out in strict accordance with the Canadian Council on Animal Care 
Guidelines. Ethical approval for the animal study was obtained from Health Canada (Ottawa, 
Canada) (Protocol No. 2013-008). 
 
3.2.2 Materials 
Pea protein isolate was kindly donated by Nutri-Pea Ltd. (Portage La Prairie, MB, Canada). 
Alginic acid sodium salt, calcium chloride dihydrate, Tween 80 and iota-carrageenan were 
purchased from Sigma-Aldrich (Oakville, ON, Canada). Deacetylated gellan gum (Kelcogel F) was 
purchased from CP Kelco U.S., Inc. (San Diego, CA, USA). 
 
3.2.3 Bacteria and culture conditions 
Bifidobacterium adolescentis ATCC
®
 15703
TM
 was stored at −80°C in a 1:2 (v/v) suspension 
of glycerol and MRS broth. Prior to bacterial encapsulation, frozen stock was plated on de Man, 
Rogosa and Sharpe (MRS; Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) semi-solid medium 
containing 0.05 % (v/v) L-cysteine and 1.5 % (w/v) agar and then incubated for 24 h at 37°C under 
anaerobic conditions (80 % N2, 10 % CO2 and 10 % H2) in an anaerobic chamber (Forma Scientific 
Inc., Marietta, GA, USA). Pure colonies of B. adolescentis were then transferred from plates to 50 
mL tubes containing 45 mL of MRS-cys broth for incubation under the same conditions for 24 h, 
which corresponded to the stationary phase of growth (Wood, 2010). Bacterial cells were then 
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recovered by centrifugation (2000 g x 12 min) (Sorvall SS-1, Sorvall Inc., Newtown, Connecticut, 
USA), washed twice with 1.0 % alkaline peptone water (APW; 10 % (w/v) peptone, 10 % (w/v) 
sodium chloride; pH 8.5) and used for preparation of capsules. 
 
3.2.4 Preparation of bacteria-containing capsules 
The methodological approach of this research was based on encapsulation and extrusion 
techniques used by Klemmer et al. (2011) and Krasaekoopt et al. (2003), with modifications. The 
composition of the wall material was as follows: 2.0 % PPI + 0.5 % (w/w) polysaccharide (alginate, 
iota-carrageenan or gellan gum). Concentration of PPI was adjusted to the protein content of the 
isolate (85 %); whereas, the polysaccharide concentration was used as is, on a per-weight basis. 
Protein isolate was dissolved at 85°C and pH 9.0 for 2 h. Then pH was then adjusted to 7.0 and a 
specific polysaccharide was added to the mixture. After complete dissolution of the polysaccharide 
(1-1.5 h at 85°C), the solution was cooled to room temperature (21-23°C) and mixed with a 2.0 % 
(v/v) bacterial slurry preparation, recovered by centrifugation from 24 h bacterial broth culture 
(optical density at 600 nm was equal to 1.305 (n=3) as measured using a Genesys 10S UV-Vis 
Spectrophotometer, Thermo Fisher Scientific, Madison, WI, USA).   
 The final mixture (a blend of protein, polysaccharide and bacteria) was then extruded using a 
syringe and 18G (G, gauge) needle into 200 mL of deionized distilled water (ddH20) containing Ca
2+ 
ions (cross-linking agent) and Tween 80 (emulsifier). The concentrations of Ca
2+
 (CaCl2) and Tween 
80 were determined empirically, depending on their effect on uniformity of capsule morphology and 
protective properties of capsules. For PPI-sodium alginate capsules, concentrations of CaCl2 and 
Tween 80 were 1.0 % (w/v) each; for PPI-iota-carrageenan microcapsules they were 2.0 % (CaCl2; 
w/v) and 1.5 % (Tween 80; w/v); and for PPI-gellan gum capsules, concentrations of 2.25 % (CaCl2; 
w/v) and 1.0 % (Tween 80; w/v) were used. Lower concentrations of CaCl2 were not sufficient for 
proper cross-linking to occur in order to form a capsule, whereas at higher CaCl2 concentrations, 
irregular-shaped microcapsules (i.e., bell-shaped) were formed. Prepared microcapsules were 
immediately used in subsequent survival and release experiments, as described below (and labeled as 
„fresh‟ capsules). To investigate the performance of dried microcapsules with immobilized B. 
adolescentis, microcapsules containing bacteria were freeze-dried (Labconco FreeZone, Kansas 
City, MO, USA) for 15 h and then were used in survival and release studies, conducted according to 
methods described below (and labeled as „freeze-dried‟ capsules). 
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3.2.5 Survival of B. adolescentis in PPI-polysaccharide microcapsules under simulated 
stomach conditions  
 For survival studies, aliquots of 0.1 g of fresh or 0.01 g of freeze-dried microcapsules were 
added to centrifuge tubes (2 mL) containing 0.9 mL (or 0.99 mL in case of dried capsules) of 
synthetic stomach juice (SSJ; 8.3 g/L proteose peptone, 3.5 g/L glucose, 2.05 g/L NaCl, 0.6 g/L 
KH2PO4, 0.11 g/L CaCl2, 0.37 g/L KCl, 0.05 g/L bile salts, 0.1 g/L lysozyme, 13.3 mg/L pepsin; pH 
1.8) (Pedersen et al., 2004; Khan et al., 2013) and incubated for 2 h at 37°C. Starting at time 0, then 
every 5 min over the first 30 min, and subsequently every 30 min, tubes of each capsule type (fresh 
and freeze-dried, PPI-alginate, -iota-carrageenan and -gellan gum capsules) were removed from the 
incubator. Capsules were immediately washed with 1.0 % APW, homogenized (Omni-mixer, Sorvall 
Inc., Newtown, USA) at 2,000 rpm for 2 min, serially-diluted with 1.0 % APW and plated on MRS-
cys agar to evaluate cell survival. The same procedure, but without SSJ treatment, was used to 
determine the initial counts of cell within capsules. Plates were incubated at 37°C in an anaerobic 
chamber for 48 h and then enumerated and reported as log CFU/g. Survival of non-encapsulated free 
bacterial cells were determined according to the same method, but without homogenizing, and was 
used as a control. Experiments were conducted in triplicate. The amount of time for a 1-log 
reduction in cell number to occur was determined and represented as the D-value, which was 
calculated by the end-point method, utilizing initial and terminal time points: D = U/(log No-logNu), 
where D is the D-value, U = exposure time, No = CFU/g at 0 min, Nu = CFU/g at 120 min.  
 
3.2.6 Release of B. adolescentis from PPI-polysaccharide microcapsules under simulated 
intestinal conditions  
For cell release studies, 0.1 g of fresh- and 0.01 g of freeze-dried microcapsules of each type 
were added to 9.9 mL or 9.99 mL of simulated stomach juice, respectively, and then incubated for 2 
h at 37°C. After 2 h, 0.1 g of microcapsules were removed from SSJ and added into 9.9 mL of 
simulated intestinal fluid (1.25 % (w/v) NaHCO3, 0.60 % (w/v) bile salts, 0.09 % (w/v) pancreatin; 
pH 6.5) and incubated under anaerobic conditions for 3 h at 37°C. Every hour, a 0.1 mL aliquot of 
the sample was removed, serially-diluted using 1.0 % APW, and plated on MRS-cys agar. The plates 
were incubated at 37°C in anaerobic chamber for 48 h and then enumerated. Viable counts were 
conducted in triplicate. 
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3.2.7 Size of bacteria-containing capsules 
PPI-polysaccharide-bacteria mixtures were extruded through an 18G needle into cross-
linking solution. The size of fresh and freeze-dried microcapsules was measured using an electronic 
digital caliper (model 62379-531, Coltrol Company, Friendswood, TX, USA). Fifteen microcapsules 
from two separate batches for each capsule type were measured and averaged. 
 
3.2.8 Confocal Laser Scanning Microscopy (CLSM) 
The internal structure of bacteria-containing microcapsules was analyzed by CLSM. Both 
fresh and simulated stomach juice-treated microcapsules were cut in half with a sterile scalpel, 
stained and immediately immobilized on the surface of a cover glass using molten 0.8 % (w/v) agar, 
tempered to 40-45°C. After the agar solidified, the agar cover glass was inverted and transferred to a 
glass chamber made from glass slides and filled with tempered, but still liquid agar, for further 
immobilization of the capsules. Staining of the microcapsules was performed using SYTO 9 (5 mM 
solution in DMSO; Life Technologies
TM
 Corp., Carlsbad, CA, USA) according to the guidelines 
provided by Life Technologies™ (SYTO 9 Manual, 2011). The dye (1 μL) was then added to 2 ml 
water, vortexed, directly applied to the capsule surface and then incubated for 15 min in the dark. 
Glass chambers with stained bacteria-containing microcapsules were analyzed by a Nikon C2 CLSM 
microscope (Nikon, Mississauga, ON, Canada) equipped with a 60X Plan Apo VC (N.A. 1.4, Nikon) 
objective lens and a blue diode 488 nm laser. Three representative locations on the samples were 
randomly-chosen for obtaining optical thin sections of the capsule surface and stained bacteria. 
Accordingly, a series of xy confocal images of microcapsules were obtained over the z-dimension (to 
a 50 m depth) using a z-step increment of 0.5 m (or 1.0 m in case of fresh PPI-alginate capsules). 
Each image was taken with a xy-resolution of 512 by 512 pixels and a pinhole radius of 20. Selected 
stacks of images were then converted to maximum intensity projections. 
3.2.9 Animal feeding study 
PPI-alginate microcapsules containing B. adolescentis were fed to rats. The animal feeding 
trial was conducted at the Bureau of Nutritional Sciences at Health Canada (Ottawa, ON, Canada). 
Wistar rats (Health Canada, Animal Resources Division; n = 24) were fed an AIN93G purified diet 
(Research Diets, Inc., New Brunswick, NJ, USA) over a period of 7.5 weeks. Freeze-dried PPI-
alginate microcapsules (0.5 g) were mixed with peanut butter (PB) prior to feeding. Animals were 
observed to consume all the PB-capsules per feeding time. Dosing of bacteria-containing 
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microcapsules was started 2.5 weeks after animal arrival. In order to ensure the nutritional adequacy 
of the supplement, an AIN mineral mix (Reeves et al., 1993: 1.0 %; w/w) and AIN vitamin mix (1.5 
%) were added to the PB. Capsules were first ground for 1 min using an ethanol-sterilized Black & 
Decker CBM210 coffee grinder (low speed setting) (Black & Decker Corp., Towson, Maryland, 
USA) to make smaller pieces to minimize the animal‟s ability to selectively graze the PB-capsule 
treatment. Animals were grouped according to diet, as follows: 1) AIN93G + PB; 2) AIN93G + PB 
+ PPI-alginate microcapsules without encapsulated bacteria, and 3) AIN93G + PB + PPI-alginate 
microcapsules containing B. adolescentis. PB was added to the diet 6 days prior to the start of 
encapsulated bacterial treatment (day 1). The capsule intake was ceased on day 28. Reverse 
light/dark cycles were used: 7:00 pm – light, 7:00 am – dark. Animals were fasted for 4 h before 
feeding. Diet supplementation occurred at 11:00 am. Fecal pellets were collected from screens at 1 
pm on days 0, 3, 8, 15, 23, 29, 36, 43, 51 and 57. Fecal pellets from each rat were preserved at -80ºC 
until time of DNA extraction.  
DNA was extracted from feces (0.1 g) taken from fecal pellets from two rats from each group 
using the Fast DNA SPIN Kit for Soil (MP
 
Biomedicals LLC, Solon, OH, USA), quantified using a 
Qubit® 2.0 Fluorometer (Life Technologies
TM 
Corp., Carlsbad, CA, USA) and amplified by the 
polymerase chain reaction (PCR), using primers B_ado-F and B_ado-R (see Table 3.1) (Junick and 
Blaut, 2012), specific for the groEL gene of B. adolescentis, and a TC-412 thermocycler (Techne 
Ltd., Duxford, Cambridge, UK). The reaction mix (50 L) contained: Taq PCR Master Mix (Qiagen 
Sciences, Maryland, USA) – 20.0 L, B_ado-F – 1.0 L, B_ado-R – 1.0 L, DNA template – 1.0 
L, nuclease-free ddH2O (HyClone Laboratories Inc., Logan, Utah, USA) – 27.0 L. The thermal 
cycle program was as follows: initial denaturation at 95ºC for 5 min, followed by 35 cycles of 
denaturation (95ºC, 45 s), annealing (62ºC, 45 s) and elongation (72ºC, 45 s), with a final elongation 
step of 10 min at 72ºC. PCR products were analyzed using gel electrophoresis on a 1.5 % (w/v) 
agarose gel.   
The DNA for qPCR was extracted from fecal samples using QIAamp DNA Stool Mini kit 
(Qiagen Sciences, Maryland, USA) according to manufacturer‟s protocol, with modifications. 
Quantitative PCR assays were conducted in polypropylene PCR plates in a ViiA7 Real-Time PCR 
System (Applied Biosystems, Foster City, CA, USA). All determinations were carried out in 
triplicate. The 10.0 μL qPCR reactions contained: 5.0 µL of 2X Brilliant III SYBR Green qPCR 
Master Mix (Agilent Technologies, Mississauga, ON), 1.0 µL of each primer (5.0 µM; Sigma-
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Genosys Canada, Oakville, ON; Table 3.1), 2.0 µL molecular-grade water (Thermo Fisher Scientific, 
Waltham, MA, USA) and 1.0 μL of template DNA.  PCR conditions were 3 min at 95ºC, followed 
by 35-40 cycles of 95ºC for 5 s and 15 s at the annealing temperature (Table 3.1).  A melting curve 
analysis was conducted following the PCR reaction.   
 
3.2.10 Statistics 
Standard deviation, mean values and P-values within each group, as well as between groups, 
were determined using Two-Way ANOVA. The level of statistical significance was set at p < 0.05. 
All statistical analyses were performed using SPSS software (SPSS Inc., Ver. 17.0, 2008, Chicago, 
IL, USA). Graphs were created in SigmaPlot 11.0 (Systat Software, Inc., Chicago, IL).  
 
  
 
Table 3.1. Primers and cycling conditions for PCR and qPCR. 
Primer 
name  
Target Primers sequence (5‟-3‟) Anneal. 
temp. 
No. of 
cycles 
Reference 
Bif582 
Bif815 
Bifidobacterium spp. GGTGTGAAAGYCCATCGC 58 35 Health Canada  
(S. Brooks)  CACATCCAGCRTCCACCG 
HDA1 
HDA2 
Total bacteria ACTCCTACGGGAGGCAGCAGT 60 35 Walter et al., 2000 
GTATTACCGCGGCTGCTGGCA 
BiADO-1 
BiADO-2 
16S rRNA B. 
adolescentis 
CTCCAGTTGGATGCATGTC 55 40 Matsuki et al.,  
2003 CGAAGGCTTGCTCCCAGT 
B_ado-F 
B_ado-R 
groEL B. adolescentis CTCCGCCGCTGATCCGGAAGTCG 72 40 Junick and Blaut, 
2012 AACCAACTCGGCGATGTGGACGACA 
 
  
3
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3.3 Results and discussion 
3.3.1 Survival of immobilized B. adolescentis cells in microcapsules exposed to synthetic 
stomach juice (SSJ) 
Viability of B. adolescentis was monitored over a 2 h exposure to SSJ to determine the effect 
of encapsulation on their survival. Viability loss in planktonic cells was used as the control. 
Planktonic cells showed a significant decline in numbers over the first 30 min in SSJ, and a complete 
loss of viability following 90 min exposure (DSSJ = 11.46 min; Fig. 3.1A). In contrast, all three types 
of encapsulated bacteria (PPI-alginate, PPI-iota-carrageenan, PPI-gellan gum) demonstrated 
significant (p < 0.05) retention of viability compared to planktonic cells (Fig. 3.1A). Total viability 
loss was similar for all types of microcapsules (~ 1.0-1.5 log reduction in CFU/g).  
The effect of freeze-drying on the protective properties of microcapsules was also tested by 
repeating these determinations. All three types of freeze-dried microcapsules protected the cells from 
the detrimental effect of SSJ compared to planktonic cells (Fig. 3.1B). There was no significant 
difference in cell viability amongst different types of freeze-dried microcapsules (p > 0.05), similar 
to the trend observed for fresh capsules. DSSJ-values for PPI-alginate, PPI-iota-carrageenan and PPI-
gellan gum were 59.90, 56.80 and 46.20 min, respectively. Overall, the loss in viability following a 2 
h exposure to simulated stomach juice was similar for all types of freeze-dried microcapsules (~ 2-
2.5 log reduction in CFU/g).  
 
3.3.2 Release of encapsulated cells 
Following treatment for 2 h in SSJ, microcapsules were transferred to simulated intestinal 
fluid (SIF) for 3 h at 37C. All formulations of both fresh and freeze-dried microcapsules  released 
the majority of the encapsulated cells (Fig. 3.2A and B). Following treatment, PPI-iota-carrageenan 
microcapsules released the highest number of cell (7.4 log CFU/g) following incubation in SIF. 
Similar numbers of cells were released from the PPI-alginate microcapsules (7.0 log CFU/g). In 
contrast, PPI-gellan gum microcapsules released far fewer cells (4.0 log CFU/g), due to the greater 
resistance of PPI-gellan gum complex to degradation by SIF (Fig. 3.2A).  Freeze-dried 
microcapsules released slightly more bacteria than fresh microcapsules (7.9, 7.5 and 5.3 log CFU/g 
for PPI-iota-carrageenan, PPI-alginate and PPI-gellan gum capsules, respectively; Fig. 3.2B).  
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Figure 3.1. Decrease in B. adolescentis cell counts in fresh (A) and freeze-dried (B) microcapsules 
after 2 h in synthetic stomach juice. 
 
B 
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3.3.3 Size of bacteria-containing capsules 
 In these experiments, all microcapsules were produced by extrusion of the polysaccharide-
protein matrix mixed with bacterial cells into the cross-linking solution using an 18G needle. The 
resultant size of both fresh and freeze-dried PPI-alginate microcapsules was ~ 2 mm in diameter 
(Fig. 3.3A). Treatment with SSJ for 2 h at 37C had no significant effect on capsule size (Fig. 3.3B). 
PPI-iota-carrageenan microcapsules were elliptical and decreased slightly in size from ~ 3 x 2 mm to 
~ 2.5 x 1.5 mm after freeze-drying (Fig. 3A). When transferred to SSJ, these microcapsules became 
spherical and decreased in size to ~ 2 x 1.5 mm (fresh capsules) and ~ 2 x 2 mm (freeze-dried 
capsules; Fig. 3B). Fresh PPI-gellan gum microcapsules had an initial size of ~ 3.5 x 3 mm, which 
became reduced by ~ 3 x 2 mm after freeze-drying (Fig. 3.3A). After transferring to SIF, both fresh 
and freeze-dried PPI-alginate and PPI-iota-carrageenan microcapsules became dissolved in the 
solution after 3 h (Fig. 3.3C). PPI-gellan gum microcapsules of both types did not dissolve, but did 
change shape and size, becoming spherical and ~ 3 mm in diameter. The dissolution of PPI-alginate 
and PPI-iota-carrageenan microcapsules under simulated conditions of lower GIT might also be an 
asset due to the increased amount of viable bacteria released.  
 
3.3.4 CLSM imaging of the internal structure of bacteria-containing capsules 
 All three types of microcapsules (both fresh and freeze-dried) were examined using confocal 
microscopy to characterize the internal capsule structure and spatial distribution of cells. CLSM 
images of stained (SYTO-9), bisected fresh microcapsules revealed that the cells were evenly 
distributed within the microcapsules (Fig. 3.4A). Cells were immobilized on the surface of pea 
protein particles (which emitted green autofluorescence) and within the unstained polysaccharide 
(transparent background; Fig. 3.4A). In freeze-dried microcapsules (Fig. 3.4B), protein globules 
were slightly deformed and surrounded by layers of polysaccharide containing entrapped bacteria, 
forming pores separated by protein-polysaccharide walls.   
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Figure 3.2. Release of B. adolescentis cells from fresh (A) and freeze-dried (B) microcapsules after 
2 h in simulated intestinal fluid. 
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3.3.5 Animal feeding trial 
Genus-specific and species-specific oligonucleotide primer sets targeting the Bifidobacterial 
16S rRNA gene and the GroEL gene of B. adolescentis were used to confirm the presence of DNA 
from this organism in the feces of rats fed PPI-alginate-immobilized cells.  Universal primers were 
used to determine the total amount of bacteria in samples (Table 3.1).  
Fecal community DNA was extracted from rat feces on days 0 (the first day of PPI-alginate 
microcapsules intake), 8, 29 (the first day after elimination of probiotic supplement), 36, 43 and 57. 
The results of PCR with B. adolescentis-specific primers, followed by gel electrophoresis, 
demonstrated an increased amount of B. adolescentis in the GIT of rats that were fed PPI-alginate 
microcapsules containing bacteria on days 8 and 29 (data not shown). However, there were no 
amplicons that corresponded to B. adolescentis present in gels from days 36, 43 and 57, which 
suggests that the elimination of delivered bacteria from animal GIT occurred within one-week post-
supplementation.  
Quantitative PCR data showed an increase in the number of gene copies per ng (both 16S 
rRNA and groEL) of B. adolescentis in DNA extracted from fecal samples of rats receiving the 
encapsulated bacteria supplement (Fig. 3.5). The samples used in this experiment were collected on 
day 29. On average, Bifidobacteria made up 1-1.5 % of the total community 16S rRNA gene content 
(3.5-4.0, compared to 6.1 log 16S rRNA gene copies per ng of DNA) (Fig. 3.5) and there was no 
difference in 16S rRNA gene copies between dietary treatments (Fig. 3.5). Bifidobacterium 
adolescentis encompassed ~ 16-28 % of total fecal Bifidobacteria in the rat group that received the 
encapsulated bacteria supplement, depending on the primer set used for quantification (Fig. 3.5). 
There were no B. adolescentis detected by qPCR in samples taken from animals in groups that did 
not receive the encapsulated bacteria. Seven days after encapsulated B. adolescentis supplementation 
ended, DNA from this species was no longer detectable in feces. The amount of B. adolescentis 
groEL gene copies was lower than that of 16S rRNA due to differences in gene copy numbers per 
cell: only one copy is present for the chaperonin gene whereas 5 copies exist for the rRNA gene.  
Previously, Wood et al. (2010) found that microcapsules composed solely of alginate (1.0 %; 
w/v) were unable to provide any significant protection to B. adolescentis ATCC 15703 during a 2 h 
incubation in simulated gastric juice.  The inability to protect the cells was attributed to the presence 
of large pores (~ 400 µm) on the surface of these capsules. This is in marked contrast to Lee and Heo 
(2000) who reported only a 2 log CFU/mL decrease in viable cell numbers of Bifidobacterium 
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longum encapsulated in 2.0 % (w/v) alginate and held under similar conditions. This difference 
might be attributed to a higher degree of acid tolerance of B. longum, as different species of 
bifidobacteria have varying sensitivities to acidic conditions (Waddington et al., 2011). In addition, 
this may also reflect difference in the size of bead. Generally, the larger the bead, the greater the 
protective effect of immobilization.  
Our findings from in vitro survival tests are supported by other investigations. Klemmer et al. 
(2011) reported an ~ 1.0 log CFU/mL reduction of viable cell counts for PPI-alginate microcapsules 
(2.0 % w/v and 0.5 % w/v, respectively) exposed to different simulated stomach conditions – 
synthetic gastric juice (0.08 M HCl with 0.2 % (w/v) NaCl; pH 2).  Khan et al. (2013) reported a ~ 
2.0-2.6 log CFU/g reduction of viable B. adolescentis cells entrapped in 2.0 % (w/v) PPI – 0.5 % 
(w/v) alginate microcapsules after 2 h in synthetic stomach juice (pH 1.8). Interestingly, increasing 
of the concentration of PPI to 4.0 % lead to lower viable counts of B. adolescentis after 2 h in 
synthetic gastric juice – 3.6 log CFU/mL reduction (Wood, 2010). The comparative analysis of 
release data supports the conclusion that PPI-alginate and PPI-iota-carrageenan microcapsules 
provide for the more effective delivery of live bacteria than PPI-gellan gum capsules, since these two 
types of microcapsules were able to release up to 70-79 % of entrapped bacteria under simulated 
lower GIT conditions. In this case, the higher number of released cells may be explained by the 
increased susceptibility of freeze-dried probiotic microcapsules to degradation for 3 h in SIF.  
A possible reason for the dissolution of PPI-iota-carrageenan microcapsules might be 
disruption of electrostatic bonds existing between protein and polysaccharide. Since PPI has an 
isoelectric point (pI) of ~ 4.5, at pH values < pI, the protein would assume a net-positive charge; 
whereas, at pH values > pI, the protein would carry a net-negative charge. In contrast, all 
polysaccharides used in this study would carry a negative charge at pH values > 1.88 (pKa of –COO
-
) in the case of gellan gum and alginate, and > 2.00 (pKa of –SO
3-
) in the case of iota-carrageenan. 
Where the polysaccharide pKa < pH < pI (protein), both components would be oppositely-charged, 
and thus they would be electrostatically-attracted to each other (Ganzevles, 2007). Hence, in SSJ at 
pH 1.8, complexes would remain intact due to both Ca
2+-
stabilization and attractive protein-
polysaccharide interactions. However, under simulated intestinal conditions (pH 6.5), both protein 
and polysaccharide would have the same charge and thus would repel each other. 
  
 
 
 
Figure 3.3. Size of probiotic capsules. A. Initial size. B. Size after 2 h in synthetic stomach juice. C. Size after 2 h in synthetic stomach 
juice, followed by 3 h in simulated intestinal fluid. Abbreviations: PPI-AL – pea protein isolate-alginate, PPI-IC - pea protein 
isolate – iota-carrageebnan, PPI-GG - pea protein isolate –gellan gum. 
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Figure 3.4A. Maximum intensity projections of a series of CLSM images of fresh probiotic capsules, stained with SYTO-9. From left to 
right: PPI-alginate, PPI-iota-carrageenan and PPI-gellan gum capsule structure. Images were collected over a 50 µm depth 
interval, z-step – 0.5 m (1 m for PPI-alginate capsules), scale bar – 20 m. Bacteria are seen as the smallest detectable 
rod-shaped or bifurcated particles fluorescing in the green wavelength. Globular macro-structures on the images are particles 
of PPI, emitting autofluorescence. 
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Figure 3.4B. Maximum intensity projections of a series of CLSM images of freeze-dried probiotic capsules, stained with SYTO-9. From 
left to right: PPI-alginate, PPI-iota-carrageenan and PPI-gellan gum capsule structure. Images were collected over a 50 µm 
depth interval, z-step – 0.5 m, scale bar – 20 m. Bacteria are seen as the smallest detectable rod-shaped or bifurcated 
particles fluorescing in the green wavelength. Globular macro-structures on the images are particles of PPI, emitting 
autofluorescence. 
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It was hypothesized in this case that the structural integrity of a capsule would be maintained 
by the calcium-stabilizing polysaccharide network.  In comparison with other polysaccharides tested, 
iota-carrageenan had a greater net-negative charge (due to higher electronegativity of its sulphate 
groups), which would lead to higher repulsive forces within the microcapsule and, consequently, 
disruption of the calcium-carrageenan network followed by release of up to 79 % of entrapped 
bacteria into the solution (Fig. 3.2). These findings are supported by the studies of polymer and drug 
release characteristics from alginate capsules (Kim and Lee, 1992; Sugawara et al., 1994; Chen et 
al., 2004, 2007). At low pH (e.g., gastric conditions), the surface of alginate capsules would become 
porous and insoluble (George and Abraham, 2006). In contrast, in higher pH solutions (e.g., 
intestinal conditions) this so-called “alginic acid skin” becomes soluble, and alginate starts to swell, 
which, in the case of probiotic capsules might aid in the controlled release of bacterial cells under 
gastric and intestinal conditions (Kimura, 1993). 
In general, low-density dried polysaccharide gels, having an open cellular structure with thin 
walls, such as alginate, are considered very fragile (Nussinovitch et al., 2000). The stability of such 
gels can be preserved by using freeze-drying as a preferable method for dehydration, as it results in 
dry gels with improved mechanical properties (Nussinovitch et al., 1993). The addition of pea 
protein to polysaccharide gels also considerably improved their stability under acidic conditions, 
allowing effective protection of immobilized bacteria.   
A honeycomb-like ultrastructure has been previously described by Khan et al. (2013) and 
Wood (2010), based on scanning electron microscopy (SEM) and cryo-SEM of PPI-alginate 
capsules. Both these techniques require the fixation of samples followed by dehydration, which 
might explain similarities in images of fresh capsules acquired by SEM, cryo-SEM and CLSM of 
freeze-dried capsules (Liu et al., 2008; Serp et al., 2002). Cryo-SEM images of capsules made of 
sodium alginate alone also revealed a honeycomb-like internal structure (Wood, 2010). However, as 
evident from our survival studies, these pores apparently do not facilitate the diffusion of simulated 
stomach juice into the capsules, as the viability of bacteria within both freeze-dried- and fresh 
microcapsules was approximately equal. 
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Figure 3.5.  The number of gene copies per ng of DNA, extracted from fecal samples of rats, 
receiving different types of diet (day 29).  
*The DNA for qPCR analysis was extracted from fecal samples of two groups of rats: receiving 
blank PPI-alginate microcapsules or PPI-alginate microcapsules with bifidobacteria. 
 
Capsule size is a key parameter that likely would dictate the range of food products in which 
a particular size of capsule could be used. In general, the smaller the capsule, the better the 
organoleptic properties of the product. However, decreasing the capsule size leads to poorer 
protection of entrapped bacteria (Lee and Heo, 2000; Chandramouli et al., 2004). The extrusion 
method used in the present study does not require any additional raw materials, such as emulsifiers, 
and allows the production of capsules of relatively consistent size, depending on the needle gauge 
and concentration of polymers used (Wood, 2010; Klemmer et al., 2011; Gbassi 
and Vandamme, 2012; Khan et al., 2013).  A further advantage of the extrusion method is the gentle 
conditions of capsule formation, which facilitates maintenance of high cell viability (80–95 %) 
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(Krasaekoopt et al., 2003). Evidence from the literature suggests the size range of capsules that may 
be produced by extrusion to be approximately 1-3 mm in diameter. Klemmer et al. (2011), working 
with 2.0 % (w/v) PPI – 0.5 % (w/v) alginate solution, produced microcapsules with a diameter of 
1.65-1.89 mm and 2.01-2.25 mm, using 27G and 20G needles, respectively. Similar results were 
achieved by Khan et al. (2013), who used 16, 18, 19, 23 and 27G needles for the extrusion of the 
same type of microcapsules and reported mean capsule sizes ranging from 1.23 mm (27G) to 2.79 
mm (16G). In general, while smaller sized microcapsules would be preferable for potential use in 
food products, it would result in reduced protection for immobilized bacteria. 
It has been widely-reported that in order to have a health-promoting effect, the concentration 
of probiotic bacteria in a product should be at least 10
6 
CFU per ml or g (Kailasapathy and Chin, 
2000). Culture-dependent methods for bacterial enumeration are prone to false-positive and false-
negative results and cannot be applied to the quantification of many bacterial species due to the 
absence of a suitable medium, which makes culture-independent techniques, such as PCR, a useful 
tool used for this purpose (Giraffa and Carminati, 2008). Both species-specific and multiplex PCR 
have already been successfully used for the quantification of bacteria (including B. adolescentis) in 
human and animal feces (Wang et al., 1996; O‟Sullivan, 1999). In a study by Satokari et al. (2001), 
a group of human subjects were administered Bifidobacterium lactis at a concentration of about 3 x 
10
10
 CFU per day for two weeks. The presence of B. lactis during the period of administration was 
detected in feces by PCR/gel electrophoresis techniques. However, no B. lactis were detected after 
the administration had been ceased (Satokari et al., 2001).  
In general, the majority of research on probiotic delivery tools has focused on the indirect 
assessment of the efficacy – through disease treatment and presence of beneficial effects on health. 
Whereas, there remains a considerable lack of scientific research that has focused on the assessment 
of probiotic delivery into the GIT of model animals, receiving daily intake of bacteria of interest, 
entrapped within microcapsules or capsules. Though indirect approaches allows the evaluation of the 
beneficial effect of the supplement on health, it is essential to study the functional mechanisms of 
probiotic delivery tools. There is a need for research of the controlled release of bacteria from 
capsules, which requires testing of new materials and techniques. Protecting and releasing bacteria at 
specific sites could be useful in targeting a specific health problem: e.g., the immune response could 
be altered and improved by delivery of beneficial bacteria into the small intestine, while the 
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antipathogenic properties of probiotics would have the greatest effect in the colon (Cook et al., 
2012).  
The type of microorganisms used for the testing of the efficacy of a certain protection 
technique (e.g. capsulation or using of bacteria-containing beads) also plays an important role. 
Widely-used probiotic strains of lactobacilli are less pH-sensitive than bifidobacteria, which 
reportedly lack acid tolerance response mechanisms and, therefore, require enhanced protection 
during the passage through the stomach (Waddington et al., 2010; Sahadeva et al., 2011). The use of 
acid-sensitive strains would provide additional proof of the efficacy of the chosen delivery tool and 
would make it easier to deliver significant amounts of potentially-beneficial, but acid-sensitive, 
bacteria into lower GI tract. 
Encapsulation has been proven by many to be a potentially useful tool for the delivery of 
probiotic bacteria into the lower GIT in sufficiently high numbers. However, molecular techniques 
should be used to confirm the delivery of encapsulated bacteria into specific sites of the GIT as well 
as to assess any alterations this might bring to the microbiota of the host. Use of a variety of 
materials with gelling properties and ability to interact with polysaccharides to form protective 
microcapsules in conjunction with acid-sensitive bacteria as a mean of testing the capsule efficacy 
would make it possible to target an effective encapsulation technique for specific health applications. 
 
3.4 Conclusions 
A series of in vitro experiments employing simulated conditions of the human GIT revealed 
that PPI-polysaccharide microcapsules containing acid-sensitive B. adolescentis have potential for 
protecting these bacterial cells from the detrimental effects of the upper GIT, with subsequent release 
of significant amounts of bacteria in the lower GIT. The overall cell count reduction after 2 h in SSJ 
at 37C was similar for all types of capsules, and was equivalent to a loss of ~ 1.0-1.5 log viable 
CFU/g for fresh microcapsules and ~ 2.0-2.5 log CFU/g for freeze-dried capsules. However, the 
subsequent release of bacteria from the microcapsules was highest for PPI-iota-carrageenan and PPI-
alginate capsules; whereas, 70 – 74 % of the total amount of immobilized cells was released from 
fresh microcapsules and 75 – 79 % of the immobilized cells were released from freeze-dried 
capsules. Capsules formulated with PPI-gellan gum released the fewest cells, with only ~ 4.0 log 
CFU/g detected following incubation in SIF.    
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The molecular analysis of fecal samples recovered from an in vivo rat feeding study confirm 
that PPI-alginate microcapsules are an effective tool to deliver bacteria such as probiotics into the 
lower gut. During the period of feeding encapsulated B. adolescentis, DNA extracted from rat feces 
showed an increased amount of B. adolescentis, a finding together with the results of in vitro 
survival tests, reveals that PPI-alginate microcapsules indeed protect bacterial cells from highly-
acidic conditions of the stomach with subsequent release of bacteria from the microcapsules in the 
intestine.  
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3.6 Preface to next chapter 
From the results of the first study, pea-protein alginate was chosen as the best microcapsule 
type of all tested suitable for the delivery of oxygen- and acid-sensitive bacteria into an animal GIT. 
The next step would be evaluating the effects that these microcapsule wall materials would have on 
their ability to deliver and protect probiotics into the GI tract in an actual animal system. 
Accordingly, Citrobacter rodentium – induced colitis in mice was chosen as a model system to study 
the efficacy of probiotics encapsulated in PPI-alginate. In preparation for animal studies, our 
laboratory collection of lactobacilli strains was screened for antagonistic properties against the 
pathogen C. rodentium in order to choose a candidate for encapsulation.   
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4 TESTING OF ANTAGONISTIC PROPERTIES OF PROBIOTIC STRAINS  
AGAINST CITROBACTER RODENTIUM 
 
4.1 Abstract 
Bacterial strains with potential probiotic properties were tested for their ability to inhibit the 
growth of Citrobacter rodentium, a pathogen causing colitis in mice. One or several probiotic 
strains, selected in this study for their ability to inhibit the growth of C. rodentium in vitro, would 
have been encapsulated in a PPI-alginate matrix and tested in vivo in mice for their ability to prevent 
or alleviate the symptoms of colitis like symptoms (e.g. colonic epithelial cell hyperplasia) caused by 
this pathogen. In in vitro antagonism tests as well as in co-aggregation experiments none of the 
strains tested proved useful for inhibiting the growth of this pathogen. However, two strains – 
Lactobacillus rhamnosus R0052 and Lactococcus lactis ATCC 11454 – showed a strong ability to 
attach to HEp-2 cells in vitro. Based on these findings as well as on previous work in the field, a 
mixture of commercial lactobacilli strains, including L. rhamnosus R0052, was chosen for the in vivo 
testing of capsule efficiency. 
 
4.2 Introduction 
A pathogenic microorganism C. rodentium is used to model several human intestinal 
disorders, such as Crohn‟s disease, ulcerative colitis and colon tumorigenesis (Higgins et al., 1999; 
Chandrakesan et al., 2013). Its mechanisms of pathogenesis resemble those of enteropathogenic E. 
coli (EPEC) and enterohaemorragic E. coli (EHEC), which are leading causes of diarrhea, 
haemorrhagic colitis and haemolytic uremic syndrome, thus it is often used to study the molecular 
basis of infections, caused by these pathogens (Crepin et al., 2016; Flowers et al., 2016; Lackraj et 
al., 2016).  
Several studies showed that a mixture of two probiotic strains – L. rhamnosus R0011 and L. 
helveticus R0052 (used in commercial Lacidofil
®
 preparation; Lallemand Health Solutions, 
Montreal, QC, Canada) – is able to inhibit C. rodentium infection in vivo by downregulation of the
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expression of pro-inflammatory cytokines and reduction of the attachment of the pathogen to 
colonocytes (Johnson-Henry et al., 2005; Gareau et al., 2010; Rodrigues et al., 2012). In vitro 
experiments testing these strains against multiple pathogens were conducted using cell cultures, such 
as T84 and Caco-2, and proved that probiotics were effectively inhibiting pathogen attachment to 
cells (Sherman et al., 2005; Atassi et al., 2006; Wine et al., 2009). Additionally it has been 
previously shown that the growth of C. rodentium can be inhibited in vitro by co-culturing with 
bacteria, producing lactic acid, as well as by the addition of ascorbic acid to the culture medium 
(Idoui, 2014; Abu-Ghazaleh, 2006; Pasteris et al., 2011).  
The potential antagonistic activity of several LAB strains against the pathogen was tested in a 
series of in vitro tests. Additionally, the ability of probiotic bacteria to coaggregate with C. 
rodentium was tested as an important trait that could potentially inhibit the pathogen activity, 
including its attachment to epithelial cells.  
Citrobacter rodentium is an attaching and effacing (A/E) type of pathogen which is able to 
attach to the apical cell membrane of the cecal and colonic epithelia, forming a non-invasive 
structure (“pedestal”) on the host cell (Bhinder et al., 2013). In order to test possible inhibition of 
such attachment by a set of lactobacilli strains, HEp-2 cells were used in in situ experiments, since it 
has been shown previously that C. rodentium forms “pedestals” on the surface of these cells (Frankel 
et al., 1994; Newman et al., 1999). The cell line have been established via HeLa cell contamination 
and is positive for the presence of human papilloma viral DNA. The specific strain used was HEp-2 
ATCC CCL-23.  
The hypothesis was as follows: probiotic strains having the ability to inhibit the growth of C. 
rodentium (Schauer et al.) ATCC 51459 in vitro will be identified based on a series of bacterial 
growth antagonism assays, co-aggregation tests and their ability to inhibit the attachment of C. 
rodentium to human cells in vitro.  
 
 
4.3 Methods  
4.3.1 Bacterial strains 
The following strains from our laboratory collection were tested: Lactobacillus delbrueckii 
ATCC 9649, Lactobacillus fermentum NRRL B4524, Lactobacillus fermentum Beierinck ATCC 
14931, Lactobacillus fermentum Beijerinck ATCC 11739, Lactobacillus helveticus ATCC 15009, 
Lactobacillus maltaromicus (Miller et al.) ATCC 27865, Lactobacillus plantarum ATCC 14917, 
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Lactococcus lactis ATCC 11454, Lactobacillus rhamnosus ATCC 1469, Lactobacillus rhamnosus 
ATCC 15820, Pediococcus acidilactici ATCC 25740, Pediococcus parvulus 2.6 and Pediococcus 
pentosaceus ATCC 33316. Additionally L. rhamnosus R0011 and L. helveticus R0052 were received 
from Lallemand Health Solutions (Montreal, QC, Canada) and tested as well. 
 
4.3.2 Antagonism tests 
Antagonistic activity of bacteria against C. rodentium was determined using a cross-streak 
method (Kotikalapudi (2009) with modifications). In brief, strains of lactobacilli were streaked on 
Plate Count (PC) agar plates, after which C. rodentium was streaked perpendicular to LABs. Plates 
were then incubated at 37˚C for 48 h and the distance between streaks measured (n = 6).  
For direct antagonism plate test (Touré et al., 2003), 2 µL of overnight culture of LAB 
isolates, grown in MRS broth, were spotted on 1.5 % MRS agar containing 2 g/L of sodium 
bicarbonate to avoid interference from acid production. Plates were dried for 30 min at room 
temperature and incubated anaerobically at 37˚C for 18 h, then overlaid with 10 ml of PC containing 
0.8 % agar at 45˚C that was seeded with 1 % (v/v) of an active overnight culture of C. rodentium. 
Overlaid plates were incubated aerobically at 37˚C for 18 h. Testing was carried out in triplicate. 
Results (zones of inhibition) were reported as the distance (mm) from the edge of the LAB colony to 
the outer edge of the inhibition zone.  
The ability of cell-free culture supernatants to inhibit the growth of pathogens was tested 
utilizing well diffusion assay (Meshref and Korny, 2014). LAB-inoculated 24 h broths were 
centrifuged at 12000 × g for 10 min (Microfuge 16; Beckman Coulter, Brea, CA, USA); the pellet 
was discarded and the supernatant was neutralized to pH 6.2 with 1M NaOH and filter sterilized 
through 0.45 um pore size filter. Aliquots of 150 µl of supernantants were added into well, cut in the 
MRS agar. Well diameter was 9 mm; the bottom of each well was sealed beforehand with a drop of 
liquid MRS agar. Inhibition zone diameter was measured after 24 h incubation at 37˚C (n = 3).  
Acid production by individual LAB strains was also observed on MRS agar with 
bromocresol purple and assessed in 24 and 48 h after inoculation as being low (+), medium (++) or 
high (+++). 
 
4.3.3 Coaggregation assay 
The coaggregation assay was performed as described in Kotikalapudi, 2009. Overnight 
cultures were harvested by centrifugation at 3,250 × g (Microfuge 16; Beckman Coulter) for 15 min 
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at 4°C and washed once with PBS and resuspended in the same buffer to an OD600 = 0.250 
(BioSpetrophotometer; Eppendorf, Hamburg, Germany). Aliquots of 0.5 mL of C. rodentium 
suspension was added to each of the LAB suspensions in sterile test tubes and mixed for 10s on a 
vortex mixer, and then incubated at 37ºC for 24 h without agitation, aerobically or anaerobically. 
The absorbance (A600) of the cell suspension was measured after 2, 4 and 24 h of incubation. The 
co-aggregation (%) was calculated according to the following equation: [(Apat + Aprobio) - (Amix)/(Apat 
+ Aprobio)] × 100, where, Apat and Aprobio represent OD600 of the pathogen (pat) and probiotics (probio) 
suspensions at time 0 min and Amix represents OD600 of the mixed bacterial suspension at different 
times. Additionally co-aggregation abilities of bacteria were screened by visual observation, and the 
degree of aggregation was recorded on a scale 0 to 4+: a score of 0 for no visible aggregates in the 
cell suspension, 1+ for small uniform aggregates in the suspension, 2+ for aggregates that were 
easily seen but did not settle, 3+ for large aggregates which settled and left some turbidity in the 
supernatant fluid, and 4+ for large aggregates which settled and left clear supernatant fluid. Auto-
aggregation of LAB strains was also tested by using monocultures and was used as a control to 
measure co-aggregation, which was considered to occur when the score in the bacterial mixtures was 
greater than the auto-aggregation score of either strain in monoculture. 
 
4.3.4 Attachment of C. rodentium and lactobacilli to human cells 
The human epithelial laryngocarcinoma (HEp-2) cells were propagated in Dulbeccos‟s 
Modified Minimum Essentail medium (DMEM; Thermo Fisher Scientific, Madison, WI, USA) with 
10 % (v/v) fetal bovine serum (Thermo Fisher Scientific, Madison, WI, USA) in 75 mL flasks at 
37˚C in a cell incubator maintained under 5 % CO2 atmosphere (Fisher Scientific Isoterm CO2 
incubator, Thermo Fisher Scientific, Madison, WI, USA). Cells were reseeded every time confluence 
reached ~ 95 %. For this, cells were trypsinized with TrypLE Express (Thermo Fisher Scientific, 
Madison, WI, USA), washed from flasks using sterile DMEM, transferred to 50 mL tubes, 
centrifuged at 1300 rpm for 5 min, and then transferred to new flasks with fresh DMEM. Adhesion 
assays were performed according to Bai et al. (2012) with minor modifications, using E. coli HB101 
as negative control. In brief, HEp-2 cells were seeded into 24-well plates 24 h before infection at a 
density of 5 × 10
4
 cells per well. Before infection the medium was replaced with new DMEM 
medium containing 1% mannose. A mixture with a MOI (number of bacteria per number of 
mammalian cells) of 100:1 was added to wells and allowed to adhere for 3 h at 37˚C in 5 % CO2. 
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After incubation, each well was rinsed five times with PBS, cells were fixed in pre-cooled to -20˚C 
methanol for 15 min and stained with a mixture of 0.5 % safranin (Safranin T; Sigma-Aldrich, 
Oakville, ON, Canada), 0.5 % methylene blue (Sigma-Aldrich) and 0.4 % trypan blue (Mediatech 
Inc., Manassas, VA, USA). After staining wells were washed once with 1 × PBS and examined 
using inverted microscope (Olympus IX71; Olympus corp., Tokyo, Japan) under brightfield 
illumination at a magnification of × 400. An adhesion index (< 1, > 1, < 50 and > 50) was 
determined by examining 10 visual fields per well. Experiments were repeated three times in 
duplicate.  
 
4.4 Results  
Most of the tested LAB strains showed no antagonism towards C. rodentium, as was evident 
from growth using the cross-streak method. In contrast, direct antagonism testing and the well-
diffusion assay did show some inhibition of the growth of this pathogen. However, those data were 
not considered sufficiently significant to warrant using these strains in in vivo studies (Table 4.1).  
Though multiple species of LAB are able to coaggregate with pathogens (Ekmekci et al., 
2009; Kotikalapudi, 2009; Twetman et al., 2009; Keller et al., 2011; Younes et al., 2012), there is a 
very limited data available on the coaggregation of C. rodentium with other bacteria (Stevens et al., 
2015). Co-aggregation experiments did not provide positive results for any of the strains tested (data 
not shown). None of the LAB strains were able to co-aggregate with C. rodentium, which was 
evident from both optical density measurements, which did not change significantly in time, and 
from visual analysis of the culture mixtures – no flocculation was observed.  
Others have previously reported that C. rodentium was cytotoxic towards HEp-2 cells, 
though the ability to attach to cell surface differed significantly among isolates (Bai et al., 2012).  In 
this study, there was no attachment observed of C. rodentium to human cells (Figure 4.1), which 
made it impossible to test whether LAB inhibit the attachment of the pathogen. However, two of the 
lactobacilli strains – L. helveticus R0052 and L. lactis ATCC 11454 showed a strong ability to attach 
to HEp-2 cells with adhesion indeces > 50 and < 50, respectively (Fig. 4.1). Sherman et al. (2005) 
have previously reported that L. helveticus R0052 has the ability to adhere to host epithelial cells, 
and, when using in a mixture with L. rhamnosus R0011, is able to reduce the binding of both E coli 
O157:H7 and E. coli E2348/69 to HEp-2 and T84 cells. Since C. rodentium utilizes mechanisms of 
epithelial cell attachment that are very similar E. coli, it can be hypothesized that the adhesion of 
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lactobacilli to receptors on the surface of human cells could decrease numbers of available binding 
sites for this enteric pathogen. 
The ability of L. lactis ATCC 11454 to attach to HEp-2 cells could also be considered a 
beneficial trait, which, to the best of my knowledge, has not been reported before. According to 
previous research this strain was able to inhibit the growth of Staphylococcus aureus, Enterococcus 
faecalis and Enterococcus faecium in vitro (Millette et al., 2004).  
Table 4.1. Results of antagonism tests 
Strain Cross-
streak 
method, 
mm 
Direct 
antagonism 
test,  
mm 
Well-
diffusion 
assay,  
mm 
Acid 
production  
at 24 h 
Lactobacillus delbrueckii ATCC 9649 0 1.25 ± 0.25 17.17 + 
Lactobacillus fermentum B4524 0 1.50 ± 0.00 17.50 ++ 
Lactobacillus fermentum Beierinck 
ATCC 14931 
0 2.00 ± 0.00 16.33 ++ 
Lactobacillus fermentum Beijerinck 
ATCC 11739 
0 2.00 ± 0.50 16.83 ++ 
Lactococcus lactis ATCC 11454 0 1.50 ± 0.00 17.50 ++ 
Lactobacillus helveticus ATCC 15009 0 1.17 ± 0.29 16.33 ++ 
Lactobacillus maltaromicus Miller et 
al. ATCC 27865 
0 1.83 ± 0.29 17.00 ++ 
Lactobacillus plantarum ATCC 14917 0 4.00 ± 0.50 17.83 +++ 
Lactobacillus rhamnosus ATCC 1469 0 2.00 ± 1.00 16.83 ++ 
Lactobacillus rhamnosus ATCC 
15820 
0 2.50 ± 0.50 17.83 + 
Lactobacillus rhamnosus R0011 0 2.00 ± 0.05 17.00 + 
Lactobacillus helveticus R0052 0 1.15 ± 0.05 16.00 + 
Pediococcus acidilactici ATCC 25740 3.33±2.25 1.67 ± 0.58 16.00 ++ 
Pediococcus parvulus 2.6 0 1.83 ± 0.29 15.33 ++ 
Pediococcus pentosaceus ATCC 
33316 
3.16±1.57 2.17 ± 0.29 15.83 ++ 
 
 
 
 
 60 
 
  
  
Figure 4.1. Microscopic images of HEp-2 cells, stained with safranin, methylene blue and trypan 
blue, 400 × magnification, scale bar – 100 µm. A – cell culture with C. rodentium, B – cell 
culture with E. coli HB101 (control), C – cell culture with L. rhamnosus R0052, D – cell 
culture with L. lactis ATCC 11454. 
  
A B 
C D 
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4.5 Conclusions 
Testing of our laboratory collection of LAB strains using in vitro antagonism tests and co-
aggregation assay did not reveal a candidate having significant antagonistic effects on the growth of 
C. rodentium.  
Since the attachment of C. rodentium to HEp-2 cells was not observed, it was not possible to 
test whether lactobacilli strains would affect the attachment.  
However, L. helveticus R0052 and L. lactis ATCC 11454 showed a strong ability to attach to 
human cells. Based on these results and on previous research in the field it was decided to choose L. 
helveticus R0052 and L. rhamnosus R0011 strains that had been described by others as Citrobacter 
antagonists in vivo for future experiments using animal model of infectious colitis (Johnson-Henry et 
al., 2005; Gareau et al., 2010; Rodrigues et al., 2012). 
 
4.6 Preface to next chapter 
Multiple lactobacilli strains were tested to select a bacterium able to inhibit the growth of C. 
rodentium in vitro. A strain L. helveticus R0052 showed a strong ability to attach to HEp-2 cells. 
Probiotics were chosen based on this result as well as on previous work done by others focusing on 
C. rodentium (Johnson-Henry et al., 2005; Gareau et al., 2010; Rodrigues et al., 2012). Two 
lactobacilli strains – L. rhamnosus R0011 and L. helveticus R0052 – were selected for encapsulation 
to test the effects of PPI-alginate on the ability of these probiotic bacteria to inhibit pathogen-
induced colitis in mice.  
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5 EFFICACY OF PEA-PROTEIN ALGINATE CAPSULES CONTAINING  
PROBIOTIC BACTERIA IN A MURINE MODEL OF  
CITROBACTER RODENTIUM-INDUCED COLITIS
 
 
5.1 Abstract 
In the current study, I assessed the efficacy of two strains of Lactobacillus probiotics 
immobilized in a pea protein isolate - alginate microcapsules for efficacy using a mouse model of 
Citrobacter rodentium-induced colitis. The objective was to determine whether PPI-alginate 
encapsulation of a combination of Lactobacillus rhamnosus strain R0011 and Lactobacillus 
helveticus strain R0052 reduced the symptoms of colitis and/or caused any other non-target effects 
on the host. Accordingly, 4-week old mice were fed diets supplemented with freeze dried probiotics 
(group P), probiotic containing microcapsules (group PE) (lyophilized PPI-alginate microcapsules 
containing bacteria; 0.5 g of microcapsules per day; 10
8
 CFU) or PPI-alginate microcapsules 
containing no bacteria (group E) (0.5 g per day). Half of the mice (controls, groups P, PE and E) 
were were challenged by gavage with C. rodentium 2 weeks after the initiation of feeding. Daily 
monitoring of disease symptoms (abnormal behavior, diarrhea, etc.) and body weights were 
undertaken. At the termination of the study analyses of histopathological changes in colonic and 
cecal tissues, cytokine expression levels, pathogen and probiotic densities in fecal samples, as well 
as high throughput sequencing of mucosal microbial communities in the distal colon were also 
carried out. Infection of mice with C. rodentium led to marked progression of infectious colitis, 
which was evident from symptomatic and histopathological data and changes in cytokine expression.  
Administration of the probiotics L.rhamnosus R0011 and L. helveticus R0052 led to changes 
in most of the disease markers. However, probiotics did not have a significant impact on
altering cytokine profiles in infected animals. Based on cytokine expression analyses and 
histopathological data, it was evident that encapsulation materials (pea protein and calcium alginate) 
contributed to the development of inflammation and worsened a set of symptoms in the cecum. 
These results suggest that even though food ingredients may be generally recognized as safe, they 
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may in fact contribute to the development of an inflammatory response in certain animal disease 
models. 
 
5.2 Introduction 
The effective delivery of probiotics in sufficiently high numbers to the intestine for a 
beneficial effect is an ongoing challenge. When entering the human stomach, bacteria are exposed to 
adverse environmental conditions, such as low pH and pepsin. Ideally, a probiotic food product 
should contain protective substances or a technology that protects viable bacteria from these factors, 
allowing the bacteria to reach the colon in sufficient numbers in order to provide a functional or 
beneficial effect in the human or animal host. The most efficient methods for protection of bacteria 
from the harmful effects of acid and bile is their encapsulation within single or multiple biopolymer 
coatings, along with varying of biopolymer concentration and increasing of the initial cell loads 
(Chandramouli et al., 2004; Petrović et al., 2007; Annan et al., 2008). The survival of bacteria is 
mainly related to the structural integrity of capsules, which involves various testing of different wall 
components to select favourable variants, such as microcapsules that are insoluble at acidic pH but 
dissolve under the more alkaline pH of the intestine (Narayani and Rao, 1995a,b; Nickerson et al., 
2006). One of the main criteria for success of a candidate encapsulation method is to promote the 
survival of bacteria in amounts equal to or greater than 7 log CFU/ml
-1
 after being exposed to 
unfavorable conditions in stomach (Kotikalapudi et al., 2009). Capsules also need to be non-toxic 
and pepsin-resistant.  
With respect to the capsule wall composition, preference has been given to natural 
hydrocolloids and gums that are generally recognized as safe (GRAS) for human health. Compounds 
that have shown good protection of bacterial cells against acidic environment of the gut include 
alginate, carrageenans and gums (Holzapfel and Schillinger, 2002; Shah et al., 2007; Bajaj et al., 
2007; Morris et al., 2012). These biopolymers possess various useful features such as viscosity 
(thickening or gelling), water binding, emulsion stabilization, adhesion, foam stabilization and film 
formation (Chaplin, 2012). Due to these properties, it is easy to achieve various textures and forms 
by altering and combining physical factors. According to many probiotic encapsulation studies 
(Champagne and Fustier, 2007; Annan et al., 2008; Chávarri et al., 2010; Voo et al., 2011), the most 
common material for immobilization of bacterial cells is alginate. This biopolymer is of algal origin 
and composed of (1 → 4)-linked β-d-mannuronic and α-l-guluronic acid residues (Voo et al., 2011). 
 64 
 
Water-holding capacity and solubility of alginate depends on various extrinsic factors such as pH, 
ionic strength and the origin of ions. For example, when sodium alginate is added to aqueous 
calcium chloride, it forms calcium alginate, a water-insoluble, gelatinous substance. This property of 
alginate is widely-used for the entrapment of probiotic bacteria. Bacterial cultures are added into an 
aqueous alginate solution, and in the presence of calcium chloride, leads to the formation of alginate 
microcapsules enmeshing the bacteria.  
The use of pea protein isolate (PPI) in the food industry is gaining popularity because of its 
hypoallergenic properties and low concentration of isolate by-products (8-12 %) (Franco et al., 2000; 
Tömösközi et al., 2001). PPI is extracted from field peas (Pisum sativum) and contains two major 
globulin proteins: legumin (350-400 kDa) and vicilin (150 kDa) (Ducel et al., 2004). Several studies 
have proven the advantages of using PPI in combination with sodium alginate during the formation 
of probiotic-containing microcapsules (Kotikalapudi et al., 2010; Klemmer et al., 2011), where PPI-
alginate microcapsules showed enhanced protection of bacterial cells in simulated gastric juice. In 
order to form stable interactions with polyanions such as alginate, carrageenan or gellan gum, PPI 
should have an overall positive charge. Since the isoelectric point of PPI is pH ~ 4.5, favourable 
conditions for coacervation occur at pH < 4.5. On the contrary, at pH > pI, PPI is negatively-
charged, and leads to segregative phase separation upon mixing with polyanions. In order to 
determine the proper conditions for formulation of stable interaction between protein and 
polysaccharide, the influence of various factors on complex formation needs to be evaluated (e.g., 
concentration, ratio, biopolymer-type, reactive groups present, molecular weight, pH, temperature, 
concentration of ions in the solution) (de Kruif et al., 2004). 
The efficacy of immobilized probiotics ultimately requires testing in vivo. In these cases, an 
animal model of a human disease is a valuable option. One such model, previously used for testing 
of probiotic properties of lactobacilli, is Citrobacter rodentium-induced colitis in mice (Johnson-
Henry et al., 2005; Rodrigues et al., 2012). The infectious colitis caused by C. rodentium in mice is 
in many ways analogous to human disease caused by enteropathogenic and enterohemorrhagic 
Escherichia coli (EPEC and EHEC, respectively) (Wong et al., 2011; Crepin et al., 2016). The 
infection of mice with 10
8
-10
9
 CFU of C. rodentium ATCC 51459 leads to infectious colitis 
characterized by colonic hyperplasia or elongation of the epithelial crypts, mononuclear immune cell 
infiltration, goblet cell depletion and other symptoms. The infection starts with the cecal patch, 
followed by progression to the distal colon 2-3 days post infection. In immunocompetent mouse 
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strains, the infection reaches its peak at day 7 post-infection (p.i.), and the clearance of the pathogen 
is achieved 3 to 4 weeks after infection (Collins et al., 2014, 2016).  
A mixture of Lactobacillus strains, L. rhamnosus R0011 and L. helveticus R0052, was used 
as a probiotic formulation. These two strains, mixed at a 95:5 ratio, have been patented and marketed 
as the probiotic Lacidofil™ and previously shown to reduce the severity of C. rodentium infection in 
mice (Johnson-Henry et al., 2005; Gareau et al., 2010; Rodrigues et al., 2012).  
Citrobacter rodentium as well as human pathogens EPEC and EHEC are collectively known 
as attaching and effacing (A/E) pathogens. They use a type III secretion system to inject effectors 
into enterocytes where they reprogram cell signaling (Wong et al., 2011). Infection of mucosal 
surfaces by C. rodentium leads to the formation of attaching and effacing lesions. These lesions are 
characterized by effacement of the brush border microvilli and localized actin polymerization at the 
bacterial attachment site (Crepin et al., 2016).  
The infection of mice with C. rodentium causes colitis and a transmissible murine crypt 
hyperplasia (TMCH), characterized by intestinal dysbiosis: alterations of the structure, diversity and 
composition of both mucosa-associated and luminal microbiota (Hoffman et al., 2009; Collins et al., 
2014). At the peak of the infection, C. rodentium numbers can reach 1 % - 3 % of the total bacterial 
counts shed in feces (Lupp et al., 2007). The infection causes a reduction in obligate anaerobic 
bacteria, such as Bacteroidaceae and Lachnospiraceae families, and a loss of the genus 
Ruminococcus (Hoffman et al., 2009). On the contrary the amounts of Enterobacteriaceae (of which 
C. rodentium is a member) increase, possibly due to ability of some bacteria of this family to 
metabolize reactive nitrogen and oxygen species in the inflamed intestine (Winter et al., 2010; 
Winter et al., 2013; Pham et al., 2014). 
The excessive induction of epithelial regeneration and repair mechanisms during TMCH 
leads to the development of colonic crypt hyperplasia, characterized by thickening of the colonic 
mucosa and marked elongation of the crypts (Schauer and Falkow, 1993). These repair mechanisms 
result in an accumulation of undifferentiated colonocytes at the luminal surface and a reduction in 
the number of goblet cells (Papapietro et al., 2013). Colitis also causes the loss of epithelial barrier 
integrity and the transit of bacteria into the sterile lamina propria (Barker, van de Wetering and 
Clevers, 2008). 
Clearance of C. rodentium is usually achieved within 2-3 weeks, when colonized epithelial 
cells are shed into the intestinal lumen, and the pathogen, opsonized by IgG antibodies directed 
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against virulence factors, is eliminated via phagocytosis by neutrophils and via the competing 
microbiota (Maaser et al., 2004; Lebeis et al., 2008; Kamada et al., 2012). 
According to previous studies administration of L. rhamnosus R0011 and L. helveticus 
R0052 to mice infected with C. rodentium improved survival of animals, ameliorated weight loss, 
colonic epithelial cell hyperplasia, mucosal barrier dysfunction (Johnson-Henry et al., 2005; Gareau 
et al., 2010; Rodrigues et al., 2012). Pretreatment with probiotics reduced epithelial thickness, 
decreased bacterial internalization, restored goblet-cell formation, and increased mucus secretion 
(Johnson-Henry et al., 2005). Probiotics also suppressed the fecal load of C. rodentium and the 
overgrowth of Enterobacteriacea (Rodrigues et al., 2012). Additionally a global decrease in 
diversity following C. rodentium infection was reported (Johnson-Henry et al., 2005; Rodrigues et 
al., 2012). Gareau et al. (2010) reported that in infected neonatal mice beneficial effects of probiotics 
were observed in B cell-deficient animals, indicating the requirement of T cells in reducing the 
adverse effects of colitis. In terms of cytokine expression levels, only a preliminary administration of 
probiotics (before infection with C. rodentium) was associated with suppression of Ifnγ and Tnfα 
transcripts 10 days after infection, while all other regimes, except for 6 days after infection, reduced 
Il17 transcripts (Rodrigues et al., 2012). In general a shift from a primarily pro-inflammatory Th1 
cell response to a more balanced Th1/Thr (regulatory) host immune response was observed when 
probiotic treatment of infected mice was implemented (Johnson-Henry et al., 2005; Rodrigues et al., 
2012). 
We have previously shown that pea-protein alginate microcapsules were able to protect acid-
sensitive Bifidobacterium adolescentis in vitro and to deliver these bacteria to the lower parts of the 
rodent GIT (Varankovich et al., 2015a). In this chapter, I tested whether L. rhamnosus R0011 and L. 
helveticus R0052 retain efficacy against C. rodentium induced colitis in mice, when encapsulated in 
the same type of matrix. Accordingly, the objective of the current study was to determine whether 
the PPI-alginate microcapsule delivery method of L. rhamnosus R0011 and L. helveticus R0052 
interferes with their ability to reduce the symptoms of C. rodentium-induced colitis, or induces any 
other non-target effects on the host. It was hypothesized that probiotics would effectively inhibit the 
development of C. rodentium-induced colitis, and the use of PPI-alginate encapsulation would not 
cause any significant alterations in: a) microbiome composition of distal colon mucosa, b) 
expression levels of pro- and anti-inflammatory cytokines, c) disease symptoms, or d) cecal and 
colonic tissue inflammation and lesions, compared to non-encapsulated probiotics. 
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5.3 Materials and methods 
5.3.1 Ethics statement 
The study was carried out in strict accordance with the Canadian Council on Animal Care 
Guidelines. The project was approved by the Lethbridge Research and Development Centre (LRDC) 
Animal Care Committee (Animal Use Protocol 1511), and the LRDC Biosafety and Biosecurity 
Committee before commencement of the research. 
 
5.3.2 Bacterial strains 
Two bacterial strains, L. rhamnosus R0011 and L. helviticus R0052, provided by Lallemand 
(Lallemand Inc., Montreal, QC, Canada), were used in this study. These strains, mixed at a 95:5 
ratio, have been patented as a probiotic mixture marketed under the name Lacidofil™ and have been 
previously shown to inhibit C. rodentium infection in C57BL/6 mice mice (Johnson-Henry et al., 
2005; Gareau et al., 2010). Lyophilzed cells were prepared as follows: strains were grown on MRS 
agar at 37°C for 48 h under anaerobic conditions. Isolated colonies were then separately seeded into 
MRS broth, incubated until the exponential phase (24 h and 36 h for strains R0011 and R0052, 
respectively), centrifuged at 5000 x g for 10 min, mixed with trehalose to a final concentration of 10 
% and lyophilized (Labconco FreeZone 12 Free Dry System, Labconco Corp., Kansas, KS, USA. 
Freeze-dried cells of two strains were combined at a ratio of 95:5 and stored at 4˚C. The number of 
living bacteria in the freeze-dried powder was monitored by plate counting on MRS every week. 
 
5.3.3 Preparation of probiotic capsules 
Capsule preparation was based on encapsulation and extrusion techniques described in 
Varankovich et al. (2015a). Pea protein isolate was kindly donated by Nutri-Pea Ltd. (Portage La 
Prairie, MB, Canada). Alginic acid sodium salt (medium viscosity; 61 % mannuronic and 39 % 
guluronic acid (M/G ratio of 1.56)), calcium chloride dehydrate and Tween 80 were purchased from 
Sigma-Aldrich (Oakville, ON, Canada). The composition of the wall material of microcapsules was 
as follows: 2 % PPI + 0.5 % (w/w) alginate. Concentration of PPI was adjusted to the protein content 
of the isolate (85 %); whereas, the polysaccharide concentration was used as is, on a per-weight 
basis. PPI was dissolved at 85°C and pH 9.0 for 2 h. Then, pH was adjusted to 7.0 and alginate was 
added to the mixture. After complete dissolution of the alginate (1-1.5 h at 85°C), the solution was 
cooled to room temperature (21-23°C) and mixed with 2 % (v/v) of the bacterial slurry, recovered by 
 68 
 
centrifugation from 24 h bacterial broth (optical density at 600 nm was equal 1.305 (averaged; n=3)) 
(measured using Genesys 10S UV-Vis Spectrophotometer, Thermo Fisher Scientific, Madison, WI, 
USA). The final mixture (a blend of protein and alginate) was then extruded using a syringe and 18G 
(G, gauge) needle into 200 mL of ddH20 containing Ca
2+
 ions (cross-linking agent) and Tween 80 
(emulsifier). Prepared microcapsules were freeze-dried (Labconco FreeZone, Kansas City, MO, 
USA) for 15 h and stored at 4°C. The size of lyophilized microcapsules was ~ 2 mm in diameter. 
Capsules were ground to a size of ~ 0.5-1 mm to facilitate uptake by mice during feeding. The 
number of living probiotic bacteria in capsules was monitored by plate counting on MRS every 
week. 
 
5.3.4 Animals and study design 
The experiment was conducted as a four-by-two factorial design (i.e. probiotic/encapsulation 
× infection) arranged as a completely randomized design with four replicates. Every mouse was kept 
in a separate cage, and cages of the same treatment group were separated to make sure samples 
would be as independent as possible. Two replicates were conducted simultaneously, which was 
later accounted for in the statistical model as a random factor. 
Specific pathogen-free (SPF) female C57BL/6 mice (n = 32, 3-week old) were purchased 
from Charles River Laboratories (Montreal, QC, Canada) and allowed to acclimatize to the 
Lethbridge Research Center Vivarium for 7 days before commencement of the experiment. Mice 
were fed with freeze-dried probiotic cells (group P), probiotic microcapsules (group PE) (lyophilized 
PPI-alginate microcapsules containing bacteria; 0.5 g of microcapsules per day; 10
8
 CFU) or blank 
PPI-alginate microcapsules (group E) (0.5 g per day), starting at four weeks of age. Half of the 
control mice, and half from P, PE and E groups, were gavaged with C. rodentium 2 weeks after the 
start of feeding (groups C, PC, PEC and EC, respectively). Sterile rodent chow (basal AIN-93G diet; 
Harlan laboratories, Madison, WI, USA) and water were available at all times. Capsules were first 
ground then mixed with 5 g of jello (“Jell-o” brand; contents: sugar, gelatin, adipic acid, disodium 
phosphate, sodium citrate, fumaric acid, red 40) to ease the feeding process. Control mice were fed 5 
g of plain jelly per day. AIN-93G-VX vitamin mix (94047; 10 %, w/v) and AIN-93G-MX mineral 
mix (94046; 15 %, w/v) (Harlan laboratories, Madison, WI, USA) were dissolved in the jelly.  
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5.3.5 Infection of mice with Citrobacter rodentium 
Initially, C. rodentium Schauer et al. (ATCC
®
 51459
™
;
 
laboratory collection of Dr. G. 
Douglas Inglis, Lethbridge Research Centre) was plated from frozen glycerol stock onto LB agar and 
incubated for 24 h at 37˚C. Then, 150 μl of sterile LB broth was applied to a plate of C. rodentium. 
Cells from ¼ of plate were gently suspended in broth and transferred to a flask with 150 ml of sterile 
LB. Broth was then incubated on a shaker (110 rpm) for approximately 2 h until the absorbance 
reached approximately 0.1 at OD600. Cells were centrifuged at 4000 x g for 15 min and then 
resuspended in 3 mL of 1X sterile PBS. Each mouse was gavaged with 100 μl of the C. rodentium 
solution using a bulb-tipped gastric gavage needle attached to a 1 ml syringe. The dosage (10
8
 CFU) 
was confirmed by plating on LB agar. 
 
5.3.6 Sample collection 
Body weight, animal survival, and behavior were monitored daily throughout the 
experimental period. Fresh fecal pellets were collected every second day during four weeks of the 
experiment. At the completion of the experiment 10 days post-infection, mice were anesthetized with 
isoflurane and euthanized via cervical dislocation. Immediately after death, a mid-line laparotomy 
was used to exteriorize the intestine, and a gross pathological assessment of the intestine and 
associated tissues was completed. The intestine, liver and mesenteric lymph nodes were harvested 
aseptically. Several distal colon and cecum segments were either weighed and frozen at −80°C for 
DNA extraction and analysis of bacterial communities, or fixed in 10 % neutral-buffered formalin 
for histopathologic analyses. Samples of distal colon were also placed in RNAlater (Qiagen Inc., 
Toronto, ON) and stored at −20°C for mRNA extraction for cytokine analysis. 
 
5.3.7 Histopathological analysis 
Colonic and cecal tissue samples were fixed in 10 % buffered formalin for 24 h, dehydrated, 
embedded in paraffin, sectioned, de-paraffinized with xylene, and stained with hematoxylin and 
eosin (Jiminez et al., 2016). Epithelial cell hyperplasia, crypt height, epithelial injury, inflammation, 
goblet cell depletion, mitotic activity and fibrosis in tissues were assessed by a veterinary pathologist 
(Richard R. E. Uwiera) in a double-blind fashion using a scoring criteria described previously (Costa 
et al., 2011). In brief, tissue sections were graded from 0 to 4 for epithelial cell hyperplasia, crypt 
height, epithelial injury, inflammation, and 0 to 3 for mitotic activity of epithelial cells and goblet 
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cell depletion. A total pathology score was obtained by calculating the sum of scores for all 
categories for each mouse. 
 
5.3.8 Cytokine expression 
Changes in the expression of the cytokines of pro-inflammatory- (Il17, Infγ) and anti-
inflammatory (Il4, Tgfβ) profiles were determined.  
Total RNA from samples of distal colon tissue was isolated using Qiagen RNeasy Mini Kit 
(Qiagen, Valencia, CA, USA) according to the manufacturer‟s instructions. RNA was then reverse 
transcribed using the QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA, USA). 
Expression differences of cytokine genes between groups were analyzed by real-time PCR using 
QuantiTect SYBR Green MasterMix (Qiagen, Valencia, CA, USA). The reaction master mix was 
prepared as follows: QuantiTect SYBR MM – 10 µl, primers – 1 µl each, bovine serum albumin 
(BSA; Promega Inc., Madison, WI, USA) – 2 µl, RNase free water – 4 µl. Template volume – 2 µl. 
Total reaction volume – 20 µl. Cycling conditions: 95°C for 15 min, followed by 40 cycles of 94°C 
– 15 s, 58°C – 30 s, and 72°C – 30 s. Negative extraction controls, as well as non-template controls, 
were added to the plate in every qPCR run. Melting curve analysis was performed as an additional 
quality control. Only one peak for each qPCR product was present on the curve. 
Samples were run in triplicate on a Bio-Rad CFX Connect thermocycler (Bio-Rad 
Laboratories Inc., Mississauga, ON, Canada). Primer sequences are listed in Table 5.1. Beta-
glucuronidase (GusB), hypoxanthine guanine phosphoribosyl transferase (Hprt) and peptidylpropyl 
isomerase A (Ppia) were used as endogenous controls. Hprt and Ppia were selected as the optimal 
set of normalization genes using NormFinder software (Andersen et al., 2004). Results were 
analyzed using the relative quantification (ΔΔCt) method and expressed as fold change ± SEM. The 
qPCR efficiency for every target and reference gene was calculated according Liu and Saint (2002). 
Relative Expression Software Tool (REST, version 2009; Pfaffl and Qiagen, Hilden, Germany) was 
used to perform calculations.  
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Table 5.1. Primers for qPCR. 
Name Sequence (5‟-3‟) Annealing 
temperature 
Source 
mGusB-f GCT CAT CTG GAA TTT CGC CG 58˚C Brown et al., 
2016 
 
mGusB-r CGG TTT CGT TGG CAA TCC TC 58˚C 
Ppia-f CTA AAG CAT ACA GGT CCT GGC A 58˚C 
Ppia-r ATG CCT TCT TTC ACC TTC CCA 58˚C 
Hprt-f ACA GGC CAG ACT TTG TTG GAT 58˚C 
Hprt-r ACT TGC GCT CAT CTT AGG CT 58˚C 
mIL17a-f GCA GCG ATC ATC CCT CAA AG 58˚C 
mIL17a-r ACG TGG AAC GGT TGA GGT AG 58˚C 
mIfng-f ACG GCA CAG TCA TTG AAA GC 58˚C 
mIfng-r TCT GGC TCT GCA GGA TTT TCA 58˚C 
murTGFbeta-f TGC TGC TTT CTC CCT CAA CCT 58˚C 
murTGFbeta-r CAC TGC TTC CCG AAT GTC TGA 58˚C 
IL4-f CAT CGG CAT TTT GAA CGA GGT CA 58˚C 
IL4-r CTT ATC GAT GAA TCA GGC ATC G 58˚C 
CrodF GCTTCTGCGAAGTCTGTCAA 58˚C Jiminez et 
al., 2016 CrodR CAGTAAAGCGACTTAACAGATT 58˚C 
R0011-f ACTCCAAAGAGCATTACCTCCG 60˚C Lallemand 
Health 
Solutions 
 
R0011-r TGAATATGCCGGATCTAAGTCCA 60˚C 
R0052-f AGAATCAAGCAGAGACTGGCTACG 60˚C 
R0052-r GGACCGGATTTGAGTAGAGGTA 60˚C 
 
 
5.3.9 Quantification of pathogen and probiotics in mice fecal samples 
Extraction of DNA from murine fecal samples was carried out with QIAamp DNA Stool 
Mini Kit (Qiagen, Valencia, CA, USA) as per the manufacturer‟s instructions. Primer sequences for 
L. rhamnosus R0011 and L. helveticus R0052 were provided by Lallemand (Lallemand Inc.). The 
primer pair for strain R0011 is specific to phage 113A29, which is unique to this strain; plasmid 
pIR52 was used to design a primer for R0052 (plasmid strain-specific for L. helveticus R0052) 
(Table 5.1). Primers used for qPCR-based quantification of C. rodentium were CrodF and CrodR 
(Table 5.1).  
All samples were run in triplicate on a Bio-Rad CFX Connect thermocycler (Bio-Rad 
Laboratories Inc., Mississauga, ON, Canada). Master mix was prepared as follows: QuantiTect 
SYBR MM – 10 µl, primers – 1 µl each, bovine serum albumin (BSA; Promega Inc., Madison, WI, 
USA) – 2 µl, RNase free water – 4 µl. Template volume – 2 µl. Total reaction volume – 20 µl. 
Cycling conditions were: 95°C for 15 min, followed by 40 cycles at 94°C – 15 s, 60˚C (58°C in the 
case of CrodF/R primers) – 30 s, 72°C – 30 s. Negative extraction controls, as well as non-template 
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controls, were added to the plate in every qPCR run. Dilutions of DNA, extracted from pure cultures 
of C. rodentium, L. rhamnosus R0011 and L. helveticus R0052 and quantified fluorometrically 
(Qubit, Life Technologies, Burlington, ON, Canada), were used to construct standard curves (10
6
 to 
10
1
 copies; n = 2) for each run. Primer efficiency was between 85–105 % and a single peak for each 
target gene was present on a melting curve.  
 
5.3.10 High-throughput amplicon sequencing 
5.3.10.1 Library preparation and sequencing 
Phylogenetic profiles of the mouse mucosa-associated microbiome of distal colon tissue were 
generated by performing massively-parallel sequencing of the 16S rRNA gene on an Illumina MiSeq 
system (Illumina Inc., San Diego, CA, USA) using the V3 MiSeq Reagent kit (600 cycles; Illumina 
Inc.). DNA was extracted from equally-sized pieces of distal colon samples (two pieces, ~ 15 mg 
each) with the DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA, USA) according to the 
manufacturer‟s protocol. The primers used to target the 16S V3 and V4 regions of the gene were S-
D-Bact-0341-b-S-17 (forward) and S-D-Bact-0785-a-A-21 (reverse) (expected sequence length – 428 
pb) (Klindworth et al., 2013). The library preparation step of the MiSeq workflow was based on 16S 
Metagenomic Sequencing Library Preparation guide (Illumina Inc.) with modifications: the first out 
of two PCR clean-ups was done through gel extraction/purification (0.7 % agarose (w/v), 110V, 
500A, 45 min); Qubit (Life Techologies
TM 
Corp., Carlsbad, CA, USA; HS DNA assay) was used 
instead of a Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA); PhiX was added to final 
pooled libraries at a concentration of 10 %. Libraries were normalized to 4 nM in 6 ml volumes 
each. The loading concentration was 8 pM. Loading of the libraries onto the instrument was 
performed according to the MiSeq Reagent Kit V3 Reagent Preparation Guide (Illumina Inc.).  
 
5.3.10.2 Analysis of 16S rRNA genes 
De-multiplexing was performed using MiSeq Reporter software (Illumina Inc.) allowing for 
a single mismatch in index recognition. Sequencing data were processed using QIIME (Quantitative 
Insights Into Microbial Ecology; Caporaso et al., 2010). To classify experimental data, de-
multiplexed reads were merged in QIIME, using FLASH (Magoc and Salzberg, 2011) with 
minimum and maximum overlap settings of 20 and 200 bp, respectively. Reads were then pooled 
together and filtered using default settings with multiple_split_libraries_fastq.py. OTU assignment 
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was performed with parallel_pick_otus_uclust_ref.py using Silva database v. 123 and the open-
reference method (Edgar, 2010; Yilmaz et al., 2013).  
 
5.3.10.3 Taxonomic diversity analysis and statistics 
A rarefaction depth of 16000 was chosen based on the lowest number of sequences among 
the 31 samples (one of the samples was excluded due to poor quality). The core microbiome at 
Phylum and Family levels was calculated with compute_core_microbiome.py. For alpha diversity 
statistics Chao1, shannon and simpson metrics were calculated and compared (Student‟s t-test, p-
value was set to ≤ 0.05) using alpha_diversity.py, collate_alpha.py and compare_alpha_diversity.py 
in QIIME. Unweighted UniFrac was chosen for calculation of beta diversity metrics (Lozupone and 
Knight, 2005). Dissimilarity matrix calculations and principal coordinate analyses were performed 
using jackknifing at the rarefaction depth of 16000 (jackknifed_beta_diversity.py), and analyzed 
using dissimilarity_mtx_stats.py and make_distance_boxplots.py, which calculates two-sample t-
tests for all pairs of boxplots with Bonferroni-corrected p-values for each test (Vazquez-Baeza et al., 
2013). Statistics for histology scoring and cytokine expression was performed in SPSS Statistics v. 
23.0 (IBM Corp., Armonk, NY, USA; 2015) (level of significance for every test used was set to ≤ 
0.05).  
 
5.3.11 Statistics 
 Continuous data (weight gain, food intake, etc.) was checked for normality and tested using 
MIXED procedure in SPSS v. 23.0 (IBM Corp.) with replicate structure factor (1, 2 versus 3, 4) 
treated as a random effect. The lowest Akaike‟s Information Criterion was used in each case to 
choose a best-fitted model with an appropriate covariance structure. Relative expression of cytokines 
was calculated using the pair-wise fixed reallocation randomization test (PWFRR test) in REST
©
 
(5000 randomizations) (Pfaffl et al., 2002). Fisher‟s Exact Test and a Two-way ANOVA on ranks 
(for interactions analyses) in SPSS were used to analyze histology scores. Pathogen and probiotic 
qPCR quantification results were analyzed by a One-way ANOVA with repeated measures in SPSS. 
Probability values of ≤ 0.050 were considered significant. Correlations were performed using 
Spearman‟s rank correlation method in SPSS. Corrections for multiple comparisons were performed 
using Bonferroni (high throughput sequencing analyses) or Sidak (in all other cases) methods. 
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Graphs were constructed in GraphPad Prism (Version 7.02; GraphPad Software Inc., San Diego, 
CA, USA). 
 
5.4 Results 
5.4.1 Symptoms and necropsy data 
Infection of mice with C. rodentium ATCC 51459 can result in severe weight loss and 100 % 
mortality ten days post-infection (Rodrigues et al., 2012); however, this effect was not always 
observed in C57BL/6 mice (Johnson-Henry et al., 2015). In the present study, none of the animals 
showed any abnormal behavior or overt disease symptoms, such as diarrhea. There was no 
significant effect of any single treatment type (PEC, PE, PC, P, C, E or EC) on loss of weight in 
mice (Fig. 5.1A); however, and in general, non-infected mice gained more weight by the end of the 
experiment compared to infected mice (F = 6.796, p = 0.014). Necropsies of infected mice revealed 
inflammation of the colon (p < 0.001; compared to non-infected groups; data not shown), enlarged 
spleens (p = 0.052 for spleen weight (Fig. 5.1C), but F = 4.691 at p = 0.039 for spleen length (Fig. 
5.1D)) and notably enlarged lymph nodes (p = 0.056; Fig. 5.1B). Food intake was also slightly 
increased in non-infected mice, though the effect was not significant (data not shown). The average 
feed intake per mouse per day was 2.68 ± 0.22 g. Treatment type did not affect (F = 1.668, p = 
0.167) the length of the colon (data not shown), however, infected mice had (F = 4.913, p = 0.037, 
mean difference = 0.342 mm) shorter colons than non-infected. Liver weights did not differ between 
infected and non-infected mice, or between treatment groups.  
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Figure 5.1. Effect of treatment on the weight gain and necropsy data of mice, challenged with C. 
rodentium, and/or treated with probiotics. A – weight gain, B – lymph node weight, C – 
spleen length, D – spleen weight. Data represents mean ± standard error of the mean 
(SEM) and an asterisk represents the probability value p ≤ 0.050 (n = 4) as determined 
by F-test (Mixed ANOVA). Group abbreviations key: P – probiotics, C – C. rodentium 
infection, E – encapsulation. 
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5.4.2 Histopathology 
Histopathological analysis confirmed the effect of C. rodentium infection on the development 
of epithelial hyperplasia and injury, fibrosis, mitotic activity and other symptoms in both the colon 
and cecum (data not shown). The impact of infection differed considerably for those two segments 
of the gut. A worsening of epithelial hyperplasia was observed in infected vs. non-infected mice in 
the colon (F = 10.878, p = 0.008), with an interaction between infection and probiotic in cecum (F = 
7.604, p = 0.001). Infected mice that received probiotics (PC) had lower histopathological scores 
than either the control group or mice fed probiotics (P; data not shown). A similar interaction 
between probiotic and infection was observed in the cecum for goblet cell depletion (F = 9.000, p = 
0.006), inflammation (F = 20.557, p < 0.001), epithelial injury (F = 5.064, p = 0.034) and mitotic 
activity (F = 6.313, p = 0.019). In all these cases a corresponding symptom was less prominent with 
the addition of probiotic.  
Interestingly, EC treatment (blank microcapsules + infection) (p < 0.05) worsened symptoms 
in the cecum, including epithelial hyperplasia, increased crypt height (also in colon), inflammation, 
mitotic activity and goblet cell depletion – compared to some of the other treatments (data not 
shown). In the colon, pathogen challenge had a negative impact (p < 0.05) on all the observed 
symptoms, with the exception of fibrosis. 
Average total histopathological scores for colon were higher (F = 14.517, p = 0.001) in 
infected compared to non-infected mice, whereas the total score for the cecum was  mediated by the 
probiotic-infection interaction (F = 11.680, p = 0.02); infected mice receiving probiotics had lower 
total histopathological scores compared to  mice  not fed probiotics (Fig. 5.2). In general, and as 
expected, the most prominent effect of C. rodentium – induced colitis was observed in infected 
groups of mice, with probiotics mediating the development of the disease in cecum. One 
complicating factor was the development of mild colitis symptoms (e.g., inflammation) in control 
mice as well as in other non-challenged treatment groups. 
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Figure 5.2. Effect of treatment on average total histopathological scores in the colon and cecum of 
mice challenged with C. rodentium. Data represents an average (mean ± SEM) of total 
scores for all histopathological markers of each mouse in a treatment group (n = 4) and 
asterisks represent the probability value *p ≤ 0.050 and **p ≤ 0.010 (F-test in Mixed 
ANOVA). Bars marked with different letters are significantly different from each other. 
Group abbreviations key: P – probiotics, C – C. rodentium infection, E – encapsulation. 
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Figure 5.3. Histomicrographs of the mouse colon. A – control mouse, B – mouse infected with C. 
rodentium. Prominent crypt extension and epithelial hyperplasia were evident in mice 
treated with C. rodentium. Arrows indicate the difference in crypt height. Scale bar = 
100 µm. 
 
5.4.3 Cytokine expression 
Concentrations of Th1- (Infγ), Th2- (Il4), Th17- (Il17), and Treg- (Tgfβ) cytokines in tissues of 
distal colon were quantified by qPCR (Fig. 5.4). Il17 was expressed at higher levels in the distal 
colon tissues of infected compared to non-infected mice (F = 7.559, p = 0.012) (Fig. 5.4), and was 
up-regulated (in comparison to the control group) in the PEC group by a mean factor of 43.708 
(PWFRR test, p = 0.049; Fig. 5.4).  
Infγ was up-regulated in the EC group by a mean factor of 4.401 (PWFRR test, p = 0.035), 
and in the PEC group by a mean factor of 12.688 (PWFRR test, p = 0.042) in comparison to the 
control group (Fig. 5.4). No effects from infection, probiotic or encapsulation were found on 
concentrations of Infγ mRNA. In general, infected animals had three times-higher relative expression 
levels of this cytokine than did non-infected animals (4.179 (SE = 1.212) vs. 1.366 (SE = 1.212), p = 
0.058). In the PEC group, probiotics were not able to suppress the expression of the pro-
inflammatory cytokine.  
Il4 was up-regulated in the EC group (in comparison to control group) by a mean factor of 
4.235 (PWFRR test, p = 0.005; Fig. 5.4). Infected mice were found to have higher concentration of 
Il4 mRNA in distal colon tissue than did non-infected mice (F = 8.246, p = 0.010). In general, 
neither encapsulation material nor probiotic administration affected Il4 mRNA expression.  
A B 
 79 
 
There was no difference in expression levels of transforming growth factor beta (Tgf-β1) 
between treatments. Though not considered significant, there was an approximate two-fold increase 
in relative concentration of mRNA of this cytokine in infected animals compared to non-infected 
animals (2.954 (SE = 0.522) vs. 1.410 (SE = 0.579); p = 0.061) (Fig. 5.4).  
 
5.4.4 Pathogen and probiotic densities in mice fecal samples 
 Pathogen and each probiotic were quantified by qPCR in fecal samples of mice taken at three 
time points – before probiotic administration, before C. rodentium inoculation (before infection), and 
before necropsy (Fig. 5.5). No pathogen was detected in fecal samples collected prior to initiation of 
the experiment (data not shown). Prior to necroscopy, C. rodentium was present in feces at a 
concentration of ~ 7-7.5 log CFU/g, and there was no difference in numbers of the pathogen between 
treatments (Fig. 5.5A).  
L. rhamnosus R0011 was present in treated mice at concentrations of ~ 6.5-7 log CFU/g of 
feces up to the final sampling period (Fig. 5.5B). Additionally, at the end of the experiment, the PE 
group (probiotic capsules) had significantly higher densities of strain R0011 compared to the P 
group (non-encapsulated probiotic), which suggests that encapsulation of probiotics increased their 
numbers in fecal samples (F = 4.698, p = 0.006). Interestingly, numbers of R0011 decreased slightly 
(by ~ 0.5 log CFU/g in each group; F = 49.386, p < 0.001; Fig. 5.5B). The second strain, L. 
helveticus R0052, was also present in feces of all mice treated with probiotics at a concentration of ~ 
5-6 log CFU/g (Fig. 5.5B). No difference in its numbers was found between treatments. However, a 
downward trend in CFU/g for this probiotic was observed by the end of the experiment, but only for 
challenged groups (by less than 0.5 log CFU/g; F = 6.577, p = 0.015).  Primers for qPCR used in 
these experiments were targeted the small cryptic plasmid, pIR52, specific to strain R0052, and the 
gene for the 113A29 phage head protein, specific for strain R0011 (Hagen et al., 2010; Lallemand 
Inc., unpublished data).  
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Figure 5.4. Relative cytokine expression in the distal colon of mice challenged with C. rodentium 
and/or treated with encapsulated or non-encapsulated probiotics in comparison with the 
control group as measured using qPCR (Ppia and Hprt as reference targets). Data is 
presented as fold change ± SEM (n = 4; 2 in case of IL4/C group) and asterisks represent 
the probability value *p ≤ 0.050 (F-test in Mixed ANOVA). Group abbreviations key: P 
– probiotics, C – C. rodentium infection, E – encapsulation. 
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Figure 5.5. C. rodentium  (A) and probiotic (B) counts in fecal samples from  mice challenged with 
this pathogen or treated with encapsulated or non-encapsulated probiotics. A – C. 
rodentium counts before necropsy, B – L. rhamnosus R0011 and L. helveticus R0052 
concentrations before infection and before necropsy. Data is presented as log CFU/g ± 
SEM (n = 4) and asterisks represent the probability value **p ≤ 0.010 (F-test in repeated 
measures ANOVA). Group abbreviations key: P – probiotics, C – C. rodentium 
infection, E – encapsulation. 
 
5.4.5 16S rRNA gene analysis 
 The mucosa-associated microbial communities in the distal colon were characterized by 16S 
rRNA gene analysis.  One sample (PEC treatment group) was excluded from all downstream 
analyses due to poor quality. Sequences were assigned to the phylogeny using SILVA database. The 
sequences were assigned to 5-14 different OTUs at the Phylum level and from 21 to 66 OTUs at the 
Family level – (Table 5.2).  
Chao1, shannon and simpson metrics were used to assess alpha diversity of samples. Though 
control mice and animals fed with blank microcapsules had the highest richness and diversity in 
mucosa-associated microbial composition, there was no detectable difference in total species 
richness (Chao1) or diversity (shannon, simpson) within samples of different treatment groups 
(Table 5.2). 
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Table 5.2. Number of OTUs and alpha diversity metrics. Abbreviations key: P – probiotics, C – C. 
rodentium infection, E – encapsulation. 
Sample 
Number of OTUs 
at the Phylum 
level 
Number of OTUs 
at the Family level 
chao1 
shannon 
(min-max) 
simpson 
(min-max) 
Control1 13 56 2869 ± 2632 6.907-8.613 0.968-0.973 
Control2 12 49 4403 ± 4158 7.243-9.22 0.973-0.974 
Control3 11 60 4744 ± 5629 6.824-8.204 0.977-0.979 
Control4 12 57 4105 ± 5131 6.793-7.803 0.982-0.983 
C1 9 41 4057 ± 5104 6.667-7.744 0.979-0.98 
C2 7 23 1322 ± 1749 2.616-2.748 0.745-0.744 
C3 10 48 4937 ± 6045 7.323-8.497 0.989-0.991 
C4 5 21 962 ± 1266 3.11-3.246 0.818-0.812 
E1 10 43 5026 ± 6243 6.981-8.292 0.986-0.989 
E2 8 32 1846 ± 1691 6.696-7.929 0.96-0.963 
E3 9 44 4803 ± 6054 7.061-8.301 0.987-0.989 
E4 11 40 2918 ± 3525 6.786-7.687 0.984-0.986 
EC1 9 39 1679 ± 2097 2.667-3.075 0.747-0.762 
EC2 8 38 2670 ± 2221 6.281-7.807 0.945-0.943 
EC3 11 56 3595 ± 4577 5.134-5.91 0.923-0.925 
EC4 9 35 1390 ± 1849 2.701-2.933 0.762-0.767 
P1 14 66 3290 ± 3454 7.068-8.611 0.98-0.982 
P2 9 39 2900 ± 2254 7.027-8.713 0.968-0.97 
P3 11 53 1808 ± 2381 3.244-3.418 0.805-0.792 
P4 10 43 2467 ± 2585 6.653-7.643 0.981-0.983 
PC1 6 27 1383 ± 1834 2.603-2.927 0.748-0.757 
PC2 10 37 2631 ± 3087 4.947-5.789 0.899-0.908 
PC3 9 48 4997 ± 6265 7.12-8.244 0.987-0.988 
PC4 11 47 2462 ± 2582 5.697-6.825 0.93-0.932 
PE1 10 42 3818 ± 4765 7.028-8.183 0.988-0.991 
PE2 9 32 1115 ± 1294 4.457-4.992 0.887-0.892 
PE3 11 41 2030 ± 2536 4.017-4.442 0.875-0.872 
PE4 9 40 3240 ± 3890 6.465-7.43 0.973-0.975 
PEC2 8 28 1027 ± 1222 2.71-3.029 0.748-0.762 
PEC3 9 42 1684 ± 2166 3.035-3.272 0.773-0.773 
PEC4 9 33 1499 ± 1801 3.725-4.04 0.829-0.821 
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5.4.5.1 Taxonomy 
 At the phylum level samples were primarily composed of OTUs aligning within the 
Bacteroidetes, Defferibacteres, Firmicutes and Proteobacteria, all of which are typically occurring 
taxa for the murine gut (Figs. 5.6, A.1). At the family level, Enterobacteriaceae, Lachnospiraceae, 
Ruminococcaceae, Bacteroidaceae, Deferribacteraceae and Lactobacillaceae were present in all the 
samples (Figs. 5.8, A.2).  
 In general, mucosa-asscociated communities of control mice were dominated by Firmicutes 
(Lachnospiraceae, Ruminococcaceae and Lactobacillaceae) (Figs. 5.6, A.1, 5.7, A.2). Infection with 
C. rodentium caused increase in Proteobacteria (Enterobacteriaceae) up to 95% of the recovered 
OTUs in two out of four animals, while the microbiome of the other two mice was dominated by 
Firmicutes (Lachnospiraceae and Ruminococcaceae) (Figs. 5.6, A.1, 5.7, A.2). The administration 
of probiotics to infected mice (PC) led to the decrease in Firmicutes (Lachnospiraceae) and increase 
in Bacteroidetes (Bacteroidaceae) (Figs. 5.6, A.1, 5.7, A.2). Mucosal community of non-infected 
animals receiving probiotics (P) differed greatly from animal to animal in terms of major phyla, 
either dominated by Proteobacteria or Firmicutes (Figs. 5.6, A.1, 5.7, A.2). Microbiome of mice 
receiving empty capsules was mostly compised of Firmicutes (~ 60-80% of Lachnospiraceae and ~ 
10-20% Ruminococcaceae) (Figs. 5.6, A.1, 5.7, A.2; E). Infection of the group of animals that were 
on the same diet with C. rodentium led to the increase of OTUs that aligned with Proteobacteria up 
to ~ 98% in half of the animals, while in the other half ~ 30-45 % of OTUs were Firmicutes 
(Lachnospiraceae and Ruminococcaceae) (Figs. 5.6, A.1, 5.7, A.2; EC). One mouse from the group 
also had ~ 37 % of sequences classified as Bacteroidetes (Figs. A.1, A.2; EC3). Probiotic 
administration and infection with C. rodentium caused shifts in phyla composition in general 
towards Proteobacteria, however one animal had > 70% of OTUs identified as Firmicutes (mostly 
Lachnospiraceae) (Figs. 55.6, A.1, 5.7, A.2; PC). In PE group (probiotic capsules, no infection) 
mucosal community was again greatly different among animals with Firmicutes dominating in two 
mice (80-90 %), Proteobacteria (~ 60 %) – in one animal, and Firmicutes, Verrucomicrobia and 
Bacteroidetes comprising a community of the fourth mice (~ 20, 30 and 35 %, respectively, of the 
total OTUs) (Figs. 5.6, A.1, 5.7, A.2; PE). Lastly, infection of animals, fed with probiotic capsules 
caused a major shift towards Proteobacteria (> 87 % of OTUs in the communities) (Figs. 5.6, A.1, 
5.7, A.2; PEC).    
 
 84 
 
5.4.5.2 Analysis of the colonic mucosal community   
 Distances between pairs of samples were calculated, using unweighted UniFrac. Non-metric 
multidimensional scaling graph indicating the relationships among the individual mice is shown on 
Figure 5.8. 
 No distinct clustering of infected vs. non-infected mouse samples was found (Fig. 5.8). 
Samples from one of the mice from the control group (Fig. 5.8) clustered further from other controls. 
This was due to much higher abundance of OTUs aligning within the Proteobacteria (approximately 
30 % of all sequences), while the other three samples were dominated by OTUs aligning within the 
Firmicutes. Also, two out of four infected controls (C2 and C4) consisted almost exclusively of 
OTUs homologuous with Proteobacteria (> 95 %), while the other two had more than 90 % of 
sequences assigned to Firmicutes. All three samples from the infected group that received probiotic 
microcapsules (PEC) were grouped together, with all three having similar profiles with more than 80 
% of their reads being identified as Proteobacteria.   
Histopathological data from this study revealed positive correlations between the percentage 
of Proteobacteria in mucosal bacterial community and disease development (Proteobacterial 
percentage vs. average histopathological scores in both colon and cecum resulted in Spearman‟s 
correlation coefficients (R
2
) > 0.400 at p-values < 0.050; Fig. 5.9, A, B). At the same time, 
Firmicutes numbers negatively-correlated with development of colitis symptoms in both parts of the 
intestine, though the effect was considered significant only for the colon score (Spearman‟s R2 = - 
0.639 at p < 0.001; Fig. 5.9, C).  
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Figure 5.6. Composition of mucosa-associated community (10 dominant phyla) of distal colon of 
mice challenged with C. rodentium and/or treated with encapsulated or non-
encapsulated probiotics, as sequenced on Illumina MiSeq and calculated using QIIME. 
The y-axis shows relative abundance. Treatment groups (n = 3-4) are shown on x-axis. 
Group abbreviations key: P – probiotics, C – C. rodentium infection, E – encapsulation. 
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Figure 5.7. Composition of mucosa-associated community (10 dominant families) of distal colon of 
mice challenged with C. rodentium and/or treated with encapsulated or non-
encapsulated probiotics, as sequenced on Illumina MiSeq and calculated using QIIME. 
The y-axis shows relative abundance. Treatment groups (n = 3-4) are shown on x-axis. 
Group abbreviations key: P – probiotics, C – C. rodentium infection, E – encapsulation. 
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Figure 5.8. Non-metric multidimensional scaling plot, representing sample clustering and based on 
unweighted UniFrac dissimilarity matrix. Each sample represents a composition of 
mucosa-associated community of distal colon of mice challenged with C. rodentium 
and/or treated with encapsulated or non-encapsulated probiotic. Group abbreviations 
key: P – probiotics, C – C. rodentium infection, E – encapsulation. 
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Figure 5.9. Spearman correlations between average total histopathological scores in colon (A, C) or 
cecum (B) and the numbers of Proteobacteria (A, B) and Firmicutes (C) (percentage 
of the total community) in the mucosal microbiome of distal colon of mice (n = 32).  
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5.5 Discussion 
Infectious colitis, caused by C. rodentium in immunocompetent mice has been described as a 
good model of human EPEC/EHEC infections (Higgins et al., 1999; Luperchio et al., 2000; 
Luperchio and Schauer, 2011; Bhinder et al., 2013; Chandrakesan et al., 2013; Crepin et al., 2016). 
Several studies provided well-documented evidence that L. rhamnosus R0011 and L. helveticus 
R0052, administered as a mixture to mice, infected with this pathogen, were able to decrease the 
severity of colitis, which was evident from symptomatic and histopathological data, and alteration in 
pro-inflammatory cytokines expression (Johnson-Henry et al., 2005; Gareau et al., 2010; Rodrigues 
et al., 2012). Hence this animal model of human disease was chosen to test wheather L. rhamnosus 
R0011 and L. helveticus R0052 would have the same beneficial effect on infected animals, when 
immobilized in pea protein-alginate microcapsules.       
In my study, no abnormal behavior or other overt symptoms were observed in any of the 
animals over the course of the experiment following the C. rodentium challenge. Some of the 
observations (differences in weight, spleen size and weight, and liver weight) of disease progression 
in infected mice are supported by the findings of others (Johnson-Henry et al., 2005; Gareau et al., 
2010; Costa et al., 2011; Crepin et al., 2016). Encapsulation had no effect on mediating any of the 
aforementioned symptoms. However, it should be noted that both PEC (probiotic microcapsules + 
infection) and EC (blank microcapsules + infection) treated mice had enlarged lymph nodes and 
spleens compared to those treated with the PC (freeze-dried probiotic cells + infection), which 
suggests that encapsulation may have exacerbated the progression of infection in this model system.  
Histopathological analysis was consistent with previous studies on C. rodentium (Higgins et 
al., 1999; Johnson-Henry et al., 2005). While the pathogen exerted an adverse effect on various host 
markers, it was observed that the treatment with probiotics decreased the severity of infection. This 
is consistent with previous research using this disease model (Johnson-Henry et al., 2005; Gareau et 
al., 2010; Rodrigues et al., 2012). However, in challenged mice, blank microcapsules also enhanced 
the development of the disease, particularly in the cecum. C. rodentium – induced colitis causes 
goblet cell depletion, followed by thickening of the gut mucosal layer, especially during pathogen-
clearing phase (days 14 - 20 p.i.) (Gustafsson et al., 2013). In response to stimuli (in this case, 
pathogenic infection), intestinal goblet cells may accelerate their discharge of mucin, resulting in 
deep cavitation of the apical membrane surface of mucoid cells and, in some cases, cause a total 
depletion of mucus granules making cells impossible to stain with regular histological methods 
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(Forstner, 1995). Barcelo et al. (2000) used alginate to stimulate mucin secretion and reported that 
exposure of rat colonic tissue to 25 mg/l sodium alginate for 30 minutes led to cavitation of large 
numbers of goblet cells. This outcome supports our observation of increased goblet cell depletion in 
the EC (blank microcapsules + infection) group of mice. 
Infection with C. rodentium initially causes a predominantly-Th17 immune response that  
later changes to a Th1 response (Higgins et al., 1999; Costa et al., 2011). Probiotics L. rhamnosus 
R0011 and L. helveticus R0052 have been shown to suppress the expression of pro-inflammatory 
cytokines in this infection model (Johnson-Henry et al., 2005; Rodrigues et al., 2012). However, in 
the current study probiotic administration did not significantly impact cytokine profiles of infected 
animals.  
One of the major functions of Il17 is to enhance innate barrier defenses at mucosal surfaces 
(antimicrobial peptide production, neutrophil recruitment, etc.) (Rubino et al., 2017). Il17 receptor 
A-deficient (IL17RA
−/−
) mice were found more susceptible to C. rodentium infection (Ishigame et 
al., 2009). Here, Il17 was expressed at high levels in the distal colon tissues of infected mice, 
consistent with previous work on C. rodentium (Johnson-Henry et al., 2005; Rodrigues et al., 2012). 
No decrease in Il17 copy numbers was observed in infected mice fed with probiotics only as was 
described in the aforementioned studies. However, Il17 was up-regulated (in comparison to the 
control group) in the PEC group, which suggests that the complex of encapsulation materials and 
probiotics had an impact on the immune system, contributing to the C. rodentium induced 
inflammation.  
The pro-inflammatory cytokine – Infγ –promotes the activation of antigen-specific CD4+ T 
cells and macrophage phagocytosis (Shiomi et al., 2010). The observed increase in expression of 
Infγ in infected animals was expected, based on previous studies of C. rodentium infection (Higgins 
et al., 1999; Costa et al., 2011). The concentration of Infγ might have not been as high as would 
otherwise occur due to the suppression of inflammatory response by probiotics in the PC group, and 
low concentrations of it in the tissue of infected control mice. High concentrations of Infγ in EC and 
PEC groups might be attributed to the effect of alginate or to the manner in which the encapsulation 
materials are presented to the immune system: ground calcium-crosslinked alginate mixed with 
protein might have had an effect similar to that of adjuvants of polysaccharide origin, though the 
mechanism of such effect has yet to be investigated in detail (Petrovsky and Cooper, 2011). 
Dobakhti et al. (2009) previously showed the ability of sodium alginate to induce a Th1 immune 
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response in mice when used as an adjuvant for Bacillus Calmette-Guerin vaccine against 
tuberculosis. Also, a significant increase in the production of IFN-γ, but a decrease in the production 
of Il4, in a sodium alginate-adjuvant enhanced vaccine was reported by AbdelAllah et al. (2016). An 
indicator of a Th2 response – Il4 – was up-regulated in the EC group in comparison to control group. 
Alginate has previously been shown not to induce the expression of Il4 (AbdelAllah et al., 2016); 
however, this parameter may have been influenced by the presence of calcium ions, used for 
microcapsule crosslinking, impacting cytokine mRNA abundance in the EC group. It is a known fact 
that Ca
2+
 is required for the production of Il4 by T cells and for the secretion of multiple cytokines 
by dendritic cells (Brown et al., 1995; Li et al., 2002; Parekh, 2010). Transforming growth factor-
beta is a multifunctional cytokine that plays a central role in wound healing and tissue repair 
(Branton and Kopp, 1999; Penn et al., 2012). It is also critical for TH17 development (Mangan et al., 
2006). In our study, there was no significant difference in expression levels of Tgfβ1 between 
different treatment groups. A slightly higher (two-fold) increase in relative concentration of mRNA 
of this cytokine in infected animals compared to non-infected animals could be indicative of fibrosis 
and repair processes in the distal colon.  
In general, infection of mice with C. rodentium caused an increase in the expression of both 
pro-inflammatory cytokines, as well as Il4; however, the effect was not uniform. The highest copy 
numbers of Infγ and Il17 mRNA were found in the distal colon of infected mice that received 
probiotic microcapsules (PEC), suggesting that encapsulation materials contributed to the 
development of inflammation. Previous work suggested that alginates may induce the immune 
response in rodents, especially the expression of tumor necrosis factor alpha and interleukins 1 and 6 
(Otterlei et al., 1991, 1993; Son et al., 2001). This immuno-stimulatory effect of alginate has been 
linked with its interaction with the CD14 receptor on macrophages, which is similar to the activation 
of these cells by lipopolysaccharides (Espevik et al., 1993). This effect is especially prominent in 
case of alginates with high mannuronic acid content (Otterlei et al., 1993). Alginate, used in the 
current research, consisted of approximately 61 % mannuronic (along with 39 % guluronic acid for a 
mannuronic/guluronic acid ratio of 1.56), which could have been high enough to induce the 
expression of pro-inflammatory cytokines in some mice groups receiving capsules. 
A very high degree of variation was observed in the structure of mucosal communities in 
these mice independent of treatment.  However, some trends were noted.  For example, similar levels 
of community richness and diversity were found in control mice and those fed with blank capsules. 
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These two metrics were affected by challenge in most of the other groups, where the microbiome 
profiles became more simplified (less diverse and rich). The exception was the infection control (C) 
group, where high within-group variability effected diversity and richness metrics. There was an 
obvious correlation between the numbers of Proteobacteria and total histopathological scores. This 
data is supported by observations of others, where higher Proteobacteria counts in animals infected 
with C. rodentium were reported (Lupp et al., 2007; Berry et al., 2015; Shin et al., 2016). Since the 
PEC group was dominated by Proteobacteria, it may also be concluded that the impact of infection 
on bacterial community structure was much stronger than that of either probiotics or encapsulation 
materials. The composition of the microcapsules that were used for delivery of probiotics into the 
animal gut was pea protein and alginate, either of which could influence the mouse microbiome 
composition (the capsule materials comprised ~ 18 % (0.5 g) of a mouse daily dietary intake). Such 
an effect, though present in most of the mice in corresponding groups (E, PE, EC, PEC), was not 
uniform. However, alterations to mouse gut mucosal gut communities may not be as obvious as 
those changes which have been shown to occur in feces.  Moreover, there is little information on the 
mucosal gut communities in mice or the extent that these may vary in terms of community 
composition or structure under identical experimental conditions. It is possible that within those 
same groups of mice, alginate could also have influenced the abundance of different bacterial 
groups. Alginate is considered to have low fermentability (Brownlee et al., 2005). Intake of this 
polysaccharide usually results in development of a more simplified fecal microbiota that includes a 
few highly abundant phylotypes within the Firmicutes and an increased proportion of Bacteroidetes 
(An et al., 2012; Umu et al., 2015). This supports our observations of Firmicutes dominating the 
mucosal communities of E group mice. In humans, the consumption of alginate has been shown to 
result in a significant increase in the number of Bifidobacteria and a decrease in the number of 
Enterobacteriaceae (Terada et al., 1995).  
 
5.6 Conclusions 
Infection of mice with C. rodentium led to marked progression of infectious colitis, which 
was evident from symptomatic and histopathological data and changes in cytokine expression. A 
combination of infection and probiotic microcapsules administration (PEC group) led to significantly 
elevated levels of both Infγ and Il17, suggesting a major impact on the immune system, similar to 
that of an adjuvant, that triggered inflammation. EC treatment (blank microcapsules + infection) also 
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worsened symptoms in the cecum compared to some of the other treatments. This correlated with the 
upregulated expression of Infγ and Il4 in the same (EC) mouse group. Administration of the 
probiotics L. rhamnosus R0011 and L. helveticus R0052 led to changes in most of the disease 
markers in the cecum in infected animals. There was no such effect observed in the colon.  
Testing of the PPI-alginate two-component encapsulation matrix in a murine model of 
infectious colitis was challenging due to the large within-group diversity that accompanied almost 
every symptom or marker assessed, along with the inability to separate the effects of each of the 
components of the matrix. Additionally, we were not able to completely assess the interference of 
PPI-alginate with the ability of probiotics to lessen the severity of a disease due to the lack of such a 
beneficial effect of the lactobacilli strains in some infected animals. However, my results did show 
that PPI-alginate microcapsules used for delivery of probiotic lactobacilli worsened several 
symptoms of a disease and led to the induction of an inflammatory immune response in infected 
mice, though this effect was not uniform. Consequently, some questions remain with respect to the 
utilization of PPI-alginate matrix for probiotic delivery, including possible combined pathogen-
ingredient inflammation responses, species-dependent responses, and the mode of action of each 
component under the conditions of C. rodentium-induced colitis in mice.  
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5.8 Preface to next chapter 
 During the analysis of the results of the previous study it was decided to conduct a parallel 
experiment to investigate the ability of PPI-alginate microcapsules to protect probiotics during long 
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term storage. In an attempt to improve protective properties of the formulation, an extra layer of 
chitosan was added to the microcapsule, and the ability of PPI-alginate-chitosan to protect bacteria in 
vitro was tested.   
 3
Varankovich, N., Martinez, M. F., Nickerson, M. T., and Korber, D. R. (2016). Survival of 
probiotics in pea-protein-alginate microcapsules with or without chitosan coating during storage and 
in simulated gastrointestinal environment. Food Sci Biotechnol 26, 189-194. doi:10.1007/s10068-
017-0025-2 
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6 SURVIVAL OF PROBIOTICS IN PEA-PROTEIN-ALGINATE MICROCAPSULES 
WITH OR WITHOUT CHITOSAN COATING DURING STORAGE AND IN 
SIMULATED GASTROINTESTINAL ENVIRONMENT
3 
 
6.1 Abstract 
Pea protein–alginate microcapsules containing bacteria with or without a chitosan coating 
were produced by extrusion and tested for their ability to increase survivability of the bacteria during 
storage and an in vitro gastrointestinal environment. Both microcapsule formulations provided 
significant protection for cells incubated in synthetic stomach juice at 37°C for 2 h, followed by 3 h 
in simulated intestinal fluid, relative to non-encapsulated bacteria. However, evaluation of cell 
viability during 9 weeks of storage at room temperature revealed that chitosan coating significantly 
improved microcapsule ability to protect bacteria compared to non-coated microcapsules. 
Refrigerated storage had no negative impact on capsule protective ability in both types of capsules. 
Notably, chitosan-containing microcapsules showed much higher viable counts during challenge 
tests even after the storage. Moreover, the addition of chitosan to the microcapsule formulation was 
not observed to increase the microcapsule size.  
 
6.2 Introduction 
In 2001, FAO/WHO experts defined probiotics as living microorganisms that confer a health 
benefit when administered in adequate amounts (FAO/WHO, 2001). Although there have been 
numerous studies describing the potential of probiotics in the prevention and treatment of multiple 
gastrointestinal (GIT) disorders, the efficacy of these microbial strains remains arguable. Probiotic-
based strategies for therapeutic and prophylactic use against GIT diseases have been 
recently reviewed by our group (Varankovich et al., 2015b). Apart from the challenge of finding the 
right species that would „confer a health benefit‟ to its host, there are also technical issues, such as 
 96 
 
delivery of the probiotic to a certain part of GIT where it could perform its function. One way to 
circumvent this issue is through the immobilization of bacteria in a protective polymer matrix. 
Microencapsulation of probiotic bacteria has become a widely and successfully used in the 
protection of acid-sensitive bacteria during storage and/or passage through a simulated GIT 
environment (Chandramouli et al., 2004; Jiménez-Pranteda et al., 2012; Khan et al., 2013). With 
respect to materials used for encapsulation it is preferable to choose plant proteins (soy, pea) and 
natural biopolymers, such as alginate or carrageenan, that are generally recognized as safe (GRAS) 
and are able to provide a good protection for bacterial cells 
(Holzapfel et al., 2002; Annan et al., 2008; Varankovich et al., 2015a). However, since not all of 
such materials provide sufficient protection by themselves, there has been a growing interest in using 
various mixtures, coatings and layers of different biopolymers to increase viability of encapsulated 
bacteria. 
Sodium alginate, pea protein isolate and chitosan, used for microencapsulation in this study, 
have GRAS status. Sodium alginate is a polymer of algal origin, composed of (1→4)-linked β-D-
mannuronic (M) and α-L-guluronic acid (G) residues, and undergoes gelation in the presence of 
divalent calcium ions, making it ideal for the extrusion-based encapsulation process (Voo et al., 
2011). The use of pea protein isolate (PPI) in the food industry is gaining popularity as an alternative 
to both animal-derived proteins and to soy, a known allergen. Pea proteins are comprised of mainly 
of globulin-type proteins of molar mass of 320-400 kDa (legumin) and 150 kDa (vicilin), and 
albumin (Stone et al., 2015). Chitosan (β-(1→4)-poly-D-glucosamine) is a biodegradable, 
biocompatible, nontoxic and non-allergenic linear cationic polysaccharide derived from chitin via 
deacetylation (Türkoðlu and Taþcýoðlu, 2014). It is widely used in medicine, agriculture, functional 
foods, biotechnology and cosmetics (Wang et al., 2012). For encapsulation, typically a gel-like 
capsule matrix is initially formed, followed by the addition of the coating. The binding of the coating 
material in the proposed capsule formulations will be due to polyelectrolyte complexation involving 
the positively-charged chitosan reacting with negatively-charged alginate (Zheng et al., 2016). 
My earlier research (chapter 3) has shown that PPI-alginate microcapsules have the potential 
to protect acid-sensitive bacteria in vivo (Varankovich et al., 2015a). In attempt to improve 
microcapsule formulation I added chitosan to the mixture, since this polymer has been shown by 
others to improve protective properties of microcapsules made of alginate (Chávarri et al., 2010). 
The bacteria used in the study were Lactobacillus rhamnosus R0011 and L. helveticus R0052 (mixed 
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in 95:5 ratio; Lacidofil®; Lallemand Health Solutions, Montreal, QC, Canada), whose probiotic 
potential in suppressing Citrobacter rodentium infection in mice has previously been reported 
(Gareau et al., 2010; Rodrigues et al., 2012). The goal of this study was to examine the ability of 
chitosan coating to improve protective properties of PPI-alginate microcapsules and also to 
determine how different storage conditions affect the viability of bacteria entrapped in both types of 
capsules.  
 
6.3 Materials and methods 
6.3.1 Materials 
Pea protein isolate was donated by Nutri-Pea Ltd. (Portage La Prairie, MB, Canada). Alginic 
acid sodium salt, calcium chloride dehydrate, Tween 80 and chitosan (low molecular weight) were 
purchased from Sigma-Aldrich (Oakville, ON, Canada). Probiotic strains L. rhamnosus R0011 and 
L. helveticus R0052 were received from Lallemand Health Solutions (Montreal, QC, Canada). 
 
6.3.2 Bacteria and culture conditions 
Probiotic strains were stored at −80°C in a 1:2 (v/v) suspension of glycerol and de Man, 
Rogosa and Sharpe broth (MRS; Sigma-Aldrich Chemie GmbH, Buchs, Switzerland). Prior to 
bacterial encapsulation, frozen stocks were plated on MRS medium containing 1.5 % (w/v) agar and 
then incubated for 24 h at 37°C under anaerobic conditions (80 % N2, 10 % CO2 and 10 % H2) in an 
anaerobic chamber (Forma Scientific Inc., Marietta, GA, USA). Pure colonies of L. rhamnosus 
R0011 and L. helveticus R0052 were then transferred from plates to 50 mL tubes containing 45 mL 
of MRS broth for incubation under the same conditions for 24 h. Bacterial cells were then recovered 
by centrifugation (2000 g × 12 min) (Sorvall SS-1; Sorvall Inc., Newtown, Connecticut, USA), 
washed twice with 1.0 % alkaline peptone water (APW; 10 % (w/v) peptone, 10 % (w/v) sodium 
chloride, pH 8.5) and used for the preparation of microcapsules. 
 
6.3.3 Preparation of bacteria-containing microcapsules 
Encapsulation and extrusion techniques used in this study were based on methodology 
described by Krasaekoopt et al. (2003), Chávarri et al. (2010) and Klemmer et al. (2011) with 
modifications. The composition of the capsule material was as follows: 2.0 % PPI + 0.5 % (w/w) 
sodium alginate. Concentration of PPI was adjusted to the protein content of the isolate (85 %). PPI 
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was dissolved at 85°C and pH 9.0 for 2 h under constant mechanical stirring. The pH was then 
adjusted to 7.0 and sodium alginate powder was added to the mixture. After complete dissolution of 
the polysaccharide (1–1.5 h at 85°C), the solution was cooled to room temperature (21–23°C), 
corrected for evaporative water loss with the addition of sterile water and mixed with a 2.0 % (v/v) 
bacterial slurry preparation (L. rhamnosus R0011 and L. helveticus R0052 at a 95:5 ratio). The final 
mixture of protein, polysaccharide and bacteria was then extruded using a syringe and 18 G (G, 
gauge) needle into 200 mL of ddH20 containing Ca
2+
 ions (cross-linking agent) and Tween 80 
(emulsifier). The concentrations of Ca
2+
 (CaCl2) and Tween 80 were 1.0 % (w/v) as previously 
described (Varankovich et al., 2015a). A portion of microcapsules were extruded into a cross-linking 
solution of the same composition, but with the addition of chitosan (0.4 %, w/v). After extrusion, 
microcapsules were left in the cross-linking solution on a shaker for 15 min, removed by filtration 
and left to air-dry for 15 min, then afterwards freeze-dried (Labconco FreeZone, Kansas City, MO, 
USA) for 15 h in the absence of cryoprotectants.  
 
6.3.4 Viability of bacteria in microcapsules during storage  
Both types of microcapsules – with and without chitosan coating were stored for 9 weeks in 
bags (200 x 300 mm) of plastic barrier film (75 micron nylon/polyethylene, oxygen transmission rate 
63 cc/sq. m/24 h at 23°C) in triplicate under four different conditions: 4°C, 20°C, 4°C + vacuum 
(KOMET Vakuun-Verpacken, KOMET Maschinenfabrik Gmbh, Plochingen, Germany), and 20°C + 
vacuum. Aliquots of microcapsules (0.1 g) were removed from bags every week, homogenized 
(Omni-mixer, Sorvall Inc., Newtown, USA) at 2000 rpm for 2 min, serially diluted, plated on MRS 
agar in triplicate, incubated at 37°C for 48 h and enumerated. Results were presented as log CFU/g 
of microcapsules. 
 
6.3.5 Survival of probiotics under simulated stomach conditions 
To determine the survival of encapsulated bacteria before and after the storage period (on 
weeks 0 and 9) 0.1 g aliquots of microcapsules were added to 0.9 ml of synthetic stomach juice (SSJ; 
8.3 g/L proteose peptone, 3.5 g/L glucose, 2.05 g/L NaCl, 0.6 g/L KH2PO4, 0.11 g/L CaCl2, 0.37 
g/L KCl, 0.05 g/L bile salts, 0.1 g/L lysozyme, 13.3 mg/L pepsin; pH 1.8) (Krasaekoopt et al., 2003; 
Khan et al., 2013) and incubated for 2 h at 37°C, then transferred to 0.9 ml of simulated intestinal 
fluid (SIF; 1.25 % (w/v) NaHCO3, 0.60 % (w/v) bile salts, 0.09 % (w/v) pancreatin; pH 6.5) and 
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incubated for another 3 h at 37°C. By the end of incubation all microcapsules were completely 
dissolved in SIF, and numbers of live bacteria cells were determined by serial dilutions in 1.0 % 
APW and plating on MRS agar. The same method, but without exposure to SSJ, was used to 
quantify the initial cell counts within microcapsules. 
To assess the viability of planktonic cells in SSJ, 0.01 g aliquots of lyophilized bacteria were 
added to centrifuge tubes (2 mL) containing 0.99 mL of SSJ and incubated at 37°C. Starting at time 
0, then every 5 min over the first 30 min, and subsequently every 30 min (2 h in total), tubes were 
removed from the incubator, serially-diluted with 1.0 % APW and plated on MRS agar. Plates were 
incubated at 37°C in an anaerobic chamber for 48 h and enumerated. All experiments were 
conducted in triplicate. 
 
6.3.6 Morphology and size of capsules 
Lyophilized microcapsules were cut in half using a scalpel, stained and immediately 
immobilized on the surface of a cover glass using molten 0.8 % (w/v) agar tempered to 40–45°C. 
After the agar solidified, the cover glass was inverted and transferred to a glass chamber made from 
glass slides. The chamber was then filled with tempered liquid agar. Staining of the microcapsules 
was performed using SYTO 9 and propidium iodide (5 mM solutions in DMSO; Life 
Technologies™ Corp., Carlsbad, CA, USA) according to the guidelines provided by Life 
Technologies™ (SYTO 9 and propidium iodide manuals, 2011). Dyes (1 μL each) were added to 2 
mL water, vortexed, directly applied to the capsule surface and then incubated for 15 min in the 
dark. Bright field and fluorescent images of stained microcapsules were obtained using a Nikon C2 
confocal laser scanning microscope (CLSM; Nikon, Mississauga, ON, Canada) using 488 nm and 
543 nm wavelength excitation in conjunction with an oil immersion, 60X Plan Apo VC (1.4 N.A., 
Nikon) objective lens. Three capsule locations were randomly chosen for obtaining optical thin 
sections representative of the capsule surface and stained bacteria. Each image was taken with a xy-
resolution of 512 by 512 pixels and a pinhole radius of 20 µm.  
Microcapsule size was measured using an electronic digital caliper (model 62379-531, 
Control Company, Friendswood, TX, USA). Fifteen microcapsules for each capsule type were 
measured and averaged. 
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6.3.7 Statistics 
Mean values, standard deviation, t-values and p-values within each group, as well as between 
groups, were determined using Welch t-test and Two-Way ANOVA (One-Way ANOVA in case of 
capsule size analysis). The level of statistical significance was set at p < 0.05. All statistical analyses 
were performed using SPSS software (SPSS Inc., Ver. 17.0, 2008, Chicago, IL, USA).  
 
6.4 Results and discussion 
6.4.1 Protective properties of microcapsules during storage 
The viability of encapsulated bacteria was monitored over a period of 9 weeks to determine 
the effect of temperature and vacuum packaging on their survival for both PPI-alginate and PPI-
alginate-chitosan microcapsules (Fig. 6.1). Results showed that cell viability in both types of 
capsules improved (p = 0.001) when stored at 4°C compared to 22°C. When stored at room 
temperature, chitosan-coated microcapsules provided better protection for cells compared to plain 
PPI-alginate capsules. There was a decrease in bacterial viability of 0.7 log CFU/g (from initial 8.10 
log CFU/g) in PPI-alginate-chitosan microcapsules stored at 22°C by week 9, while viable counts in 
PPI-alginate microcapsules, stored under the same conditions, reached 6.68 log CFU/g by week 5 
(Fig. 6.1). By week five, viable cell numbers continued to decrease, but plating results started to 
fluctuate considerably and are not shown on the graph (Fig. 6.1A). Vacuum sealing did not have any 
effect on cell survival in either PPI-alginate or PPI-alginate-chitosan microcapsules stored at room 
temperature (p > 0.05; Fig. 6.1A, B). However, stored PPI-alginate-chitosan microcapsules held 
under vacuum at 4°C, elicited no reduction in viable bacterial numbers (Fig. 6.1B). 
These findings are in accordance with other studies, where it was reported that stability of 
dried cultures decreased significantly when stored at room temperature (Champagne and Mondou, 
1996; Foerst et al., 2012). Obradović and Krunić (2015) also observed greater survival of bacteria in 
chitosan-coated alginate beads, compared to non-coated ones, during 21 days of refrigerated storage 
(4°C). Chávarri et al. (2010) reported that bacterial numbers in chitosan-coated alginate 
microcapsules decreased by 2.0 log CFU/g over 28 days of storage at 4°C. However, our results 
showed considerably less viability loss in pea protein alginate microcapsules, coated with chitosan – 
only 0.3 log CFU/g during 9 weeks of refrigerated storage (Fig. 6.1B). Improved protective 
properties might be caused by the addition of pea protein isolate to the formulation. According to the 
results, the best way to preserve viable probiotic cells of L. rhamnosus R0011 and L. helveticus 
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R0052 for 9 weeks was encapsulating them in PPI-alginate with chitosan coating and storing at 4°C 
under vacuum.  
 
6.4.2 Survival of probiotic bacteria in microcapsules during simulated GIT conditions  
Free non-encapsulated bacterial cells were incubated in synthetic stomach juice (SSJ) for 2 h 
as a control, where viable cells became undetectable by plating after 60 min (L. rhamnosus R0011) 
and 90 min (L. helveticus R0052) incubation (Fig. 6.2). To assess the survival of immobilized 
bacteria under simulated gastrointestinal tract conditions after 9 weeks of storage, PPI-alginate and 
PPI-alginate-chitosan microcapsules were incubated for 2 h in synthetic stomach juice (SSJ) and 
then for 3 h in simulated intestinal fluid (SIF). Cell viability within freshly prepared PPI-alginate and 
PPI-alginate-chitosan (control) and after incubation 2 h in SSJ and 3 h in SIF revealed that PPI-
alginate-chitosan microcapsules provided better protection, with only having a decrease in viable 
counts by 0.7 log CFU/g compared to a 1.5 log CFU/g decline in PPI-alginate microcapsules after 
the 5 h test (p < 0.05) (Fig. 6.3).  
 
 
 
Figure 6.1. Viability of probiotic bacteria in pea-protein-alginate (A) and PPI-alginate –chitosan (B) 
microcapsules during storage at 4 and 22
o
C without and under vacuum over a 9-week 
duration. Data represent the mean ± one standard deviation (n = 3). 
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Figure 6.2. Decrease in viable cell counts of non-encapsulated probiotic bacteria (L. rhamnosus 
R0011 and L. helveticus R0052) during incubation 2 h in synthetic stomach juice. Data 
represent the mean ± one standard deviation (n = 3). 
Viability tests were repeated after 9 weeks of storage under different temperature (4 or 22°C) 
and atmospheric (with and without vacuum) conditions (Fig. 6.4). Microcapsules were tested for cell 
viability before (control) and after incubation within SSJ (2 h) followed by SIF (3 h). PPI-alginate 
microcapsules stored at room temperature provided the least protection for immobilized cells, with a 
4.1 log CFU/g decrease in viable counts (Fig. 6.4A). Storage at 22°C under vacuum did not improve 
their performance (Fig. 6.4A). When stored at 4°C, cell viability was improved relative to the room 
temperature storage, and losses in cell viability were only 1.3 log CFU/g and 1.9 log CFU/g with or 
without vacuum, respectively (Fig. 6.4A). The addition of a chitosan coating to the PPI-alginate 
microcapsules led to  improved cell viability (p < 0.05), where no loses cell viability was observed 
after treatment with SSJ + SIF in samples stored under different temperature (4 or 22°C) or 
atmosphere (with or without vacuum) conditions (Fig. 6.4). Zanjani et al. (2013) reported that 
chitosan coating played a significant role in the protection of Lactobacillus casei ATCC 39392 and 
Bifidobacterium bifidum ATCC 29521 immobilized in calcium-alginate gelatinized starch 
microcapsules during simulated gastric- and intestinal juices challenge test. Chitosan-coated alginate 
beads similarly provided good protection for L. acidophilus and L. casei cells during survival tests as 
reported by Krasaekoopt et al. (2004).  
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Protection of bacterial cells immobilized in PA microcapsules is mainly provided by an outer 
membrane that is formed upon extrusion of the microcapsules material into a crosslinking solution 
containing divalent cations. The improvement in the protective properties of PAC microcapsules 
compared to those consisting of PA only can be attributed to an additional polyelectrolyte complex 
membrane that forms on the surface of negatively charged alginate when positively charged chitosan 
diffuses into its three-dimensional network (Zheng et al., 2016).  
 
 
Figure 6.3. Cell viability within freshly prepared PPI-alginate (PA) or PPI-alginate-chitosan (PAC) 
microcapsules (control)) and after incubation for 2 h in synthetic stomach juice (SSJ) 
followed by 3 h in simulated intestinal fluid (SIF). Data represent the mean ± one 
standard deviation (n = 3). 
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Figure 6.4. Cell viability in PPI-alginate (PA; A) and PPI-alginate-chitosan (B) microcapsules after 
9 weeks of storage at 4 and 22°C without and under vacuum, before (control) and after 
incubation for 2 h in synthetic stomach juice (SSJ) followed by 3 h in simulated 
intestinal fluid (SIF). Data represent the mean ± one standard deviation (n = 3). 
6.4.3 Microscopy and size of microcapsules 
The morphology of the surface of PPI-alginate and PPI-alginate-chitosan microcapsules were 
imaged using CLSM (Fig. 6.5). No discernable differences could be seen with the addition of 
chitosan, since the coating thickness was too thin to be visualized by this technique which has a 
minimum resolving power of 0.2 microns. On average, the size of PPI-alginate microcapsules was ~ 
2.4 mm, where the addition of the chitosan coating had little impact on capsule diameter (Fig. 6.6). 
However, after incubation in SSJ for 2 h, the diameters of both types of microcapsules became 
reduced slightly to approximately 2.2 mm, although this was not considered significant (p > 0.05) 
(Fig. 6.6). Alginate (only) microcapsules have previously been shown to shrink at low pH (Ouwerx 
et al., 1998; Valenzuela et al., 2016). Alginate molecules have a pKa of ~ 3.5 and therefore they lose 
50 % of their charge at pH values less than 5.5, leading to a dense structure and shrinkage of 
alginate-based microcapsules (Valenzuela et al., 2016). 
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Figure 6.5. CLSM images of the surface of PPI-alginate (left) and PPI-alginate-chitosan (right) 
microcapsules stained with propidium iodide and SYTO 9. Arrows indicate entrapped 
bacteria. Scale bar – 50 µm. 
 
Figure 6.6. Diameter of PPI-alginate and PPI-alginate-chitosan capsules, before and after incubation 
for 2 h in synthetic stomach juice (SSJ). Data represent the mean ± one standard 
deviation (n = 15 for each capsule type). 
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6.5 Conclusions 
To conclude, PPI-alginate microcapsules formulated with and without a chitosan coating 
enhanced the survival of probiotic cells during refrigerated (4°C) storage for 9 weeks, with little 
differences observed in cell viability before and after incubation in simulated gastrointestinal 
condition (SIF + SSJ) challenge. In contrast, storage at 22°C worsened the performance of both 
types of capsules. While addition of chitosan to the microcapsule formulation significantly improved 
storage and viability during simulated GIT challenges, the coating was so thin it couldn‟t be 
visualized using CLSM. Vacuum packaging did not have any significant impact on the protective 
properties of microcapsules stored at room temperature, but improved cell survival at 4°C in PPI-
alginate-chitosan microcapsules. These results suggest that PPI-alginate microcapsules coated with 
chitosan can be successfully used to preserve high viable counts of L. rhamnosus R0011 and L. 
helveticus R0052 during long-term refrigerated storage. 
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7 GENERAL DISCUSSION 
The delivery of live probiotics in sufficiently high numbers to the intestine remains a major 
challenge. Probiotic products should contain substances that protect viable bacteria from detrimental 
conditions of the stomach so that they can reach the colon in sufficient number in order to provide a 
functional benefit to the host. The most efficient method for protection of bacteria from harmful 
influence of acid and bile is their encapsulation within biopolymer coatings, and preference has 
usually been given to natural hydrocolloids and gums that are generally recognized as safe for 
human health and show good protection of bacterial cells against the acidic environment of the gut. 
Examples of such polysaccharides used for encapsulation include alginate, carrageenans and gums, 
all of which possess acceptable properties of viscosity, water binding, emulsion stabilization, 
adhesion, foam stabilization and film formation (Holzapfel and Schillinger, 2002; Shah et al., 2007; 
Bajaj et al., 2007; Chaplin, 2012; Morris et al., 2012). Previously, Wood et al. (2010) found that 
alginate capsules (1.0 %; w/v) were unable to provide sufficient protection to B. adolescentis ATCC 
15703 during a 2 h incubation in simulated gastric juice, an outcome that was attributed to the 
presence of large pores (~ 400 µm) on the surface of the alginate capsules. However, Lee and Heo 
(2000) reported only a 2 log CFU/mL decrease in viable cell numbers of Bifidobacterium longum 
encapsulated in 2.0 % (w/v) alginate under similar conditions. This difference might be explained by 
the fact that B. longum has a higher degree of acid tolerance, as different species of bifidobacteria 
have varying sensitivities to acidic conditions (Waddington et al., 2011).  
In my research, microcapsules with immobilized B. adolescentis, and containing PPI-
alginate, PPI-iota-carrageenan or PPI-gellan gum, demonstrated significant retention of viability in 
SSJ compared to planktonic cells. This is in agreement with the results of Klemmer et al. (2011), 
who reported that  pea  protein isolate-alginate microcapsules prepared using extrusion offered 
protection to B. adolescentis in simulated  gastric  juice over 2 h at 37˚C, and showed prolonged 
release in simulated intestinal fluids. Wang et al. (2015) showed that B. adolescentis cells trapped in 
pea, soy, faba, and lentil protein-alginate microcapsules showed 1.9, 3.3, 5.1, and 
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5.5 log reductions in cell numbers, respectively, after a 2 h challenge. In our experiments pea-protein 
alginate microcapsules showed slightly better performance in SSJ – live cell count decreased by ~ 1 
log CFU/g for fresh microcapsules. As for release of entrapped bacteria, Wang 
et al. (2015) reported the release of almost all bacterial cells encapsulated in legume protein-alginate 
microcapsules after 10 min in SIF, which also supports our data for PPI-alginate capsules. 
Interestingly, increasing of the concentration of PPI to 4.0 % led to decreased viable counts of B. 
adolescentis after 2 h in synthetic gastric juice (Wood, 2010). Even better results were achieved with 
iota-carrageenan (74 % of cells released, compared to 70 % for PPI-alginate). In contrast, PPI-gellan 
gum microcapsules released far fewer cells (~ 40 %) due to the greater resistance of PPI-gellan gum 
complex to degradation by SIF. 
Alginate and iota-carrageenan have been previously described to have good freeze/thaw 
stability and potential for cell protection during lyophilization, which is an important method for 
probiotic preservation for long-term storage (Giulio et al., 2005; Gbassi and Vandamme, 2012). In 
this research, the effect of freeze-drying on the protective properties of microcapsules was also tested 
using the same above-described methodology. All three types of lyophilized microcapsules provided 
sufficient protection for bacterial cells from the detrimental effect of SSJ compared to planktonic 
cells, with no significant difference in cell viability observed amongst different types of 
microcapsules (~ 2-2.5 log reduction in CFU/g). Freeze-dried microcapsules released slightly more 
viable bacteria than fresh microcapsules (79 %, 75 % and 53 % of entrapped cells for PPI-iota-
carrageenan, PPI-alginate and PPI-gellan gum capsules).  
Treatment with SSJ caused PPI-iota-carrageenan microcapsules to slightly decrease in size 
and change in shape. Contrary to the reports of others (Klemmer et al. 2010; Wang et al. 2015), 
there was no significant shrinking of PPI-alginate observed at low pHs. After transfer to SIF, both 
fresh and dried PPI-alginate and PPI-iota-carrageenan microcapsules became dissolved in the 
solution after 3 h; however, PPI-gellan gum microcapsules of both types did not dissolve, but did 
change shape and size, becoming spherical. The dissolution of PPI-alginate and PPI-iota-
carrageenan microcapsules under simulated conditions of lower GIT is an asset since it allows 
release of all the immobilized bacteria. A possible reason for the dissolution of PPI-iota-carrageenan 
matrix might be disruption of electrostatic bonds existing between protein and polysaccharide. Since 
PPI has an isoelectric point (pI) of ~ 4.5, at pH values < pI the protein would assume a net-positive 
charge, while all polysaccharides used in the study would carry a negative charge at pH values > 
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1.88 (pKa of –COO
-
) in the case of gellan gum and alginate, and > 2.00 (pKa of –SO
3-
) in the case of 
iota-carrageenan. According to Ganzevles (2007), when the polysaccharide pKa < pH < pI (protein), 
both components would be oppositely-charged, and thus they would be electrostatically-attracted to 
each other. Hence, under simulated intestinal conditions (pH 6.5), both protein and polysaccharide 
would have the same charge and thus would repel each other, and the structural integrity of a capsule 
would be maintained only by the calcium-stabilizing polysaccharide network. Additionally, iota-
carrageenan has a greater net-negative charge (due to higher electronegativity of its sulphate groups), 
which led to higher repulsive forces within the microcapsule, followed by a disruption of the 
calcium-carrageenan network and a release of the majority of entrapped bacteria into the solution. 
These findings are supported by the studies of polymer and drug release characteristics from alginate 
capsules (Kim and Lee, 1992; Sugawara et al., 1994; Chen et al., 2004; Chen et al., 2007). It has 
also been shown that at low pH the surface of alginate capsules becomes porous and insoluble 
(George and Abraham, 2006), while in higher pH solutions this so-called “alginic acid skin” 
becomes soluble, and alginate starts to swell, which, in the case of probiotic capsules, might aid in 
the controlled release of bacterial cells (Kimura, 1993). In general, alginate gels are considered 
fragile, since they reveal an open cellular structure after drying (Nussinovitch et al., 2000). The 
stability of such gels can be preserved by using lyophilization as a dehydration method, as it results 
in dry gels with improved mechanical properties (Nussinovitch et al., 1993). The addition of pea 
protein to alginate also considerably improved their stability under acidic conditions, allowing 
effective protection of immobilized bacteria.   
Confocal microscopy (CLSM) images of all three types of fresh microcapsules (stained and 
bisected) revealed that the cells were evenly distributed within the capsules, immobilized on the 
surface of pea protein particles and within the unstained polysaccharide. After freeze-drying protein 
globules were slightly deformed and surrounded by layers of polysaccharide containing immobilized 
bacteria, forming pores separated by protein-polysaccharide walls. These pores could be the result of 
ice sublimation, occurring during lyophilization (Shamblin et al., 2004). Such honeycomb-like 
ultrastructure has been previously described by Khan et al. (2013) and Wood (2010), based on 
scanning electron microscopy (SEM) and cryo-SEM of PPI-alginate capsules. However, as evident 
from the survival studies in this research, pores apparently do not facilitate the diffusion of SSJ into 
the capsules, as the viability of bacteria within both freeze-dried- and fresh microcapsules was 
approximately equal. 
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Culture-dependent methods for bacterial enumeration cannot be applied to the quantification 
of most of the bacterial species found in GIT due to the absence of a suitable medium, which makes 
culture-independent techniques, such as PCR, a required tool for this purpose (Giraffa and 
Carminati, 2008). PCR have already been successfully used for the quantification of bacteria 
(including B. adolescentis) in human and animal feces (Wang et al., 1996; O‟Sullivan, 1999). In the 
study by Satokari et al. (2001), a group of human subjects were administered Bifidobacterium lactis 
at a concentration of 3 x 10
10
 CFU per day for two weeks. The quantification of B. lactis in feces 
was conducted using PCR/gel electrophoresis techniques. However, no B. lactis were detected after 
the administration was ceased (Satokari et al., 2001). In the current study, the results of PCR with B. 
adolescentis-specific primers, followed by gel electrophoresis, demonstrated an increased abundance 
of B. adolescentis in the GIT of rats that were fed PPI-alginate microcapsules containing bacteria. 
Additionally, similar with the data reported by Satokari et al. (2016), the elimination of fed probiotic 
bacteria from the animal GIT occurred within one-week post-supplementation.  
The effect of encapsulation materials on the GIT as well as their possible interference with 
the action of encapsulated probiotics has to be investigated as well. In this research, the animal 
model of infectious disease (C. rodentium-induced colitis) was used to test the effects of PPI-alginate 
matrix on the action of probiotics L. rhamnosus R0011 and L. helveticus R0052. To the best of my 
knowledge, the effect of encapsulation materials (alginate, pea protein, calcium ions) on the 
development of C. rodentium infection in mice have not yet been investigated.  
The infection did not cause any of the animals to develop an abnormal behavior. However, 
the pathogen had the strongest negative effect on most of the symptoms (weight of animals, spleen 
size and weight, liver weight, etc.), and on histopathological changes in epithelium (epithelial 
hyperplasia, mitotic activity, etc.), which is supported by the findings of others, who studied effects 
of probiotics in murine model of infectious colitis (Johnson-Henry et al., 2005; Gareau et al., 2010; 
Costa et al., 2011; Crepin et al., 2016). Symptomatic data showed that both PEC (probiotic 
microcapsules + infection) and EC (blank microcapsules + infection) groups of mice had enlarged 
lymph nodes and spleens compared to the PC (probiotic powder + infection) group. However, blank 
microcapsules, administered to infected animals, seemed to enhance the development of the disease 
in cecum. Increased goblet cell depletion in cecum from infected mice within this group could be 
explained by the effects that alginate has on mucin-secreting cells (Forstner, 1995; Barcelo et al., 
2000).  
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Infection of mice with C. rodentium usually leads to the increased expression of pro-
inflammatory cytokines (Higgins et al., 1999; Costa et al., 2011). Probiotics L. rhamnosus R0011 
and L. helveticus R0052 have been previously shown to suppress the expression of pro-inflammatory 
cytokines in mice that have been infected with C. rodentium (Johnson-Henry et al., 2005; Rodrigues 
et al., 2012). In this research this effect was not observed in most of the groups. The expression of 
Il17 was not decreased in infected mice receiving probiotics compared to infection controls, while 
the concentration of Infγ was not considerably high in infected animals, which might be attributed to 
the suppression of inflammatory response by probiotics in the PC group. Il17 was up-regulated (in 
comparison to the control group) in the PEC group, indicating that the complex of encapsulation 
materials, probiotics and infection had a demonstrable impact on immune system, triggering 
inflammation. High concentrations of Infγ in EC and PEC groups can be attributed to the ability of 
alginate to induce a Th1 immune response in mice as shown on sodium alginate-adjuvant enhanced 
vaccines (Dobakhti et al., 2009; AbdelAllah et al. 2016). Il4 was also up-regulated in the EC group 
in comparison to the control group, an outcome that could have been caused by calcium ions used 
for microcapsule crosslinking and required for the production of Il4 by T cells as well as for the 
secretion of multiple cytokines by dendritic cells (Brown et al., 1995; Li et al., 2002; Parekh, 2010). 
There was a slightly higher (two-fold) increase in relative concentration of mRNA of Tgfβ in 
infected animals compared to non-infected animals, which could be indicative of fibrosis and repair 
processes in the distal colon, since this cytokine plays a central role in wound healing, tissue repair 
and TH17 development (Branton and Kopp, 1999; Mangan et al., 2006; Penn et al., 2012).  
In general, infection of mice with C. rodentium led to the increase in the expression of pro-
inflammatory cytokines, though the effect was not uniform. Probiotic administration did not 
significantly-impact cytokine profiles of infected animals. The highest copy numbers of Infγ and Il17 
mRNA were found in the distal colon of infected mice that received probiotic microcapsules (PEC), 
suggesting that encapsulation materials contributed to the development of inflammatory response. It 
has been previously suggested that sodium alginate may induce immune response in rodents, 
especially the expression of tumor necrosis factor alpha and interleukins 1 and 6 (Otterlei et al., 
1991, 1993; Son et al., 2001). This effect has been linked to the interaction of alginate with the 
CD14 receptor on macrophages, which is similar to the activation of these cells by 
lipopolysaccharides, and is especially evident in case of alginates with high mannuronic acid content 
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(Espevik et al., 1993; Otterlei et al., 1993). Alginate, used in this research, consisted of ~ 61 % 
mannuronic acid, which could have been high enough to induce inflammation. 
The interpreatation of 16S rRNA analysis of mucosal communities of the distal colon 
remains a challenge due to the lack of apparent structure of the data, however some trends should be 
noted, such as a similar richness and diversity of bacterial communities in control mice and animals 
fed with blank capsules. These two metrics were also affected by infection – microbiome profiles 
became more simplified in many of the infected animals. The numbers of Proteobacteria were high 
in animals with high total average hystopathological scores. This fact is supported by observations of 
others, where higher Proteobacteria counts in animals infected with C. rodentium were reported 
(Lupp et al., 2007; Berry et al., 2015; Shin et al., 2016). In general, mucosa-associated communities 
of control mice, as well as mice fed with blank capsules, showed similarities and were dominated by 
Firmicutes. As reported by others (Eslinger et al., 2014), the administration of pea protein can lead 
to the proliferation of Bacteroides and a decrease in the Firmicutes/Bacteroides ratio. Intake of 
alginate usually results in development of a more simplified microbiota that includes phylotypes 
with dominating Firmicutes and increased numbers of Bacteroides, which supports the present 
observation of Firmicutes dominating the mucosal communities of E group mice (An et al., 2012; 
Umu et al., 2015).  
In my final set of experiments, PPI-alginate microcapsules were tested for their ability to 
protect probiotics during long-term storage. Additionally, a chitosan layer was added to the 
microcapsules as a way to possibly improve protective properties, and both pea protein alginate and 
pea protein alginate–chitosan) were used in testing of protective properties under different 
temperature (4°C, 22°C) and atmospheric (vacuum/no vacuum) conditions. During a storage period 
of 9 weeks, the cell viability resulting from both types of microcapsules was monitored and was 
found to be significantly-improved when microcapsules were stored at 4°C compared to 22°C. When 
stored at room temperature, PPI-alginate-chitosan microcapsules provided better protection for 
probiotic cells compared to PPI-alginate capsules. Vacuum conditions did not have any major impact 
on cell survival in either PPI-alginate or PPI-alginate-chitosan microcapsules stored at room 
temperature; however, storage of PPI-alginate-chitosan microcapsules under vacuum at 4°C led to 
no reduction in live bacterial numbers and only 0.3 log CFU/g reduction over 9 weeks of refrigerated 
storage without vacuum. Similar results of enhanced protection of cells upon addition of a chitosan 
layer to microcapsules were reported by Chávarri et al. (2010); bacterial numbers in chitosan-coated 
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alginate capsules decreased by 2.0 log CFU/g over 28 days of storage at 4°C. Obradović and Krunić 
(2015) also observed greater survival of bacteria in chitosan-coated alginate beads compared to non-
coated ones during long-term refrigerated storage (4°C). Additional challenge tests (2 h in SSJ and 3 
h in SIF) revealed that PPI-alginate-chitosan microcapsules provided significantly-better protection, 
with viable counts only decreasing by 0.7 log CFU/g compared to before-storage counts (1.5 log 
CFU/g for PPI-alginate capsules). After 9 weeks of storage, the same tests showed that PPI-alginate 
microcapsules stored with or without vacuum at room temperature provided the least protection for 
entrapped cells with ~ 4.1 log CFU/g decrease in viable bacterial counts, while refrigerated storage 
improved their performance (1.3 log CFU/g and 1.9 log CFU/g with or without vacuum, 
respectively).  
The addition of a chitosan coating to PPI-alginate microcapsules led to significantly-
improved cell viability with no loses cell viability after treatment with SSJ + SIF in samples stored 
under different temperature or atmosphere conditions. These results are supported by Zanjani et al. 
(2013), who reported that chitosan coating played a significant role in the protection of Lactobacillus 
casei ATCC 39392 and Bifidobacterium bifidum ATCC 29521 immobilized in calcium-alginate 
gelatinized starch microcapsules during simulated gastric- and intestinal-juice challenge tests. 
Similarly, chitosan-coated alginate beads provided good protection for L. acidophilus and L. casei 
cells during challenge tests, as reported by Krasaekoopt et al. (2003).   
In general, according to the results of this study, the best way to preserve L. rhamnosus 
R0011 and L. helveticus R0052 cells over 9 weeks is by encapsulating them in chitosan-coated 
PPI-alginate beads along with storage at 4°C under vacuum.
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8 GENERAL CONCLUSIONS 
Pea protein-polysaccharide microcapsules were tested for their ability to provide sufficient 
protection to acid-sensitive bacteria in a series of in vitro experiments employing simulated 
conditions of human GIT. The results revealed that PPI-alginate and pea protein-iota-carrageenan 
microcapsules containing acid-sensitive B. adolescentis have potential for protecting these bacterial 
cells from the detrimental effects of the upper GIT, with subsequent release of most of the entrapped 
bacteria in the lower GIT. The overall cell count reduction after 2 h in SSJ at 37C was ~ 1.0-1.5 log 
viable CFU/g for all types of fresh microcapsules and ~ 2.0-2.5 log CFU/g for freeze-dried capsules. 
The subsequent release of bacteria from the microcapsules was the highest for PPI-iota-carrageenan 
and PPI-alginate microcapsules with 70 – 74 % of the total amount of immobilized cells were 
released from fresh microcapsules and 75 – 79 % of immobilized cells were released from freeze-
dried capsules, while PPI-gellan gum released the fewest cells, with only ~ 4.0 log CFU/g (5.3 log 
CFU/g for lyophilized capsules) detected following incubation in SIF. The molecular analysis of 
fecal samples recovered from an in vivo rat feeding study confirmed that PPI-alginate microcapsules 
are an effective tool to deliver probiotics into the lower gut.  
PPI-alginate microcapsules were selected for testing in animal model of E. coli colitis – the 
C. rodentium infection in mice. Pathogenic infection led to marked progression of colitis, which was 
evident from symptomatic and histopathological data, cytokine expression and alteration of 
composition of mucosa-associated communities. Administration of the probiotics, L. rhamnosus 
R0011 and L. helveticus R0052, led to changes in most of the disease markers in cecum; however, 
probiotics were not able to suppress the expression of pro-inflammatory cytokines. Administration of 
probiotics in microcapsules did not interfere with the effect probiotics had on histolopathological 
markers; however, EC treatment (blank microcapsules + infection) led to a set of significantly-
worsened symptoms in the cecum, compared to some of the other treatments. This effect correlated 
with the upregulated expression of Infγ and IL4 in the same (EC) mouse group.  
In general, the expression of cytokines was not affected by encapsulation materials. 
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However, a combination of infection and probiotic administration (PEC group) led to significantly-
elevated levels of both Infγ and IL17, suggesting a major impact on the immune system that 
triggered inflammation. 
Studying the effects of PPI-alginate encapsulation materials in a murine model of infectious 
colitis was challenging due to the large, within-group diversity that accompanied almost every 
symptom or marker, the inability to separate the effect of each of the components of the matrix, and 
the lack of a definite beneficial effect of probiotics in some infected animals. However, our results 
did show that PPI-alginate capsule matrix worsened a set of symptoms of a disease and led to the 
induction of an inflammatory immune response in some infected animals. Consequently, some 
questions remain with respect to the utilization of PPI-alginate matrix for probiotic delivery, 
including possible combined pathogen-ingredient inflammation responses, species-dependent 
responses, and the mode of action of each component under the conditions of C. rodentium-induced 
colitis in mice. 
In an attempt to further improve the protective properties of PPI-alginate capsules, a chitosan 
coating was added to the formulation and the effect of time and storage conditions on both capsule 
types investigated. Chitosan coating enhanced the survival of probiotic cells during refrigerated 
(4°C) storage over a 9 week period, with little difference observed in cell viability before and after 
challenge with simulated gastrointestinal conditions. In contrast, storage at room temperature 
worsened the performance (survival) of both types of capsules. Vacuum packaging did not have any 
significant impact on the protective properties of microcapsules stored at room temperature, but did 
improve cell survival at 4°C in microcapsules coated with chitosan. These results suggest that PPI-
alginate microcapsules coated with chitosan have potential for preserving high viable counts in L. 
rhamnosus R0011 and L. helveticus R0052 during long-term refrigerated storage.   
In general, a series of in vitro tests confirmed that PPI-alginate matrix is efficient in 
protecting bifidobacteria and lactobacilli from detrimental conditions of the upper GIT and assures 
the release of most of the encapsulated bacteria into the intestine. However, before   utilization of 
PPI-alginate for probiotic delivery, possible pathogen-ingredient interactions and the mode of action 
of each component under disease conditions should be carefully studied.  
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9 FUTURE STUDIES 
Difficulties in reproducing animal studies data suggest the need for the search for alternatives 
to investigate the effects that encapsulation materials and probiotics themselves might have on the 
GIT. One of the options that might be utilized is that of epithelial cell lines, such as HEp-2, to 
observe the action of pathogens, probiotics, their possible interactions and the effects encapsulation 
matrices might have on the system. Such cell-line systems are much cheaper, easier to reproduce and 
maintain (than animals), and might better allow elucidation (using gene expression analyses) of the 
impact of single components, such as pea protein and sodium alginate. However, this approach does 
not permit accounting for many of the factors that act in vivo, such as the effect of complex bacterial 
communities, immune system effects, etc. In this research, the specific strain of a pathogen and a 
type of cell line used did not produce relevant results, which, however, does not exclude this line of 
inquiry and leaves room for repeating experiments with other cell lines and probiotic and pathogen 
strains.  
PPI-alginate microcapsules could also be tested in a different animal model of a disease in 
vivo, in conjunction with using a larger group of animal subjects. The outcome of this could yield 
several benefits, including improved reliability and reproducibility of results. Furthermore, the 
interpretation of results of this type of analyses would be easier, if the probiotics used for the 
treatment of infection were to have a stronger direct or indirect antagonistic activity, such as the 
ability to compete for attachment sites, against the pathogen along with a more predictable mode of 
action.  
Capsule design is another area where multiple experiments could be conducted in order to 
improve their ability to deliver viable probiotics to specific regions of the GIT. There have been 
many designs suggested and tested in vitro; however, very few have been studied in animal models. 
Based on the results of this research chitosan coating provides enhanced protection to lactobacilli 
strains; however, its effects on GIT has not been fully described yet, therefore it is essential to test 
pea protein isolate alginate-chitosan microcapsules in vivo. Additionally, the effect of each of the 
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components of encapsulation matrix on the animal GIT should be thoroughly investigated. More 
research is also needed on the interaction of microencapsulated 
materials with different food matrices and modifying the chemistry of microcapsule matrices for 
targeted release of probiotic bacteria in specific areas of the GIT.  
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Figure A.1. Composition of mucosa-associated community (10 dominant phyla) of distal colon of 
mice challenged with C. rodentium and/or treated with encapsulated or non-
encapsulated probiotics, as sequenced on Illumina MiSeq and calculated using QIIME. 
The y-axis shows relative abundance. Separate samples (mice) are shown on x-axis. 
Group abbreviations key: P – probiotics, C – C. rodentium infection, E – encapsulation. 
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Figure A.2. Composition of mucosa-associated community (10 dominant families) of distal colon of 
mice challenged with C. rodentium and/or treated with encapsulated or non-
encapsulated probiotics, as sequenced on Illumina MiSeq and calculated using QIIME. 
The y-axis shows relative abundance. Separate samples (mice) are shown on x-axis. 
Group abbreviations key: P – probiotics, C – C. rodentium infection, E – encapsulation. 
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